Document:

EX-10.45

 Exhibit 10.45 

Execution Version 
 THE
SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN 
 IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM 

THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND 

(ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

COLLABORATION AGREEMENT 
 by and
between 
 PFIZER INC. 

and 
 BIONTECH SE 

March 17, 2020 

 TABLE OF CONTENTS 

 

							
			
	1.	  	DEFINITIONS	  	 	1	 
			
	2.	  	SCOPE OF COLLABORATION	  	 	19	 
			
	3.	  	LICENSES	  	 	19	 
			
	4.	  	COMMERCIALIZATION	  	 	27	 
			
	5.	  	PAYMENTS AND FUNDING	  	 	27	 
			
	6.	  	RESEARCH AND DEVELOPMENT PLAN	  	 	33	 
			
	7.	  	CONTRACT GOVERNANCE	  	 	34	 
			
	8.	  	MANUFACTURING	  	 	39	 
			
	9.	  	DEVELOPMENT, REGULATORY AND PHARMACOVIGILANCE	  	 	41	 
			
	10.	  	INTELLECTUAL PROPERTY	  	 	48	 
			
	11.	  	CONFIDENTIALITY	  	 	58	 
			
	12.	  	REPRESENTATIONS AND WARRANTIES	  	 	62	 
			
	13.	  	GOVERNMENT APPROVALS; TERM AND TERMINATION	  	 	70	 
			
	14.	  	CHANGE OF CONTROL	  	 	74	 
			
	15.	  	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE	  	 	75	 
			
	16.	  	MISCELLANEOUS	  	 	78	 

  
 i 

 COLLABORATION AGREEMENT 

This Collaboration Agreement (the “Agreement”) is entered into as of March 17, 2020 (the “Effective
Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States (“Pfizer”)
and BioNTech SE, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany (“BioNTech”). Pfizer and BioNTech
may each be referred to herein individually as a “Party” and collectively as the “Parties”. 
 WHEREAS,
BioNTech owns or otherwise Controls (as defined below) certain patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to
the identification, research and development of Candidates (as defined below) in the Field (as defined below) for delivery via Delivery Technology (as defined below); 

WHEREAS, Pfizer has extensive experience and expertise in the development and commercialization of pharmaceutical and biopharmaceutical
products; 
 WHEREAS, in view of the current COVID-19 crisis, Pfizer and BioNTech wish to engage in
expedited collaborative research and development pursuant to the Research and Development Plan (as defined below) to identify and develop Candidates for inclusion in the Product, seek expedited regulatory approval for such Product, and launch such
Product in all countries of the Territory (as defined below) as quickly as reasonably possible; and 
 WHEREAS, Pfizer and BioNTech wish
that Pfizer Commercializes the Product in all countries of the Territory, subject to BioNTech having the right to exclusively commercialize the Product in the BioNTech Commercialization Territory. 

NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS 

As used in this Agreement, the following terms will have the meanings set forth below: 

1.1. “Affiliate” means any entity directly or indirectly controlled by, controlling, or under common control with, a Person,
but only for so long as such control will continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common control with”) means
(a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial
ownership of more than 50% of the voting securities or other ownership or general partnership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of an entity;
provided, however, that where an entity owns a majority of the voting power necessary to elect a majority of the board of directors or other governing board of another entity, but is restricted from electing such majority by contract
or otherwise, such entity will not be considered to be in control of such other entity until such time as such restrictions are no longer in effect. Notwithstanding the foregoing, for the purposes of this Agreement, AT Impf GmbH, having its place of
business at Rosenheimer Platz 6, 81669 Munich, Germany, and any entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with AT Impf GmbH (other than BioNTech SE or any entity
that is directly or indirectly controlled by BioNTech SE) (collectively, the “Impf Group”) shall not be considered Affiliates of BioNTech. 

  
 1 

 1.2. “Anti-Corruption Laws” means all applicable anti-bribery and
anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, the U.K. Bribery Act 2010, and the local laws and regulations of any countries in which Candidates or Products, payments or services will be provided or
procured under or pursuant to this Agreement. 
 1.3. “Applicable Data Protection Law” means all applicable personal data
protection laws, rules and regulations, including the EU General Data Protection Regulation (“GDPR”). 
 1.4. “Bankruptcy
Code” means Section 101(35A) of Title 11 of the United States Code, as amended, or such other legislation, Law or code with effect in another jurisdiction to which BioNTech or its Affiliates is subject having equivalent or reasonably
similar purpose or provisions to the foregoing. 
 1.5. “Binding Obligation” means, with respect to a Party (a) any
oral or written agreement or arrangement that binds or affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement, (b) the provisions of such Party’s
charter, bylaws or other organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party’s operations or property are bound.

 1.6. “BioNTech Commercialization Territory” means (a) Germany and Turkey, until such time, on a country by country
basis, a BioNTech Territory Exit Option is exercised by BioNTech in respect of one or both of those countries; (b) those countries, on a country by country basis, which become Pfizer Exit Countries (if any); and (c) those countries within
the Developing Countries Territory for so long as BioNTech or its Affiliate or designee pursuant to the relevant Third Party Funder agreement undertakes Commercialization of the Product in such countries. 

1.7. “BioNTech Improvement” means any Research and Development Program Technology, regardless of inventorship, that is a
modification or improvement made to the RNA Technology or RNA Process Technology and (a) would also be applicable to one or more candidates or products in addition to or other than the Candidates or Products (b) is not predominantly
directed to the Pfizer Technology and (c) could have reasonably been developed without the aid, use or application of Pfizer Materials, Pfizer Improvements or Pfizer’s Confidential Information or any improvements or enhancements thereto.

 1.8. “BioNTech Know-How” means [***]. 

1.9. “BioNTech Materials” means any tangible materials (but not information about or contained in such materials) owned or
Controlled by BioNTech that relate to or embody the BioNTech Know-How or BioNTech Patent Rights. 

  
 2 

 1.10. “BioNTech Patent Right” means any Patent Right (other than Pfizer
Patent Rights or Patent Rights jointly owned by BioNTech and Pfizer pursuant to Section 10.2) in any form and whether pending or issued that (a) is Controlled by BioNTech or any of its Affiliates as of the Effective Date or comes into the
Control of BioNTech or any of its Affiliates during the Term (other than, in either case, through the grant of a license by Pfizer) and (b) claims any BioNTech Know-How. 

1.11. “BioNTech Technology” means the BioNTech Patent Rights, BioNTech Materials, BioNTech
Know-How. For avoidance of doubt, BioNTech Technology includes all Intellectual Property Rights Controlled by BioNTech pursuant to the Fosun Agreement. 

1.12. “BioNTech Territory Exit Option” is defined in Schedule 4.1. 

1.13. “BioNTech Third Party Agreement” means any agreement between BioNTech (or any of its Affiliates) and any Third Party
(such Third Party, a “Third Party Licensor”) that (a) relates to any of the BioNTech Technology or Research and Development Program Technology, or (b) otherwise grants a license or otherwise transfers any right to practice
under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. For clarity, all Current Licenses shall be deemed BioNTech Third Party Agreements
hereunder and all Current Licensors shall be deemed Third Party Licensors hereunder. 
 1.14. “Biologics License
Application” or “BLA” means an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce, or any similar application or submission for marketing
authorization of a product filed with a Regulatory Authority to obtain Regulatory Approval for such product in a country or group of countries. 

1.15. “Biosimilar Notice” means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. § 262(k)
of the Public Health Service Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biopharmaceutical product, which application identifies a Product as the Reference Product with
respect to such product, and other information that describes the process or processes used to manufacture the biopharmaceutical product. 

1.16. “Business Day” means a day other than a Saturday, Sunday or bank or other public holiday in New York, New York, USA or
Mainz, Germany. 
 1.17. “Candidate” means an immunogenic composition in the Field that comprises Unmodified RNA
Technology, Modified RNA Technology or Replicon Technology that (a) is Developed pursuant to the Research and Development Plan, (b) is Controlled by BioNTech as of the Effective Date or from time to time during the Term or (c) subject
to Section 4.1, is Exploited by any of the Parties or their Affiliates pursuant to this Agreement, the Commercialization Terms and the Commercialization Agreement. Those Candidates Controlled by BioNTech and existing as of the Effective Date
are set forth in Schedule 1.17. 
 1.18. “Calendar Quarter” means the respective periods of three consecutive
calendar months ending on March 31, June 30, September 30 and December 31. 
 1.19. “Calendar Year” means
any twelve (12) month period beginning on January 1 and ending on the next subsequent December 31. 
 1.20. “Capex
Costs” means any capital expenditure costs associated with (a) the Research and Development Program or (b) the build-out, establishment, construction, expansion or investment in any
Manufacturing facilities. 

  
 3 

 1.21. “Change of Control” means, with respect to a Party (a) the
acquisition of beneficial ownership, directly or indirectly, by any Person (other than such Party or an Affiliate of such Party, and other than by virtue of obtaining irrevocable proxies) of securities or other voting interest of such Party
representing of the combined voting power of such Party’s then outstanding securities or other voting interests, (b) any merger, reorganization, consolidation or business combination involving such Party with a Third Party that results in
the holders of beneficial ownership (other than by virtue of obtaining irrevocable proxies) of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately prior to such merger,
reorganization, consolidation or business combination ceasing to hold beneficial ownership of at least 50% of the combined voting power of the surviving entity immediately after such merger, reorganization, consolidation or business combination,
(c) any sale, lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of such Party to which this Agreement relates, other than a sale or disposition of
such assets to an Affiliate of such Party or (d) the approval of any plan or proposal for the liquidation or dissolution of such Party (other than in circumstances where such Party is deemed a Debtor pursuant to Section 13.7). 

1.22. “Clinical Trial” means a human clinical study conducted on sufficient numbers of human subjects that is designed to
(a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its intended use, and to define warnings, precautions and adverse reactions
that may be associated with the pharmaceutical product in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical product. Without limiting the foregoing,
Clinical Trial includes any Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial or other expedited clinical trial conducted by or on behalf of one or both Parties in connection with this Agreement. 

1.23. “Combination Product” means a product comprising a Candidate or Product in combination with one or more other
therapeutically active ingredients (which includes any prophylactic activity) that are co-formulated as part of the same dosage form or packaged and administered to patient together. For the avoidance of
doubt, adjuvants, including molecular adjuvants, are not considered therapeutically active ingredients for the purposes of this definition regardless of whether or not such adjuvant is packaged together with a Candidate or Product but in a separate
container. 
 1.24. “Commercialization Agreement” means the definitive agreement pursuant to which (i) Pfizer shall be
licensed to Commercialize the Product on the Commercialization Terms and (ii) BioNTech shall retain and have rights to Commercialize the Product in the BioNTech Commercialization Territory; such agreement to be entered into between the Parties
in accordance with the provisions of Section 4 and Schedule 4.1. 
 1.25. “Commercialize” or
“Commercializing” means to market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported or otherwise commercialize a compound or product. When used as a noun,
“Commercialization” and “Commercialized” means any and all activities involved in Commercializing. 
 1.26.
“Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to
accomplish a similar objective under similar circumstances, in particular taking into account the then-current urgency of the COVID-19 crisis. With respect to any efforts relating to the Development,
Regulatory Approval or Commercialization of a Candidate or Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially Reasonable Efforts if such Party has exercised
those efforts normally used by such Party having regard to the circumstances, in the relevant country, with respect to a compound or protein, product 

  
 4 

 
or product candidate, as applicable (a) of similar modality Controlled by such Party, (b) to which such Party has similar rights, (c) which is of similar market potential in such
country, and (d) which is at a similar stage in its development or product life cycle, as any Candidate or Product, in each case, taking into account all Relevant Factors in effect at the time such efforts are to be expended. Further, to the
extent that the performance of a Party’s obligations hereunder is adversely affected by the other Party’s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining
whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations. 
 1.27. “Compassionate
Use Purposes” means, with respect to the Product, providing Product under compassionate or emergency use or expanded access programs, including pursuant to an emergency use authorization granted by a Governmental Authority or Regulatory
Authority, or in jurisdictions or to vulnerable populations experiencing emergency pandemic, or crisis epidemic, coronavirus conditions. 

1.28. “Competitive Product” means a pharmaceutical product that incorporates an immunogenic composition comprising RNA in the
Field that is intended to be, has been, or is being Exploited by a Third Party. For avoidance of doubt, Competitive Product does not include Product (a) Commercialized by or on behalf of BioNTech in the BioNTech Commercialization Territory
pursuant to this Agreement or the Commercialization Agreement, as applicable; or (b) Commercialized outside of the Territory in accordance with the terms of the Fosun Agreement. 

1.29. “Compliance” means the adherence by the Parties in all material respects to all applicable Laws and Party Specific
Regulations, in each case with respect to the activities to be conducted under this Agreement. 
 1.30. “Confidential
Information” means, with respect to each Party, all Know-How or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s
or its Representatives’ technology, products, business information or objectives, that is communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, on or after the Effective Date, but only to the
extent that: (a) such Know-How or other information in written form is marked in writing as “confidential” at the time of disclosure, (b) such
Know-How or other information disclosed orally or in non-tangible form is identified by the Disclosing Party as “confidential” at the time of disclosure or
within 30 days thereafter, or (c) such Know-How or other information (regardless of the form of disclosure) is disclosed in circumstances of confidence or would be understood by the Parties, exercising
reasonable business judgment, to be confidential. Confidential Information does not include any Know-How or other information to the extent the Receiving Party can demonstrate by competent proof that such Know-How or other information (a) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing
Party, (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became generally available to the public or otherwise part of the public domain after its
disclosure to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations under this Agreement, (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by
a Third Party who had no obligation to the Disclosing Party not to disclose such information to the Receiving Party or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential
Information belonging to the Disclosing Party. The terms and conditions of this Agreement will be considered Confidential Information of both Parties. Joint Know-How shall be deemed Confidential Information of
either Party and either Party shall be deemed the Receiving Party in respect of Joint Know-How. 

  
 5 

 1.31. “Control” or “Controlled” means with respect to any
Intellectual Property Right or material (including any Patent Right, Know-How or other data, information or material), the ability (whether by sole, joint or other ownership interest, license or otherwise,
other than pursuant to this Agreement) to, without violating the terms of any agreement with a Third Party, grant a license or sublicense or provide access or other right in as provided in this Agreement, to or under such Intellectual Property Right
or material. 
 1.32. “Conversion Costs” means [***].

1.33. “Copyright” means any copyright which pertains to the promotional materials and literature utilized by Pfizer in
connection with the Commercialization of Products in the Territory. 
 1.34. “Cover”, “Covered” or
“Covering” means, with respect to (a) a given Candidate or Product and Patent Right, that a valid claim of such Patent Right would, absent a license thereunder or ownership thereof, be infringed by the making, sale, offer for
sale or importation of such Candidate or Product and (b) a given Candidate or Product and Know-How, that such Know-How would, absent a license thereunder or
ownership thereof, be misappropriated or misused by the use or making of such Candidate or Product. 
 1.35. “Current Good
Manufacturing Practices” or “cGMP” means all applicable standards and applicable Laws relating to manufacturing practices for products (including ingredients, testing, storage, handling, intermediates) promulgated by the
U.S. Food and Drug Administration and any other governmental authority (including, European Union or member state level and Japan), including, but not limited to, standards in the form of applicable laws, guidelines, advisory opinions and compliance
policy guides, and current interpretations of the applicable authority or agency thereof (as applicable to pharmaceutical and biological products and ingredients), as the same may be updated, supplemented or amended from time to time, in each case
of those jurisdictions in which the products are Manufactured. 
 1.36. “Current Licenses” means any agreement
(a) that BioNTech or its Affiliates has entered into prior to the Effective Date with a Third Party and (b) pursuant to which BioNTech or its Affiliates are (i) granted rights to any BioNTech Technology as of the Effective Date or
(ii) granted a license or otherwise transferred any right to practice under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement.
BioNTech’s Current Licenses are disclosed on Schedule 1.36. 
 1.37. “Current Licensor” means any Third Party
that is a party to a Current License. 

  
 6 

 1.38. “Delivery Technology” means the BioNTech Know-How applicable to formulating nucleic acids to enable the delivery of such nucleic acids to target cells in vivo. For clarity, Delivery Technology does not include [***]. 

1.39. “Develop”, “Developed” or “Developing” means to discover, research or otherwise
develop or improve a process, compound or product, including planning and conducting non-clinical and clinical research and development activities prior to Regulatory Approval or any research or development
conducted after receipt of Regulatory Approval, including those required by any Regulatory Authority to maintain any Regulatory Approval. When used as a noun, “Development” means any and all activities involved in Developing. 

1.40. “Developing Countries Territory” means, to the extent BioNTech or any of its Affiliates receive Third Party funding
from [***] to fund Development or Manufacturing of the Candidates or Products pursuant to this Agreement, those countries listed in Schedule 1.40 which are also defined in the relevant funding documents as “Developing Countries”;
provided that if prior to the execution of such funding documents, the price of any medicinal product (including the Product) in any country within Schedule 1.40 is made relevant as a reference price for the sale of the Product in any
country outside of the countries listed within Schedule 1.40, then such country shall be automatically removed as a country within Schedule 1.40, unless otherwise mutually agreed in writing by the Parties. 

1.41. “Development Budget” means the budget to be agreed and updated by the JSC for all activities, costs and expenses that
are to be funded as Shared Development Costs, and which initial budget for the first [***] of this Agreement is to be agreed between the Parties in accordance with Section 2.2. 

1.42. “EMA” means the European Medicines Agency or any successor agency thereto. 

1.43. “Expedited Trial Pathway” means a Clinical Trial protocol or pathway recognized or authorized by any Regulatory
Authority for the emergency or expedited approval of medicines for human use, as opposed to a traditional Clinical Trial. 
 1.44.
“Exploit” means to Develop, Manufacture, Commercialize, use or otherwise exploit. Cognates of the word “Exploit” will have correlative meanings. 

1.45. “FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations
promulgated thereunder. 
 1.46. “FDA” means the United States Food and Drug Administration or any successor agency
thereto. 
 1.47. “Field” means immunogenic compositions comprising RNA encoding a SARS-CoV-2 polypeptide or fragment thereof, including naturally occurring or engineered variants thereof, for prophylaxis against COVID-19 in humans. 

1.48. “Flu Collaboration License” means the separate research collaboration and license agreement between, inter alia, the
Parties for the development and commercialization of immunogenic compositions comprising RNA that encodes at least one Antigen for prophylaxis against influenza in humans dated July 20, 2018, as amended. 

  
 7 

 1.49. “Fosun” means Shanghai Fosun Pharmaceutical Industrial Development,
Co. Ltd, a company incorporated in China, and having a place of business at No. 1289 Yishan Road, Shanghai, China. 
 1.50.
“Fosun Agreement” means the Development and License Agreement concluded between BioNTech and Fosun on March 13, 2020. 

1.51. “Funding Event” means (a) the BioNTech Deferred Development Costs have been repaid in full (other than solely
through the payment of the Regulatory Approval Milestone in the event that the then-current Development Budget contemplates the expenditure of additional funds for the continued Development of the Product); (b) a Change of Control of BioNTech; or
(c) the date notice is served by either Party to terminate this Agreement in accordance with Section 13. 
 1.52. “Future
License” means an agreement approved by the Parties (a) that BioNTech or its Affiliates enters into on or after the Effective Date with a Third Party or (b) that Pfizer or its Affiliates enters into on or after the Effective Date;
which in the case of (a) and (b) grants a license (sublicensable in accordance with the licenses granted hereunder) to that Third Party’s (“Future Licensor”) Patent Rights for the Commercialization of the Candidates or
Products by BioNTech and Pfizer in the Field, and which license is applicable to the Candidates or Products and is necessary to avoid, overcome or settle any potential or actual infringement of those Third Party Patent Rights. 

1.53. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.54. “GEIA” means the German Employee Invention Act. 

1.55. “GEIA Technology” means all BioNTech Technology and Research and Development Program Technology invented by employees
of BioNTech or its Affiliates (solely or jointly with employees of Third Parties) under the jurisdiction of GEIA. 
 1.56.
“Government” or “Governmental Authority” is to be broadly interpreted and includes (a) any national, federal, state, local, regional or foreign government, or level, branch, or subdivision thereof; (b) any
multinational or public international organization or authority; (c) any ministry, department, bureau, division, authority, agency, commission, or body entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory, or taxing authority or power; (d) any court, tribunal, or governmental arbitrator or arbitral body; (e) any government-owned or controlled institution or entity; (f) any enterprise or instrumentality performing a
governmental function; and (g) any political party. 
 1.57. “Government Official”, to be broadly interpreted, means
(a) any elected or appointed government official (e.g., a member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental
function, (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political party or candidate for public office, (d) any member of a military or a royal or ruling family, and
(e) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity, healthcare providers employed by Government-owned or -controlled hospitals, or a person serving on a healthcare
committee that advises a Government, will be considered Government Officials. 
 1.58. “Gross Profit” means [***]. 

  
 8 

 1.59. “GxP” means, collectively, all relevant good practice quality
guidelines and regulations, encompassing such internationally recognized standards as Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Distribution Practice (GDP), and Good Review Practice (GRP).

 1.60. “HCP” or “Healthcare Professional” includes any physician, nurse, pharmacist, or other person who
may administer, prescribe, purchase or recommend pharmaceutical products or other healthcare products. 
 1.61. “Human
Material” means any biological samples of one or more Subjects collected, provided or utilized by BioNTech during the Research and Development Plan pursuant to this Agreement. 

1.62. “ICF” means an informed consent form that was approved by a qualified Institutional Review Board or Independent Ethics
Committee (“IRB / IEC”) in accordance with all applicable Laws and recognized international standards for the protection of human research subjects. 

1.63. “IFRS” means International Financing Reporting Standards, as in effect from time to time, together with its pronouncements
thereon from time to time, consistently applied. 
 1.64. “IND” means an Investigational New Drug Application submitted
under the FD&C Act, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct Clinical Trials. 

1.65. “Intellectual Property Rights” means any and all (a) Patent Rights, (b) proprietary rights in Know-How, including trade secret rights, (c) proprietary rights associated with works of authorship and software, including copyrights, moral rights, and copyrightable works, and all applications,
registrations, and renewals relating thereto, and derivative works thereof, (d) other forms of proprietary or intellectual property rights however denominated throughout the world, other than trademarks, service marks, trade names, domain names
and other indicators of origin. 
 1.66. “Joint Steering Committee” or “JSC” means the steering committee
described in Section 7.3.1. 
 1.67. “Joint Know-How” means any Research and
Development Program Know-How, whether or not patentable, made or created jointly by (a) BioNTech or any of its Representatives and (b) Pfizer or any of its Representatives, which does not constitute
BioNTech Know-How, Product Know-How or Pfizer Know-How. 

1.68. “Joint Patent Rights” means Research and Development Program Patent Rights that claim or disclose any invention
included in Joint Know-How. 
 1.69. “Joint Technology” means the Joint Know-How and the Joint Patent Rights. 
 1.70.
“Know-How” means any proprietary invention, discovery, development, data, information, process, method, technique, technology, result, cell line, cell, antibody or other protein, compound,
probe, nucleic acid, (including RNAi) or other sequences or other know-how, whether or not patentable, and any physical embodiments of any of the foregoing or any information contained in any of the foregoing.

  
 9 

 1.71. “Law” means any law, statute, rule, regulation, order, judgment or
ordinance of any Governmental Authority, including all applicable Anti-Corruption Laws, accounting and recordkeeping laws, and laws relating to interactions with HCPs and Government Officials. For the avoidance of doubt, any specific references to
any applicable Law or any portion thereof shall be deemed to include all then-current amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, promulgation, order, writ, judgment,
injunction, decree, stipulation, ruling or determination thereto. 
 1.72. “MA Holder” means, on a country by country basis
within the Territory, the Party (or its Affiliate or designee under its control) that holds the Regulatory Approval required for the Commercialization of the Product in such country. 

1.73. “Major EU Market Country” means any of France, Germany, Italy, Spain or the United Kingdom. 

1.74. “Major Market Country” means the Major EU Market Countries, the United States and Japan. 

1.75. “Manufacture” or “Manufacturing” means to make, produce, manufacture, process, fill, finish, package,
label, perform quality assurance testing, release, ship or store, and for the purposes of further Manufacturing, distribute, import or export, a compound or product or any component thereof. When used as a noun, “Manufacture”,
“Manufactured” or “Manufacturing” means any and all activities involved in Manufacturing a compound or protein, device or product or any component thereof. 

1.76. “Manufacturing Costs” means [***]. 

1.77. “Manufacturing Plan” means the plan for establishing Manufacturing and the Manufacturing facilities, as well as the
Manufacturing obligations of each Party, in respect of the Candidates and Products, as such plan may be updated and modified from time to time with the unanimous consent of the JSC, and which initial plan for the first [***] of this Agreement is to
be agreed between the Parties in accordance with Section 2.2. 

  
 10 

 1.78. “Manufacturing Variances” means [***]. 

1.79. “Materials” means the Pfizer Materials or the BioNTech Materials, as the context requires. 

1.80. “Modified RNA” means an mRNA that has been modified by the incorporation of one or more modified nucleosides, excluding
the 5’ CAP. 
 1.81. “Modified RNA Technology” means the BioNTech Know-How
applicable to Modified RNA. For clarity, Modified RNA Technology does not include [***]. 
 1.82. “Mutation” means [***].

 1.83. “Net Sales” means with respect to a Product [***]. 

[***] 

  
 11 

 [***] 

1.84. “Patent Rights” means any and all (a) issued patents, (b) pending patent applications, including all
provisional applications, non-provisional applications, substitutions, continuations, continuations-in-part, divisions and
renewals, applications sharing a priority claim and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by
existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, (e) other forms of
government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing. 

1.85. “Party Specific Regulations” means all non-monetary judgments, decrees, orders
or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the
same may be in effect from time to time and applicable to a Party’s activities contemplated by this Agreement.  
 1.86.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint
venture or similar entity or organization, including a government or political subdivision or department or agency of a government. 
 1.87.
“Personal Data” means any information relating to an identified or identifiable natural person as further specified in Art. 4 no. 1 of the GDPR. 

1.88. “Pfizer Commercialization Territory” means the Territory, except for countries within the BioNTech Commercialization
Territory from time to time. 
 1.89. “Pfizer Exit Countries” means, on a country by country basis, those countries out of
the United Arab Emirates and South-East Asia where Pfizer elects, pursuant to the Commercialization Terms or Commercialization Agreement, not to Commercialize the Product pursuant to any Pfizer Exit Option. 

1.90. “Pfizer Improvements” means any Research and Development Program Technology, regardless of inventorship, that is a
modification or improvement to the Pfizer Technology and (a) would also be applicable to one or more candidates or products in addition to or other than the Candidates or Products, (b) is not predominantly directed to the Candidates or
Products or the RNA Technology or RNA Process Technology and (c) could have reasonably been developed without the aid, use or application of BioNTech Materials, BioNTech Know-How or BioNTech’s
Confidential Information or any improvements or enhancements thereto. 
 1.91. “Pfizer
Know-How” means [***] 

  
 12 

 
[***] 
 1.92. “Pfizer Patent Right” means any Patent Right (other
than Patent Rights jointly owned by BioNTech and Pfizer pursuant to Section 10.2) in any form and whether pending or issued that (a) is Controlled by Pfizer or any of its Affiliates on the Effective Date or that comes into the Control of
Pfizer or any of its Affiliates during the Term (other than, in either case, through the grant of a license by BioNTech), and (b) claims any Pfizer Know-How. 

1.93. “Pfizer Quarter” means each of the four (4) thirteen (13) week periods (a) with respect to the United States,
commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. Wherever non-country
specific timelines are specified in this Agreement in reference to a Pfizer Quarter, such reference shall be deemed to be made to the Pfizer Year applicable in the United States. 

1.94. “Pfizer Technology” means the Pfizer Patent Rights, Pfizer Materials and Pfizer
Know-How. 
 1.95. “Pfizer Year” means the twelve (12) month fiscal periods
observed by Pfizer (a) commencing on January 1 with respect to the USA; and (b) commencing on December 1 with respect to any country in the Territory other than the USA. 

1.96. “Phase I Clinical Trial” means a Clinical Trial that generally provides for the first introduction into humans of a
pharmaceutical product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product, in a manner that is generally consistent with 21 CFR § 312.21(a), as amended (or its
successor regulation), provided, however, a Phase I Clinical Trial does not include any study generally characterized by the FDA as an “exploratory IND study” in CDER’s Guidance for Industry, Investigators, and Reviewers Exploratory
IND Studies, January 2006, irrespective of whether or not such study is actually performed in the United States or under an IND. A so-called Phase I/II Clinical Trial shall be deemed to be a Phase I Clinical
Trial unless such trial, when completed, allows Pfizer to proceed directly to a Phase III Clinical Trial. 
 1.97. “Phase II
Clinical Trial” means a Clinical Trial, the principal purpose of which is to make a preliminary determination as to whether a pharmaceutical product is safe for it intended use and to obtain sufficient information about such product’s
efficacy, in a manner that is generally consistent with 21 CFR § 312.21(b), as amended (or its successor regulation), to permit the design of further Clinical Trials. 

1.98. “Phase III Clinical Trial” means a pivotal Clinical Trial with a defined dose or a set of defined doses of a
pharmaceutical product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR § 312.21(c), as amended (or its successor regulation), for the purpose of enabling the preparation and
submission of an NDA. 
 1.99. “Price Approval” means, in any country where a Governmental Authority authorizes
reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or
determination (as the case may be). 
 1.100. “Product” means any pharmaceutical product in a formulation suitable for
administration to humans that [***]. 

  
 13 

 1.101. “Product Know-How” means any
Research and Development Program Know-How that is predominantly directed to the composition of matter, treatment with, or the delivery of, Manufacture, form, formulation, or use of a Candidate or Product in
the Field and is not generally applicable to compositions or products in addition to or other than a Candidate or Product. 
 1.102.
“Product Materials” means all raw materials (including, without limitation, active pharmaceutical ingredients and excipients, vectors, plasmids and mRNA), labeling or packaging materials and components needed for the Manufacture and
supply of a given Candidate or Product. 
 1.103. “Product Patent Rights” means any Patent Right that claims any invention
included in Product Know-How. 
 1.104. “Product Technology” means the Product Know-How and Product Patent Rights. 
 1.105. “Public Health Service Act” or “PHS
Act” means the United States Public Health Service Act (42 U.S.C. 201 et seq), as amended from time to time (including any rules and regulations promulgated thereunder) or any subsequent or superseding law, statute or regulation.

 1.106. “RNA” means ribonucleic acid. 

1.107. “RNA Process Technology” means the BioNTech Know-How used to Manufacture
Candidates or Products. 
 1.108. “RNA Technology” means Replicon Technology, Unmodified RNA Technology, Modified RNA
Technology and Delivery Technology that is, in each case, used by BioNTech in the Research and Development Program 
 1.109.
“Regulatory Approval” means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of INDs, NDAs, BLAs, supplements and amendments,
pre- and post- approvals and labeling approvals) of any Regulatory Authority, necessary or useful for the use, Development, Manufacture, and Commercialization of a pharmaceutical or biopharmaceutical product
in a regulatory jurisdiction, including commercially reasonable Price Approvals and commercially reasonable Third Party reimbursement approvals. 

1.110. “Regulatory Authority” means, with respect to a country in the Territory, any national (e.g., the FDA), supra-national
(e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in the granting of a
Regulatory Approval or, to the extent required in such country, Price Approval, for pharmaceutical products in such country. 
 1.111.
“Relevant Factors” means all relevant factors that may affect the Development, Regulatory Approval or Commercialization of a Candidate or Product, including (as applicable): [***] 

  
 14 

 [***] 

1.112. “Replicon” means an RNA molecule(s) that comprises a gene encoding a polymerase that can, when the RNA molecule(s) is
introduced into a cell, replicate the same or a different RNA molecule(s), that also comprises a gene or a sequence encoding at least one non-human polypeptide that is capable of eliciting an immune response
(an “Antigen”) and does not comprise the full set of genes required to make an infectious virus and is capable, when introduced into a cell, of expressing detectable levels of the encoded Antigen. 

1.113. “Replicon Product” means any Product comprising Replicon Technology. 

1.114. “Replicon Technology” means the BioNTech Know-How applicable to Replicons. For
clarity, Replicon Technology does not include Modified RNA Technology, Unmodified RNA Technology or Delivery Technology. 
 1.115.
“Representatives” means (a) with respect to Pfizer, Pfizer, its Affiliates, its Sublicensees and subcontractors, and each of their respective officers, directors, employees, consultants, contractors and agents and (b) with
respect to BioNTech, BioNTech, its Affiliates, its Sublicensees and subcontractors, and each of their respective officers, directors, employees, consultants, contractors and agents. 

1.116. “Research and Development Plan” means the research and development plan to define the Development activities pursuant
to the collaboration anticipated under this Agreement, which plan is initially to be agreed between the Parties in accordance with Section 2.2 for the first [***] of activities under this Agreement, and as may be amended from time to time
pursuant to Section 6.1. 
 1.117. “Research and Development Program” means the program of collaboration between the
Parties to Develop and Manufacture Candidates and Products in the Field, including the activities described in the Research and Development Plan. 

1.118. “Research and Development Program Know-How” means any and all Know-How, Candidates and Products, whether or not patentable, made or created solely by or on behalf of either Party or its Representatives in the conduct of activities under the Research and Development Plan or
made jointly by or on behalf of (a) BioNTech or its Representatives and (b) Pfizer or its Representatives in the conduct of activities under the Research and Development Plan. 

1.119. “Research and Development Program Patent Rights” means any and all Patent Rights claiming or disclosing any invention
included in Research and Development Program Know-How. 
 1.120. “Research and Development
Program Technology” means the Research and Development Program Patent Rights and Research and Development Program Know-How. 

1.121. “Residual Knowledge” means knowledge, techniques, experience and Know-How that
(a) are, or are based on, any Confidential Information of the Disclosing Party and (b) are retained in the unaided memory of any authorized Representative of the Receiving Party after having access to such Confidential Information. An
individual’s memory will be considered to be unaided if the individual has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it. 

  
 15 

 1.122. “Shared Development Cost” means [***]. 

1.123. “Signing Date” means April 9, 2020. 

1.124. “South-East Asia” means [***]. 

1.125. “Subject” means the individual donor of the Human Material or of the original tissues from which the Human Material
was derived. 
 1.126. “Sublicensee” means any Person to whom a Party grants or has granted, directly or indirectly, a
license or sublicense of any of the same Intellectual Property Rights licensed to such Party by the other Party under this Agreement in accordance with Section 3.6. For the avoidance of doubt, distributors used by a Party to Commercialize
Product in a country or region shall not be regarded a Sublicensees. 
 1.127. “Tax” means all corporation tax, advance
corporation tax, income tax, capital gains tax, value added tax, customs and other import duties, inheritance tax, purchase tax, capital duties, social insurance contributions, foreign taxation and duties and all penalties, charges and interest
relating to any of the foregoing or resulting from a failure to comply with the provisions of any enactment relating to any of the foregoing. 

1.128. “Territory” means worldwide, except for the People’s Republic of China (including Hong Kong SAR and Macau SAR)
and Taiwan. 
 1.129. “Third Party” means any Person other than Pfizer, BioNTech or their respective Affiliates. 

1.130. “Third Party License Payment” shall mean a payment due to a Third Party Licensor or Future Licensor pursuant to a
Current License or Future License, as applicable, that is [***]. For the avoidance of doubt, [***] 

  
 16 

 [***]. 

1.131. “Trademark” means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan
or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. 
 1.132.
“Transfer Price” shall mean [***] of the Manufacturing Cost of such Candidate or Product, subject to any different percentage between [***] as determined by the JCC, to be applied for Products to be supplied to the Developing
Countries Territory or to take account of any supply requirements of any Governmental Authority within the Territory or pursuant to the terms and conditions of any funding agreement with a Third Party Funder. 

1.133. “Unmodified RNA” means an mRNA that [***]. 

1.134. “Unmodified RNA Technology” means the BioNTech Know-How applicable to
Unmodified RNA. For clarity, Unmodified RNA Technology does not include Replicon Technology, Modified RNA Technology or Delivery Technology. 

1.135. “UPC Agreement” means the treaty Agreement on the Unified Patent Court signed 19 February 2013, as may be amended
or superseded from time. 
 1.136. The following terms are defined in the section of this Agreement listed opposite each term: 

 

			
	Defined Term	  	Section in Agreement
	Acquirer	  	14.2.2
	Acquisition Program	  	14.1.1
	Additional Patent Jurisdictions	  	10.3.1.1
	Affected Party	  	14.1
	Agreement	  	Preamble
	Alliance Managers	  	7.1
	 Audited Party
 Auditing Party
	  	 5.10
 5.10

	BARDA	  	5.5.1
	 BioNTech
 BioNTech Deferred Development
Costs
	  	 Preamble
 5.4.2

	BioNTech Enforcement Patent Rights	  	10.4.2
	BioNTech Indemnified Party	  	15.2
	BioNTech JSC Members	  	7.3.1
	BioNTech Prosecution Patent Rights	  	10.3.1.1
	Capex Funding	  	5.5.1

  
 17 

			
	Defined Term	  	Section in Agreement
	Change of Control Party	  	11.7
	Commercialization Terms	  	4.1
	Consequential Damages	  	15.1
	Competitive Product Infringement	  	10.4.3
	Continuing Party	  	10.3.2
	Cure Plan	  	3.7.3
	Debtor	  	13.7.1
	Declining Party	  	10.3.2
	Disputed Matter	  	7.3.5
	Disclosing Party	  	11.1
	Enforcement Action	  	10.4.1
	Effective Date	  	Preamble
	Equity Investment	  	5.2
	Force Majeure	  	16.3
	FTO Action	  	10.7.1
	Global Trade Control Laws	  	16.10
	Impf Group	  	1.1
	Incremental Withholding Tax	  	5.7.1
	Indemnified Party	  	15.4.1
	Indemnifying Party	  	15.4.1
	Infringement Claim	  	10.8
	IRB / IEC	  	1.62
	JSC Chair	  	7.3.2
	Key Patent Jurisdictions	  	10.3.1.1
	Lead Development Party	  	9.1.1
	Lead Party	  	5.5.1
	Liabilities	  	15.2
	Licensed Activities	  	10.7.1
	Litigation Conditions	  	15.4.2
	Marketing Authorization Applications	  	9.2.2
	Notice of Dispute	  	16.11.1
	Party or Parties	  	Preamble
	Patent Committee	  	10.1
	Patent Term Extension	  	10.3.4
	Pfizer	  	Preamble
	Pfizer Indemnified Party	  	15.3
	Pfizer JSC Members	  	7.3.1
	Pfizer Materials	  	7.4.1
	Pharmacovigilance Agreement	  	9.2.7
	Prosecution Proceedings	  	10.3.5
	Policies	  	12.3.20
	Program Director and Program Directors	  	7.2
	Reference Product Sponsor	  	10.4.6.2
	Receiving Party	  	11.1
	Regulatory Approval Milestone	  	5.3
	Restricted Market	  	16.10.1
	Restricted Parties	  	16.10.2
	Restricted Party List	  	16.10.2
	Review Period	  	11.5.2
	ROW	  	9.1.1

  
 18 

			
	Defined Term	  	Section in Agreement
	Term	  	13.2
	Third Party Claim	  	15.4.1
	Third Party Funder	  	5.5.1
	Third Party Licensor	  	1.12
	Upfront Payment	  	5.1
	VAT	  	5.7.2
	Withholding Tax	  	5.7.1

  

	2.	 SCOPE OF COLLABORATION 

2.1. Scope of Collaboration. Subject to the terms and conditions of this Agreement, the Parties shall (a) cooperate in good faith
to conduct their respective activities under the Agreement; and (b) establish one or more committees as described in Article 7 of this Agreement to oversee and coordinate the Development, Manufacture and Commercialization of Candidates and
Products in the Territory. 
 2.2. Initial Research and Development Plan and Manufacturing Plan. Commencing on the Signing Date each
Party shall, acting reasonably and in good faith, negotiate and seek to agree binding versions of the Research and Development Plan, Development Budget and the Manufacturing Plan, which shall be agreed by [***]. The Research and Development Plan to
be agreed shall reflect the requirements described in Sections 6.1 and 6.2. 
  

	3.	 LICENSES. 

3.1. Research Licenses. 

3.1.1. Research License from BioNTech to Pfizer. Subject to the terms and conditions of this Agreement, effective as of
the Effective Date, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer a sole license under the BioNTech Technology to use, have used, Develop, have Developed, Manufacture, and
have Manufactured [***] Candidates and Products within the Territory [***]. 
 3.1.2. Research License from Pfizer to
BioNTech. Subject to the terms and conditions of this Agreement, effective as of the Effective Date, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a sole license under the
Pfizer Technology to use, have used, Develop, have Developed, Manufacture, and have Manufactured [***] (a) Candidates and Products and within the Territory [***], and (b) Candidates or products identical to any Product within the Field for
their Development (but not Manufacture) outside the Territory by or on behalf of BioNTech (including by Fosun or its Affiliates) pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) exclude and prohibit the
disclosure and license by BioNTech of Pfizer Technology used for Manufacture or formulation of the Candidate or Products, other than to the extent necessary for Fosun or its Affiliates to undertake fill/finish of a product identical to any Product
in China or to comply with information requirements of the China National Medical Products Administration relating to such product required under applicable Law; and (ii) automatically terminate on the termination or expiration of the Fosun
Agreement and will, unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section 13. 

  
 19 

 3.1.3. Scope of Research Licenses. Each of the licenses granted under
Section 3.1.1 and 3.1.2 is (a) a sole license, such that the applicable licensor Party shall not grant a Third Party (unless it is necessary for the Third Party undertaking a
fee-for-service Development or Manufacturing activity on its behalf pursuant to this Agreement) a license under the same Intellectual Property Rights for any
Exploitation within the Field and within the Territory in respect of any product, whether or not it is a Candidate or Product; (b) royalty-free; (c) sub-licensable in accordance with and subject to
Section 3.6; (d) non-assignable, in whole or part, other than where a Party’s benefit under this Agreement may be assigned pursuant to Section 16.1; and (e) granted subject to the
provisions of this Agreement, and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless otherwise specified herein. 

3.2. Licenses for Commercial Manufacturing. 

3.2.1. License from BioNTech to Pfizer. Subject to the terms and conditions of this Agreement, effective as of the
Effective Date, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive license under the BioNTech Technology to Manufacture and
have Manufactured Candidates and Products for use within the Territory and, subject to Section 3.4, Commercialization within the Territory in any indication. 

3.2.2. License from Pfizer to BioNTech. Subject to the terms and conditions of this Agreement, effective as of the
Effective Date, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a non-exclusive license under the Pfizer Technology to Manufacture and have
Manufactured (a) Candidates and Products for Commercialization within the Territory in accordance with Section 3.4 in any indication and (b) Candidates and products identical to any Product within the Field for their use and
Commercialization outside the Territory by BioNTech or Fosun and its Affiliates pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) exclude and prohibit the disclosure and license by BioNTech of Pfizer
Technology used for Manufacture or formulation of the Candidate or Product, other than to the extent necessary for Fosun or its Affiliates to (x) undertake fill/finish of a product identical to any Product in China or (y) comply with
information requirements of the China National Medical Products Administration relating to such product required under applicable Law; and (ii) shall automatically terminate on the termination or expiration of the Fosun Agreement and will,
unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section 13. 

3.2.3. Scope of Commercial Manufacturing Licenses. Each of the licenses granted under Section 3.2.1 and 3.2.2 is
(a) royalty-free; (b) sub-licensable in accordance with and subject to Section 3.6; (c) non-assignable, in whole or part, other than where a Party’s
benefit under this Agreement may be assigned pursuant to Section 16.1; and (d) granted subject to the provisions of this Agreement, and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless
otherwise specified herein. 

  
 20 

 3.3. Regulatory Dossier Licenses. 

3.3.1. License from BioNTech to Pfizer. Effective as of the Effective Date, in respect of the Drug Master Files,
Regulatory Approvals and Regulatory Documentation (as defined in the Fosun Agreement), BioNTech hereby grants to Pfizer a sole license to rely upon and make reference to such Drug Master Files, Regulatory Approvals and Regulatory Documentation (and
the data referenced therein), to use the same in respect of any application for, and maintaining, any Regulatory Approvals (as defined in this Agreement) filed by Pfizer pursuant to this Agreement in respect of Candidates or Products. The
license granted under this Section 3.3.1 is (a) royalty-free; (b) sub-licensable in accordance with and subject to Section 3.6; (c)
non-assignable, in whole or part, other than where a Party’s benefit under this Agreement may be assigned pursuant to Section 16.1; and (d) granted subject to the provisions of this Agreement,
and for the duration of the Term or until termination or expiry of this Agreement if earlier, unless otherwise specified herein. BioNTech shall procure disclosure of such Drug Master Files, Regulatory Approvals and Regulatory Documentation upon
Pfizer’s request. Without limiting any of the foregoing, but subject to Section 3.10, BioNTech shall be permitted to use such Drug Master Files, Regulatory Approvals and Regulatory Documentation (to the extent not comprising Pfizer’s
Technology or Pfizer’s Confidential Information) with respect to any application for or maintenance of any Regulatory Approvals outside the Field. 

3.4. Commercialization Licenses. 

3.4.1. License from BioNTech to Pfizer. Subject to the terms and conditions of this Agreement, and the terms of Schedule
4.1 until the Parties execute the Commercialization Agreement, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer an exclusive (even as to BioNTech) license under the BioNTech
Technology to Commercialize and have Commercialized Products within the Pfizer Commercialization Territory in any indication. The foregoing license shall be subject to the terms of the Commercialization Agreement once executed. 

3.4.2. License from Pfizer to BioNTech. Subject to the terms and conditions of this Agreement, and the terms of Schedule
4.1 until the Parties execute the Commercialization Agreement, Pfizer on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to BioNTech a license under the Pfizer Technology to Commercialize and have
Commercialized (a) Products within the BioNTech Commercialization Territory in any indication, which license shall be granted on a sole basis; and (b) products identical to any Product within the Field but outside the Territory by BioNTech
or by Fosun or its Affiliates pursuant to the Fosun Agreement. With respect to (b) above, such license shall (i) be sole; (ii) royalty-bearing; (iii) exclude and prohibit the disclosure and license by BioNTech of Pfizer
Technology used for Manufacture or formulation of any Candidate or Product, other than to the extent necessary for Fosun or its Affiliates to (x) undertake fill/finish of a product identical to any Product in China or (y) comply with
information requirements of the China National Medical Products Administration relating to such product required under applicable Law; and (iv) shall automatically terminate on the termination or expiration of the Fosun Agreement and will,
unless earlier terminated, survive the termination or expiration of this Agreement in those circumstances described in Section 13. 

3.4.3. Scope of Commercialization Licenses. Each of the licenses granted under Section 3.4.1 and 3.4.2 is (a) sub-licensable in accordance with and subject to Section 3.6; (b) non-assignable, in whole or part, other than where a Party’s benefit under this Agreement
may be assigned pursuant to Section 16.1; and (c) granted subject to the provisions of this Agreement, the Commercialization Agreement upon its execution, Schedule 4.1 and for the duration of the Term or until termination or expiry of this
Agreement if earlier, unless otherwise specified herein. Furthermore, [***]. 

  
 21 

 3.4.4. Financial Provisions for Commercialization. The license under:

  

	 	3.4.4.1.	 Section 3.4.1 and 3.4.2(a) is royalty-free but each is subject to the Gross Profit share set out in the
Commercialization Terms; and 

  

	 	3.4.4.2.	 Section 3.4.2(b) shall be royalty bearing at a rate of (i) [***] percent of net sales of the
product(s) sold pursuant to the Fosun Agreement where such product(s) is Covered by any Pfizer Patent Right or any Joint Patent Rights (ii) if, or when, (i) does not apply, then [***] percent of net sales of the product(s) sold pursuant to
the Fosun Agreement where such product(s) is Covered by any Pfizer Know-How or any Joint Know-How with net sales having the same definition, mutatis mutandis, to
Net Sales under this Agreement, with sales and royalty reporting every Pfizer Quarter, payments on a Pfizer Quarter basis, and Pfizer having audit rights comparable with those under this Agreement); provided, however, that
(a) during the period in which a generic or biosimilar equivalent to such product(s) is Commercialized in any part of the territory that is the subject of the Fosun Agreement, the royalty under (i) above shall be reduced by [***]; or
(b) if the gross profit share earned by BioNTech in connection with sale of products under the Fosun Agreement is lower than the royalty amount to be paid to Pfizer hereunder in respect of those same sales, then no royalty shall be payable
hereunder for those sales. The foregoing royalty obligations shall commence on the first commercial sale of the product(s) sold pursuant to the Fosun Agreement, and extend (a) with respect to the royalty under (i) for so long as such
product(s) is Covered by any such Patent Rights (until such Patent Right expires, is surrendered, or is otherwise irrevocably revoked or declared invalid), and (b) with respect to the royalty under (ii), the [***] anniversary of the date of the
first commercial sale of such product(s) in the territory that is the subject of the Fosun Agreement; and in each case, such provision shall survive the termination or expiry of this Agreement. 

3.5. Additional Licenses. 

3.5.1. To Pfizer. Without limiting any other license or sublicense granted under this Agreement or the Commercialization
Agreement and subject to the terms and conditions of this Agreement, BioNTech on behalf of itself and its Affiliates, effective as of the Effective Date, hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive, royalty-free, fully paid-up, sublicensable license under all BioNTech Improvements and Product Technology that were solely or jointly made or invented by Pfizer
Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes outside the Field. In addition to the obligations set forth in
Section 3.10 for the avoidance of doubt, the license granted in this Section 3.5.1 shall not include or imply a right of Pfizer to use any of BioNTech’s Confidential Information (that is not a BioNTech Improvement or Product
Technology) outside the Field. 
 3.5.2. To BioNTech. 

 

	 	3.5.2.1.	 Without limiting any other license or sublicense granted under this Agreement or the Commercialization
Agreement and subject to the terms and conditions of this Agreement, Pfizer, effective as of the Effective 

  
 22 

	 	
Date, hereby grants to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable license under
all Pfizer Improvements that were solely or jointly invented by BioNTech Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes
outside the Field. 

  

	 	3.5.2.2.	 Without limiting any other license or sublicense granted under this Agreement or the Commercialization
Agreement and subject to the terms and conditions of this Agreement, Pfizer, effective as of the Effective Date, hereby grants to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable license under Pfizer’s interest in the Research and Development Program Technology to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have
Commercialized and otherwise Exploit any products or processes outside the Field. 

  

	 	3.5.2.3.	 For the avoidance of doubt, the licenses granted in this Section 3.5.2 shall not include or imply a right
of BioNTech to use any Pfizer Confidential Information (that is not a Pfizer Improvement or Research and Development Program Technology) outside the Field, but remain subject to the obligations set forth in Section 3.10. 

3.6. Sublicensees. Either Party shall have the right to grant sublicenses and, as applicable,
sub-sublicenses under and subject to the rights granted to it under this Section 3 to (a) its Affiliates; (b) permitted Third Party subcontractors which such Party uses to undertake services
for, or to perform its obligations under, this Agreement, the Commercialization Terms and the Commercialization Agreement; (c) Sublicensees in respect of Manufacturing, provided that, other than where a sublicense is required by a Governmental
Authority or pursuant to a Third Party Funder agreement, the sublicensing Party shall (i) discuss the proposed use of a Third Party with the other Party, and take into account any reasonable views, objections or comments with respect to the
proposed Third Party; (ii) impose industry standard obligations of confidentiality and non-use on the Third Party with respect to the other Party’s Confidential Information, and limit the disclosure
of that other Party’s Confidential Information so far as is reasonably necessary; and (iii) not, where Pfizer is the sublicensing Party, subcontract Manufacturing of the Product [***] without BioNTech’s prior consent (such consent not
to be unreasonably withheld); and (d) distributors of the Product in the Territory; and (e) in the case of BioNTech, and subject to the restrictions in Sections 3.1, 3.2, and 3.4 and the terms of Section 11, Fosun and any of
Fosun’s Affiliates pursuant to the Fosun Agreement for Commercialization in the Field outside the Territory. In respect of any and all such sublicenses (or sub-sublicenses): 

3.6.1. the sublicensing Party shall be responsible for failure by its Sublicensees to comply with the terms and conditions of
this Agreement; 
 3.6.2. the rights sublicensed under the sublicense may not be further sublicensed by the Sublicensee; 

3.6.3. the sublicensing Party shall notify the other Party in writing of any sublicenses granted to Third Parties (other than
Fosun); 

  
 23 

 3.6.4. in the event of a sublicense in respect of the Commercialization of
Product, shall provide a copy of the relevant sublicense agreement to the other Party upon request which may be redacted to delete provisions not applicable to the calculation of Gross Profits; and 

3.6.5. unless otherwise agreed between the Parties on a
case-by-case basis, all sublicenses shall automatically terminate (and the sublicensing Party shall ensure that all sublicenses automatically terminate) upon termination
(for whatever reason) or expiry of a license granted hereunder, but only to the extent necessary to terminate the sublicense in so far as it corresponds to any terminated or expired licenses granted in this Agreement. 

3.7. BioNTech Current Licenses. 

3.7.1. Maintenance of Current Licenses. BioNTech will maintain in full effect and will perform all of its obligations in
a timely manner under each of the Current Licenses. Absent Pfizer’s prior written consent (which may be provided, conditioned or withheld in Pfizer’s sole discretion), BioNTech will not terminate, modify or amend any Current License in any
manner that would adversely affect any of the rights granted or that may be granted to Pfizer under this Agreement or that would impose any obligations upon Pfizer hereunder (including any increase in Third Party License Payments) that are in
addition to those obligations that would exist under this Agreement based on the Current Licenses as they exist on the Effective Date or adversely affect BioNTech’s ability to perform its obligations under this Agreement. Further, BioNTech will
not take any action or omit to take any action that would cause it to be in breach of any Current License or that would give rise to a right of any Current Licensor to terminate the applicable Current License. 

3.7.2. Communications and Performance. Notwithstanding anything to the contrary in this Agreement, BioNTech will use
Commercially Reasonable Efforts to facilitate any communications between Pfizer and any Current Licensor required for Pfizer to exercise the rights granted to it pursuant to Section 3 and will use Commercially Reasonable Efforts to cause each
applicable Current Licensor to perform all of its obligations under the applicable Current License. 
 3.7.3. Breach of
Current License by BioNTech. If BioNTech receives notification of any actual or potential breach or otherwise becomes aware of its breach of any Current License (and if uncured, such breach could give rise to the termination of the applicable
Current License), then BioNTech will immediately notify Pfizer of such breach. To the extent that any act or omission on the part of Pfizer is the cause of such breach of a Current License, Pfizer will take all actions and provide BioNTech with all
cooperation necessary to cure such breach, in each case as reasonably requested by BioNTech and at Pfizer’s sole cost and expense. To the extent that Pfizer is not the cause of such breach of a Current License, BioNTech will have the first
opportunity to cure such breach in accordance with a plan to be mutually agreed upon by the Parties in writing, acting reasonably (each, a “Cure Plan”). If (a) BioNTech, at any time, is not using diligent efforts to cure such
breach pursuant to the applicable Cure Plan or (b) BioNTech is unable to cure such breach in accordance with the applicable Cure Plan or it becomes reasonably apparent that BioNTech will not be able to cure such breach pursuant to the
applicable Cure Plan, then Pfizer may, at its election and in its sole discretion and without prejudice to its other remedies against BioNTech, act reasonably to cure such breach and BioNTech will take all actions and provide Pfizer with all
cooperation to cure such breach, in each case as directed by Pfizer. Further, if Pfizer is not the cause of such breach of a Current License, then BioNTech will, at Pfizer’s sole election, (i) reimburse Pfizer for all out-of-pocket costs and expenses incurred by or on behalf of Pfizer or any of its Representatives in connection with curing such breach; or (ii) permit Pfizer, under the
Commercialization Agreement, to offset any such costs and expenses incurred by or on behalf of Pfizer or any of Pfizer’s Representatives in connection with curing such breach against Pfizer’s future payment obligations to BioNTech (or any
of its successor or assigns) under this Agreement. 

  
 24 

 3.7.4. Termination of any Current License. In the event that any
Current License is terminated by the applicable Current Licensor and this Agreement, as of the effective date of such termination, has not otherwise been terminated, Pfizer, to the extent permitted by such Current License (or if not permitted or
addressed in such Current License, to the extent permitted by the applicable Current Licensor), will have the right without prejudice to its other remedies against BioNTech, at Pfizer’s election, to convert the sublicenses granted under this
Agreement by BioNTech to Pfizer under such Current License to a direct license from the applicable Current Licensor to Pfizer on the terms and conditions contained in such Current License (with Pfizer assuming the applicable obligations of BioNTech
thereunder) or such other terms and conditions as may be negotiated by Pfizer and the applicable Current Licensor. In the event Pfizer enters into any such direct license with a Current Licensor, BioNTech will, at Pfizer’s sole election and
without prejudice to its other remedies hereunder: 
  

	 	3.7.4.1.	 in respect of royalties payable by Pfizer under such direct license to the Current Licensor, to the extent such
royalties are due in connection with the sale of Candidates or Products hereunder, reimburse to Pfizer the difference between (a) the amount that would have been payable by BioNTech to the Current Licensor under the Current License if the
Current License had not been terminated and (b) the amount that would have to be reimbursed by Pfizer to BioNTech in accordance with the terms of the Commercialization Agreement; or 

 

	 	3.7.4.2.	 permit Pfizer to offset any such reimbursement amounts (to the extent not reimbursed pursuant to clause
(a) above), against Pfizer’s future payment obligations to BioNTech (or any of its successor or assigns) under the Commercialization Agreement. 

3.7.5. Consents and Waivers. BioNTech represents, warrants and covenants to Pfizer that, to the extent any terms and
conditions of this Agreement do not (or will not at any time during the Term) conform to any requirements relating to the grant of sublicenses under any Current License, it has obtained the irrevocable consent (or, if applicable, the waiver of any
resultant conflict) from the applicable Current Licensor that is necessary to permit the activities contemplated under this Agreement, including, such that BioNTech may grant the applicable sublicenses granted or to be granted hereunder and perform
all of its obligations hereunder and Pfizer may exercise all of its rights and perform all of its obligations hereunder, in each case, without breaching the applicable Current License. In the event that any provision in any Current License which
conflicts with this Agreement or adversely impacts the activities contemplated under this Agreement comes to the attention of either BioNTech or Pfizer or which otherwise, at any time during the Term, would cause the representation, warranty and
covenant set forth in the preceding sentence to be untrue, BioNTech, in consultation with Pfizer, will obtain any and all additional required consents or waivers from the applicable Current Licensor(s) which may be necessary to align the conflicting
provision(s) of the applicable Current License with this Agreement and to permit the activities contemplated by this Agreement. 

3.7.6. Exceptions to the Fosun Agreements. If BioNTech (as opposed to Pfizer) has breached the Fosun Agreement [***]. In
addition, in respect of the Fosun Agreement (i) [***]; and (ii) [***]. 

  
 25 

 3.7.7. Reduction in Royalties. BioNTech shall use reasonable efforts
to obtain any reductions or waivers in royalties or other payments due under the Current Licenses that could constitute Third Party License Payments due to the pandemic status of COVID-19 or with respect to
countries or populations experiencing emergency pandemic or crisis epidemic, coronavirus conditions, including taking into account any restrictions on pricing for the Product based on applicable Law and funding agreements with Third Party Funders.
For the avoidance of doubt, BioNTech does not guarantee that any such reductions or waivers can be obtained from such licensors. 
 3.8.
Third Party Agreements. Each Party will be solely responsible for all obligations (including royalty and payment obligations) that relate to Candidates, Products, BioNTech Technology or Pfizer Technology under its or its Affiliates’ own
agreements with Third Parties that are in effect on or prior to the Effective Date, including the Current Licenses for which BioNTech has sole responsibility. 

3.9. No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed to have granted the other
Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Patent Rights, Know-How or other Intellectual Property Rights or information Controlled by
such Party. 
 3.10. Exclusivity. 

3.10.1. Mutual Exclusivity. Except if otherwise permitted by the unanimous consent of the JSC, during the Term, neither
Party shall, and shall procure that its Affiliates shall not, itself or with or on behalf of a Third Party, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise Exploit or have Exploited any [***]
in the Field within the Territory, except that each Party may continue any existing agreement with a Third Party for non-clinical research within the Field with academic institutions and consortia. For
avoidance of doubt, the foregoing exclusivity obligation shall not apply to (a) [***]; (b) [***]; (c) [***]; or (d) [***]. 

3.10.2. Exclusivity of the Licenses. Without prejudice to the licenses granted by BioNTech pursuant to this
Section 3 or pursuant to the Commercialization Agreement, BioNTech shall not, and shall procure that its Affiliates shall not, grant any license, permission, waiver, covenant not to sue, or other right to use or Exploit any of the BioNTech
Technology within the Field and within the Territory that would conflict with or erode any of Pfizer’s rights hereunder. 

  
 26 

 3.10.3. Exclusivity in the Product. Except pursuant to this Agreement
or the Commercialization Terms or Commercialization Agreement, neither Party shall, and shall procure that its respective Affiliates shall not, itself or with or on behalf of a Third Party, Develop, have Developed, Manufacture, have Manufactured,
Commercialize, have Commercialized or otherwise Exploit (a) any Candidate Controlled by BioNTech as of the Effective Date within the Field; or (b) any Candidate that, as a consequence of the Development under this Agreement, becomes
Controlled by BioNTech after the Effective Date, for any field; or (c) any Product for any field or application; in each case (a), (b) and (c) other than for non-clinical research purposes, or within
the Field pursuant to the Fosun Agreement. 
  

	4.	 COMMERCIALIZATION 

4.1. Commercialization Agreement. With respect to Commercialization, the Parties have agreed to the terms set forth in Schedule 4.1
(“Commercialization Terms”) and will, for [***] following the Signing Date (or any other time period agreed by the Parties in writing), negotiate and execute a definitive Commercialization Agreement reflecting such Commercialization
Terms. Such agreement shall be negotiated in good faith and acting reasonably, and shall set forth the rights and responsibilities of the Parties in connection with the Commercialization of the Products and which shall be consistent with the
Commercialization Terms. If the Commercialization Agreement is not executed within the [***] period the Parties will prioritize and engage in additional discussions to conclude and execute the Commercialization Agreement as soon as possible. 

4.2. Commercialization Rights Pending Agreement. If a definitive Commercialization Agreement is not executed before the Product is
first ready to be Commercialized in the Territory, each Party may still commence and continue with the Commercialization of the Product in its respective Commercialization territory, but shall do so subject to the provisions of the Commercialization
Terms until the Commercialization Agreement is executed. 
  

	5.	 PAYMENTS AND FUNDING. 

5.1. Upfront Payment. Pfizer shall make a one-time,
non-refundable (without limiting Pfizer’s right to claim for damages under this Agreement) payment of Seventy-two Million Dollars ($72,000,000) to BioNTech
(“Upfront Payment”) within thirty (30) days of receipt of BioNTech’ s invoice (such invoice to be delivered on or following the Signing Date), but not before the Research and Development Plan, Development Budget and
Manufacturing Plan are agreed between the Parties in accordance with Section2.2, which payment shall be dedicated to activities to be performed under the Research and Development Plan. 

5.2. Equity Investment. Pfizer and BioNTech shall enter into an “Investment Agreement” contemporaneously with this Agreement
pursuant to which Pfizer agrees to subscribe for shares in BioNTech in consideration for an investment amount of One Hundred and Thirteen Million Dollars ($113,000,000) based on a price per share of $47.53, subject to the conditions as prescribed in
such Investment Agreement (“Equity Investment”). 
 5.3. Regulatory Milestone Payment. Within [***] of the date upon
which either BioNTech or Pfizer first obtains all Regulatory Approvals required for the Commercialization of the Product in a Major Market Country in the Territory, Pfizer shall pay BioNTech a one-time, non-refundable (without limiting Pfizer’s right to claim for damages under this Agreement) milestone payment of [***] Dollars (US$[***]) (“Regulatory Approval Milestone”), which shall be
automatically applied to repayment of, and offset against, the BioNTech Deferred Development Costs, and to the extent that at such time the BioNTech Deferred Development Costs are less than the value of the Regulatory Approval Milestone any
difference shall be paid to BioNTech. 

  
 27 

 5.4. Sharing of Development Costs. 

5.4.1. Shared Development Costs. Except as otherwise provided herein, each Party shall bear fifty percent (50%) of all
Shared Development Costs. 
 5.4.2. BioNTech Deferred Development Costs. Without prejudice to Section 5.4.1,
BioNTech’s share of the Shared Development Costs incurred in accordance with the binding parts of the Development Budget, Research and Development Plan and the Manufacturing Plan, and this Agreement, and which are not funded by a Third Party
Funder, shall be funded initially by way of an interest free repayable loan from Pfizer unless and until there is a Funding Event (“BioNTech Deferred Development Costs”). Following a Funding Event, BioNTech shall thereafter fund its
share of the Shared Development Costs in accordance with Section 5.4.4. The BioNTech Deferred Development Costs shall be funded by Pfizer but shall be subject to the reporting and reconciliation provisions of Section 5.4.4. The BioNTech
Deferred Development Costs shall be repayable through (a) the Regulatory Approval Milestone, if paid pursuant to Section 5.3; (b) a proportion of the Commercialization Sales Milestone Payments (as defined and described in Schedule
4.1); (c) Pfizer’s retention of the Enhanced Profit Share element of Gross Profits pursuant to the Commercialization Terms set out in the Commercialization Terms and (d) an immediate lump sum paid by BioNTech upon (i) Change of
Control of BioNTech pursuant to Section 14.1.3.3, provided that the most recent published annual group net income, published prior to the date of such Change of Control, of the Third Party acquiring BioNTech is [***] Dollars or
(ii) termination of this Agreement for BioNTech’s breach or its bankruptcy or insolvency. If this Agreement is terminated by Pfizer pursuant to its right under Section 13.4, the BioNTech Deferred Development Costs shall cease to be
repayable by BioNTech. 
 5.4.3. Budgeting of Shared Development Costs. The Parties shall agree on, and regularly
update (if required), the Development Budget through the JSC. As soon as either Party determines that it is likely to overspend on the binding part of the Development Budget that is allocated to that Party by more than [***], it shall inform the JSC
accordingly, and shall only be entitled to incur such overrun costs as Shared Development Costs pursuant to Section 5.4.1 and 5.4.2 upon the JSC’s mutual consent. 

5.4.4. Reporting and Reconciliation. Wherever possible and practicable, prior to any Funding Event any external Shared
Development Costs incurred in accordance with the binding parts of the Development Budget shall initially be invoiced to and borne by Pfizer, but shall be subject to reimbursement in accordance with this Section 5.4.4. All other Shared
Development Costs incurred in accordance with the binding parts of the Development Budget shall initially be borne by the Party incurring such costs and shall thereafter be subject to reimbursement in accordance with this Section 5.4.4. Each
Party shall report to the other Party, within [***] after the end of each Pfizer US Quarter, the Shared Development Costs incurred by such Party during such Pfizer Quarter. Such report shall specify in reasonable detail all amounts included in such
Shared Development Costs during such Pfizer Quarter (broken down by activity), and out-of-pocket costs shall be allocated to the extent possible to a specific activity
in the applicable binding part of the Research and Development Plan. Each such report shall enable the receiving Party to compare the reported Shared Development Costs against the applicable binding part of the Development Budget previously approved
by the JSC, on both a quarterly basis and a cumulative basis for each activity. The Parties shall seek to resolve any questions related to such accounting statements within [***] following receipt by each Party of the other Party’s report
hereunder. Following such resolution, BioNTech shall prepare a reconciliation report for the Shared Development Costs for such Pfizer Quarter (including as against the binding parts of the Development Budget) and shall either (a) deliver an
invoice to Pfizer for any amounts due to 

  
 28 

 
BioNTech as a result of reconciliation or (b) notify Pfizer that it should issue an invoice to BioNTech for any amounts due to Pfizer as a result of reconciliation. Any such invoice from
BioNTech to Pfizer shall be payable within [***] from receipt by Pfizer. Prior to any Funding Event, any such invoice from Pfizer to BioNTech shall not be payable upon receipt, but shall be accounted as BioNTech Deferred Development Costs and shall
be payable in accordance with the mechanism described in Section 5.4.2. Following any Funding Event, any such such invoice from Pfizer to BioNTech shall be payable within [***] from receipt by Pfizer. 

5.4.5. Capex Costs. Notwithstanding anything else in this Agreement, each Party shall be solely responsible for its own
Capex Costs and any capital expenditures required in connection with this Agreement or the Commercialization Agreement. 

5.4.6. Other Costs. Except as expressly set forth otherwise in this Agreement), each Party will bear all costs
and expenses it incurs in connection with its activities under this Agreement. 
 5.5. Third Party Funding. 

5.5.1. Third Party Funders. Pfizer and BioNTech shall, in good faith and acting collaboratively, seek funding from one
or more Third Parties for such Third Party to provide financial support to the collaboration between the Parties under this Agreement (each, a “Third Party Funder”). For each potential Third Party Funder, the Parties will agree on
(a) the Party to lead the communications and discussions with such Third Party Funder (the “Lead Party”) and (b) the activities, costs or expenses for which funding support shall be sought (e.g. funding for Development
costs, funding in support of a Party’s Capex Costs (“Capex Funding”) or both). An initial list of potential Third Party Funders and their allocation as between the Parties is set forth in Schedule 5.5. Notwithstanding the
foregoing, Pfizer shall be entitled to secure funding from, and shall be the Lead Party in discussions with, [***], in the event that Pfizer, in its sole discretion, [***], and BioNTech shall be entitled to secure funding from, and shall be the Lead
Party in discussions with, [***], in the event that BioNTech, in its sole discretion, chooses to seek funding from [***]. 

5.5.2. Discussions with Funders. The Lead Party will lead any discussions with such Third Parties in any country,
provided that the Lead Party will provide regular updates to the JSC and keep the JSC reasonably informed of the status and any developments in such discussions, and shall, at the other Party’s reasonable request, update the other Party on any
such discussions. The Lead Party shall conduct any such discussions and draft and file any applications for any Third Party Funding in good faith and acting reasonably with respect to its requests for such funding. Where legally possible and unless
otherwise agreed between the Parties, each application for any Third Party funding shall be made in both Parties’ name unless the Parties have agreed in advance pursuant to Section 5.5.1 that such application shall be in respect of one
Party’s Capex Funding alone, in which case such application may be made in that Party’s own name alone. The Lead Party shall not enter into a written agreement with any Third Party Funder without prior written consent of the other Party
(such consent not to be unreasonably withheld, conditioned or delayed) unless the Parties have agreed in advance pursuant to Section 5.5.1 that such agreement shall be in respect of that Lead Party’s Capex Funding alone, in which case the
Lead Party can conclude such Third Party Funder agreement without consent from the other Party. Notwithstanding the foregoing, (a) Pfizer shall be entitled to seek any funding from [***] without requiring BioNTech’s consent; and
(b) BioNTech shall be entitled to seek any funding from [***] without requiring Pfizer’s consent. Pfizer and BioNTech acknowledge and agree that there is no guaranty that any Lead Party will be successful in securing any funding from any
Third Party Funder or that any specific amount of funding will be obtained. 

  
 29 

 5.5.3. Allocation of Funds and Balancing Payment. To the extent
possible, any Third Party funding to the extent it relates to activities in relation to which the Parties have agreed to treat the associated Development costs as Shared Development Cost shall be shared equally between the Parties. If such sharing
is not possible, a balancing adjustment shall be made in favor of the other Party to the Shared Development Costs to reflect [***] percent of such funding that that Party receives from the Third Party Funder provided that doing so does not breach
any applicable Laws or the terms of such funding. Each Party shall promptly report to the other Party in writing if and when it receives any payments from any Third Party Funder funding that relates to activities, costs or expenses that are Shared
Development Costs. 
 5.5.4. Not Applicable to Loans. For the avoidance of doubt, this Section 5.5 shall not
apply to any traditional loans provided by any Third Party to a Party provided that (a) such loans are repayable by the borrower Party and not, directly or indirectly, by the other Party; (b) this Agreement, the Commercialization
Agreement, any other agreement ancillary to this Agreement or the Commercialization Agreement, the BioNTech Technology, Product Technology and Product are not provided as security for, or otherwise encumbered by way of, such loan (excluding, for
clarity, any tangible assets). Each Party shall be entitled to seek any such loans from any Third Party without any obligations to the other Party. 

5.6. Records and Accounting Principles. Each Party shall keep books and records of any of Shared Development Costs and
any Third Party funding in accordance with good industry practice and GAAP or IFRS, as applicable. Each Party shall determine Shared Development Costs using its standard accounting procedures, consistently applied and in accordance with GAAP or
IFRS, as applicable (provided that the application of such procedures results, on balance, in outcomes that are fair and equitable to both Parties taking into consideration the interests of both Parties as reflected in this Agreement). All personnel
costs of either Party or its Affiliates are excluded from Shared Development Costs. 
 5.7. Taxes. 

5.7.1. Withholding Taxes. The Parties agree to use reasonable efforts to cooperate with one another and use commercially
reasonable efforts to avoid or reduce, to the extent permitted by applicable Law, tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by the paying Party to the receiving Party under this
Agreement (“Withholding Taxes”). If Withholding Taxes are imposed on any compensation under this Agreement, the liability for such Withholding Taxes shall be the sole responsibility of the receiving Party, and the paying Party shall
(a) deduct or withhold such Withholding Taxes from the payment made to the receiving Party, (b) timely pay such Withholding Taxes to the proper taxing authority, and (c) send proof of payment to the receiving Party within [***]
following such payment. Each Party shall comply with (or provide the other Party with) any certification, identification or other reporting requirements that may be reasonably necessary in order for the paying Party to not withhold Withholding Taxes
or to withhold Withholding Taxes at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with commercially reasonable assistance to enable the recovery, as permitted by applicable Law, of Withholding
Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing the cost of such Withholding Taxes under this Section 5.6 (Taxes and Withholding). Notwithstanding the
foregoing, if as a result of any assignment or sublicense by the paying Party, any change in the paying Party’s tax residency, any change in the entity that originates the payment, or any failure on the part of the paying Party to comply with
applicable 

  
 30 

 
Law with respect to Withholding Taxes (including filing or record retention requirements), Withholding Taxes are imposed that would not otherwise have been imposed (“Incremental
Withholding Taxes”), then the paying Party shall be solely responsible for the amount of such Incremental Withholding Taxes and shall increase the amounts payable to the receiving Party so that the receiving Party receives a sum equal to
the sum which it would have received had there been no such imposition of Incremental Withholding Taxes. 
 5.7.2. Value
Added Tax. All payments between the Parties under this Agreement are exclusive of applicable statutory value added tax or similar taxes (“VAT”), if any, which shall be listed separately on each invoice. If and to the extent any
VAT will become payable due to any supplies or services rendered under this Agreement and if and to the extent such VAT is to be paid by the Party providing the supply or service to the competent tax authorities, the receiving Party shall pay an
amount equal to such VAT to the providing Party upon receipt of a valid invoice allowing for the recovery of such VAT. 

5.7.3. Other. Except as otherwise set forth in this Section 5.7, each Party shall be solely responsible for the
payment of all Taxes imposed on such Party’s income arising directly or indirectly from the activities of the Parties under this Agreement. 

5.8. Currency, Source of Payments. All amounts payable and calculations under this Agreement will be in United States dollars,
[***]. As applicable, all costs and expenses will be translated into United States dollars at the exchange rate used by the relevant Party for public financial accounting purposes. If, due to restrictions or prohibitions imposed by national or
international authority, a given payment cannot be made as provided under this Section 5.8, the Parties will consult with a view to finding a prompt and acceptable solution. If the Parties are unable to identify a mutually acceptable solution
regarding such payment, then the Party owing the relevant payment may elect, in its sole discretion, to deliver such payment in the relevant jurisdiction and in the local currency of the relevant jurisdiction. 

5.9. Method of Payment. Except as permitted pursuant to Section 5.8, each payment hereunder will be made by electronic transfer in
immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at the paying Party’s election, to such bank account as the receiving Party will
designate in writing to the other Party within [***] of the Signing Date, and thereafter at least [***] before the payment is due. All invoice or billing related questions in relation to Pfizer should be referred to Pfizer’s Accounting
Department at 800.601.1357 or go to the Accounts Payable Invoice Portal at ap.pfizer.com. Unless otherwise specified herein, each invoice is payable within [***] of receipt of the relevant invoice. 

5.10. Audits. Upon [***] prior notice from a Party (the “Auditing Party”), the other Party (the “Audited
Party”) will permit an independent certified public accounting firm of nationally recognized standing selected by the Auditing Party and reasonably acceptable to the Audited Party, to examine, [***], the relevant books and records of the
Audited Party and its Affiliates (and where possible, its subcontractors) as may be reasonably necessary to verify the amounts reported by the Audited Party in accordance with Sections 5.4 and 5.5. An examination by the Auditing Party under this
Section 5.10 will occur not more than [***] and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] before the date of the request. The accounting firm will be provided access to such books and
records at the Audited Party’s or its Affiliates’ facility(ies) where such books and records are normally kept and such examination will be conducted during the Audited Party’s or its Affiliates’ normal business hours. The
Audited Party may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to the Audited Party’s or its Affiliates’
facilities or records. Upon completion of the audit, the accounting firm will provide both Pfizer and BioNTech the same written report disclosing any discrepancies in the reports submitted by the Audited Party, and, in each case, the specific
details concerning any discrepancies. No other information will be provided to the Auditing Party. 

  
 31 

 5.10.1. Underpayments/Overpayments. If such accounting firm concludes
that there are errors in how Shared Development Costs have been charged, allocated or reclaimed, or Third Party funding has not been allocated in accordance with this Agreement by the Audited Party, then adjustments shall be made in accordance with
the accounting firm’s recommendations in a reconciliation of Shared Development Costs and any overpayment or underpayment by the Audited Party shall be rectified either by a refund to, or payment by, the Audited Party from or to the Auditing
Party within [***] of the date the Audited Party receives such accountant’s written report. Further, if the amount of any overpayment or overallocation to the Audited Party exceeds more than [***] of the amount that was properly payable
due or allocated to the Audited Party, then the Audited Party will reimburse the Auditing Party for the Auditing Party’s out-of-pocket costs in connection with the
audit. 
 5.10.2. Confidentiality. Notwithstanding any provision of this Agreement to the contrary, all reports and
financial information of the Audited Party or its Affiliates which are provided to or subject to review by the Auditing Party will be deemed to be Confidential Information of the Audited Party and subject to the provisions of Section 11.1. 

5.11. No Guaranty of Success. 

5.11.1. Pfizer and BioNTech acknowledge and agree that any milestone payments pursuant to BioNTech hereunder or under the
Commercialization Terms: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if a certain Product is successfully Developed or Commercialized in accordance with the applicable milestone or
event, as applicable; (b) are solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of such Product as applicable, between Pfizer and BioNTech; (c) are not intended to be used as a
measure of damages if this Agreement is terminated for any reason; and (d) will only be triggered, and will only be relevant as provided, in accordance with the terms and conditions of such provisions. 

5.11.2. Pfizer and BioNTech further acknowledge and agree that nothing in this Agreement, or in any document or presentation
provided by Pfizer to BioNTech prior to the Effective Date will be construed as representing any estimate or projection of (a) the successful Development or Commercialization of any Product under this Agreement, (b) the number of Products
that will or may be successfully Developed or Commercialized under this Agreement, (c) anticipated sales or the actual value of any Products that may be successfully Developed or Commercialized under this Agreement or (d) the damages, if
any, that may be payable if this Agreement is terminated for any reason. 
 5.11.3. Neither Party makes any representation,
warranty or covenant, either express or implied, to the other Party that (a) it will successfully Develop, Manufacture, Commercialize or continue to Develop, Manufacture or Commercialize any Product in any country, (b) if Commercialized,
that any Product will achieve any particular sales level, whether in any individual country or cumulatively throughout the Territory or (c) it will devote, or cause to be devoted, any level of diligence or resources to Developing, Manufacturing
or Commercializing any Product in any country, or in the Territory. 

  
 32 

	6.	 RESEARCH AND DEVELOPMENT PLAN 

6.1. Scope of Development and Updating of Plans. Pfizer and BioNTech will collaborate during the Term to conduct
research to identify, Develop and evaluate Candidates and Products within the Field in accordance with the binding parts of the Research and Development Plan, the Development Budget, the Manufacturing Plan, and the terms and conditions set forth in
this Section 6. The Research and Development Plan may be modified by agreement and approval of the JSC pursuant to Section 7, provided that the JSC shall have no right or authority to (a) modify the Research and Development Plan in a
way not permitted under Section 7.3; or (b) modify the Research and Development Plan so as to amend the contractual provisions of this Agreement. The initial [***] of each of the Research and Development Plan, the Manufacturing Plan and
the Development Budget shall be agreed between the Parties by [***], the first [***] of each are binding upon the Parties and the second [***] are indicative but non-binding. At least [***] prior to the
expiration of such initial [***] binding period, the JSC shall decide and mutually agree on the following [***] period of each of the Research and Development Plan, the Manufacturing Plan and the Development Budget which period, upon agreement,
shall be binding upon the Parties subject to Section 7.3.4. At least [***] days prior to the expiration of the initial [***] period following the Effective Date, the JSC shall establish a rolling [***] process to decide on and update each
of the Research and Development Plan, the Development Budget and the Manufacturing Plan for subsequent [***] periods, each of which shall be updated by the JSC no later than [***] prior to the expiration of the then binding [***] period. 

6.2. Research and Development Plan. The Research and Development Plan shall (a) include a broad
non-binding overview of the first [***] of the planned Development program (specifying in reasonable detail all material Development activities) to generate the preclinical, clinical, CMC, regulatory and other
information required for submitting a marketing authorization application for Regulatory Approval for the Candidate or Product and to achieve such Regulatory Approval for the Candidate or Product in one or more selected country(ies) of the
Territory; (b) include a more detailed and binding part of the plan for the initial binding period described in Section 6.1, which will be updated in accordance with Section 6.1; and (c) set forth those obligations assigned to
each Party with respect to the performance of the Development activities contemplated by such Research and Development Plan. 
 6.3.
Allocation of Responsibilities. 
 6.3.1. General. Each Party will use Commercially Reasonable Efforts
to perform its obligations and activities identified under the binding parts of the Research and Development Plan or as allocated to it by the JSC in a professional manner in accordance with any target dates set forth in Research and Development
Plan. Further, each Party will perform its obligations under the binding parts of the Research and Development Plan or as allocated to it by the JSC in compliance with all Laws applicable to its activities under the Research and Development Plan.

 6.3.2. Mutations. If and to the extent Mutations of the SARS-CoV-2 virus arise [***] 
 6.3.3. Label Extensions. If a Party wishes to
extend the label or approved indication of any Product Developed hereunder to other indications (including any outside of the Field), it may so notify the JSC. In such event, the JSC shall discuss such label extension in good faith. If the JSC
agrees by unanimous consent that Development should be undertaken to support the label extension, the Parties shall include the Development activities required to be undertaken to support 

  
 33 

 
such label extension in the Research and Development Plan and, if appropriate, amend the Field accordingly to cover such extension. Any external cost or expense (other than Capex Cost) incurred
by either Party (or its Affiliates) solely and specifically in connection with such Development activities [***]. 
 6.3.4.
Subcontractors. Either Party may subcontract its responsibilities under the binding parts of the Research and Development Plan or those allocated to it by the JSC without the other Party’s prior written consent; provided that such
Party shall be responsible for the management of all permitted subcontractors (which will include any Affiliate of a Party). The engagement of any Third Party subcontractor by a Party shall be in writing. The engagement of any subcontractor (whether
Affiliate or Third Party) shall not relieve such Party of its obligations under this Agreement or the binding parts of the Research and Development Plan. Any agreement between the Party or its Affiliate and a subcontractor pertaining to the Research
and Development Plan activities shall be consistent with the provisions of this Agreement including (a) an obligation to assign all Intellectual Property Rights generated during its performance of such Research and Development Plan to the Party
free of any encumbrance such that the Party may fulfil its obligations hereunder and (b) terms and conditions under which such Third Party is obligated to preserve the confidentiality of the Research and Development Program, Research and
Development Program Technology and any Confidential Information are at least as restrictive as those described in Section 11.2.1. 

6.3.5. Flexibility of Resources. Due to practical consequences arising from the outbreak of the virus that is the
subject of the Field, it may become difficult or temporarily impossible (including as classified as a force majeure event) for a Party to fulfil all of its responsibilities under the Research and Development Plan or as allocated to it by the JSC.
Accordingly, a Party, in its effort to collaborate, may therefore agree to swap, substitute or perform any of the other Party’s responsibilities that were allocated to it in the Research and Development Plan or by the JSC. The JSC shall be
responsible for coordinating any such changes, which must be finally approved in writing by the Parties where the change results in a Party taking on additional financial cost and responsibility. 

6.3.6. Personnel Matters. Each Party acknowledges and agrees that it is solely responsible for the compensation of its
personnel assigned to the Research and Development Plan, and shall be responsible for withholding all national, state, local or other applicable taxes and similar items for such personnel. Each Party also shall be responsible for all other of its
employer related obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each of its employees. BioNTech personnel assigned to the Research
and Development Plan activities are not nor shall they be deemed to be employees of Pfizer, and Pfizer personnel assigned to the Research and Development Plan activities are not nor shall they be deemed to be employees of BioNTech. 

 

	7.	 CONTRACT GOVERNANCE.  

7.1. Alliance Managers. Each Party will appoint a single individual to act as the primary point of contact between the Parties to
support the activities under the Research and Development Plan and the Manufacturing Plan (the “Alliance Managers”). Each Party may change its designated Alliance Manager at any time upon written notice to the other Party. As of the
Effective Date, the Alliance Manager for Pfizer will be [***] and the Alliance Manager for BioNTech will be [***]. The Alliance Managers will: 

  
 34 

 7.1.1. use good faith efforts to attend (either in person or by
telecommunications) all meetings of the JSC, but will be non-voting members at such meetings; and 

7.1.2. be the first point of referral for all matters of conflict resolution and bring disputes to the attention of the JSC in
a timely manner. 
 7.2. Program Directors. Each Party will appoint a program director to oversee all activities conducted under the
Research and Development Plan (each, a “Program Director”). Each Party may change its designated Program Director at any time upon written notice to the other Party. The Program Directors will coordinate the efforts of their
respective Party in conducting activities under the Research and Development Plan. As of the Effective Date, the Program Directors for Pfizer and BioNTech are [***], respectively. 

7.3. Joint Steering Committee. 

7.3.1. Composition. As of the Effective Date, the Parties will establish a Joint Steering Committee, comprised of at
least [***] representatives of BioNTech (including the Alliance Manager for BioNTech) and at least [***] representatives of Pfizer (including the Alliance Manager for Pfizer). The JSC representatives for each of Pfizer and BioNTech will be referred
to herein as the “Pfizer JSC Members” and the “BioNTech JSC Members” respectively. As of the Effective Date, the Pfizer JSC Members shall be [***] and the BioNTech JSC Members shall [***]. 

Each Party may replace its representatives to the JSC at any time upon notice to the other Party, provided that at all times an equal
number of representatives from each Party are appointed to the JSC and each Party shall be responsible for ensuring any replaced representative is fully briefed and apprised of the Research and Development Program. Each Party shall procure that its
JSC representatives shall make themselves available to attend JSC meetings upon reasonable notice and in accordance with this Agreement. Each Party may invite non-voting employees and consultants to attend
meetings of the JSC. All members of the JSC and any invitees of either Party described above will agree in writing to be bound to obligations of confidentiality and assignment of Intellectual Property Rights no less restrictive than those that bind
the Parties under this Agreement. 
 7.3.2. Committee Chair. The JSC will be chaired by a BioNTech JSC Member (the
“JSC Chair”). BioNTech may replace the JSC Chair at any time upon notice to Pfizer. The responsibilities of the JSC Chair will be: 
  

	 	7.3.2.1.	 to notify each Party at least [***] Business Days in advance of each JSC meeting; 

 

	 	7.3.2.2.	 to collect and organize agenda items for each JSC meeting; and 

  
 35 

	 	7.3.2.3.	 to prepare the written minutes of each JSC meeting and circulate such minutes for review and approval by the
Parties and identify action items to be carried out by the Parties. 

 7.3.3. Meetings. Until the
initiation of a Phase I Clinical Trial or Expedited Trial Pathway, the JSC shall meet at least weekly, unless otherwise unanimously agreed. Thereafter, the JSC will meet on at least bi-weekly basis (or less or
more frequently as the JSC so determines), either in-person or by audio or video teleconference. Meetings of the JSC will occur at such times and places as mutually agreed by the Parties. Any sub-committees or working groups established in accordance with Section 7.3.4 may meet via audio or video teleconference on a regular basis and in-person at such times
and places as the Parties may agree. Meetings of the JSC will only occur if at least two representatives of each Party are present at the meeting or participating by teleconference or videoconference. Each Party will be responsible for, and will not
be entitled to any reimbursement from the other Party with respect to, any and all personnel costs or expenses (including travel expenses) which are incurred by or on behalf of its personnel in connection with participation in any JSC meetings or sub-committee or working group meetings, or any other travel required to be undertaken by either Party’s personnel in connection with the performance of the Agreement. The JSC Chair will use good faith efforts
to (a) prepare and circulate to BioNTech and Pfizer each JSC meeting agenda on or before the day prior to the scheduled date for each JSC meeting and (b) circulate for review and approval by BioNTech and Pfizer written minutes of each JSC
meeting within [***] Business Days after such meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the day before the next meeting of the JSC. 

7.3.4. Responsibilities. The JSC will coordinate and provide operational and strategic oversight of the Development and
Manufacturing activities to be performed under the Research and Development Plan and the Manufacturing Plan by each Party and, within such scope will: 
  

	 	7.3.4.1.	 review and approve all proposals of whether to seek funding from a Third Party Funder, and the terms of any
proposed agreement with a Third Party Funder, which (with the exceptions specified in Section 5.5.2 for [***] and [***]) will require unanimous consent of the JSC; 

 

	 	7.3.4.2.	 monitor and assess the progress of activities under the Research and Development Plan and the Manufacturing
Plan; 

  

	 	7.3.4.3.	 decide on the Candidates or Products that will be studied in the Clinical Trials; 

 

	 	7.3.4.4.	 decide on the design of the Clinical Trials, including the protocol governing the Clinical Trials;

  

	 	7.3.4.5.	 decide on and revise and approve any revisions of the Research and Development Plan, the Development Budget and
the Manufacturing Plan (including in accordance with the mechanism described in Section 6.1 and any adjustments pursuant to Section 6.3.3 and 6.3.5), each of which shall require unanimous consent of the JSC except as expressly set forth in
Section 7.3.5; 

  
 36 

	 	7.3.4.6.	 discuss any Intellectual Property Rights of a Third Party which may be relevant to Candidates and Products;

  

	 	7.3.4.7.	 oversee the Development of Manufacturing processes relating to the Candidates or Products, establishment of
Manufacturing capacity, and endorse a strategy for Manufacturing Candidates and Product for both the Clinical Trials and planned Commercialization; 

  

	 	7.3.4.8.	 review and discuss all preclinical data and data arising from Clinical Trials investigating the Candidate or
Product in the Territory, including adverse events; 

  

	 	7.3.4.9.	 review and discuss all preclinical data and data arising from Clinical Trials under the Fosun Agreement,
including adverse events; 

  

	 	7.3.4.10.	 form such other committees and sub-committees as the JSC may deem
appropriate, such as a Joint Development Committee, a Joint Manufacturing Committee and the like, provided that the JSC may, with unanimous consent, delegate decision-making authority (that is within the JSC’s own authority) relevant to
such committee’s and sub-committee’s area of expertise only (and the Parties agree that they will form Joint Manufacturing Committee within [***] days of the Effective Date);

  

	 	7.3.4.11.	 address such other matters relating to the activities of the Parties under the Research and Development Plan or
the Manufacturing Plan as either Party may bring before the JSC, including any matters that are expressly for the JSC to decide as provided in this Agreement; 

 

	 	7.3.4.12.	 agree on a Development Budget, as well as any amendments to such budgets, provided that the Development Budget
and any amendments to it shall require unanimous consent of the JSC; 

  

	 	7.3.4.13.	 discuss, collaborate on and oversee any applications for Regulatory Approvals in respect of the Candidates and
Products, both within and outside the Territory; 

  

	 	7.3.4.14.	 discuss, collaborate on and agree on mutations pursuant to Section 6.3.2 or any label extension pursuant
to Section 6.3.3, each of which must be agreed by unanimous consent of the JSC; and 

  

	 	7.3.4.15.	 attempt to resolve any disputes between the Parties with respect to (a) the performance of activities
under the Research and Development Plan or the Manufacturing Plan on an informal basis or (b) matters before the Patent Committee, in each case subject to Section 7.3.5. 

7.3.5. Decision-making. Notwithstanding the number of Pfizer JSC Members or BioNTech JSC Members, each Party will have
one (1) vote, and the JSC will make decisions on a unanimous basis. The JSC will use good faith efforts to reach agreement on any and all matters properly brought before it. If, despite such good faith efforts, the JSC is unable to reach
unanimous 

  
 37 

 
agreement on a particular matter, within [***] days after the JSC first meets to consider such matter, or such later date as may be mutually acceptable to the Parties (each such matter, a
“Disputed Matter”), then: 
  

	 	7.3.5.1.	 Pfizer will have final decision making authority in relation to all decisions applicable to the Execution Task
where the Decision Making Right is allocated to Pfizer as set out in Schedule 7.3.5; and 

  

	 	7.3.5.2.	 BioNTech will have final decision-making authority in relation to all decisions applicable to the Execution
Task where the Decision Making Right is allocated to BioNTech as set out in Schedule 7.3.5; and 

  

	 	7.3.5.3.	 all other Disputed Matters (including those for which the Decision Making Right is identified as Mutual) shall
be subject to the Parties reaching unanimous or mutual consent ( including in respect of the Development Budget). 

 The
Parties agree that the JSC will further refine the details of the decision-making rights and processes in accordance with Schedule 7.3.5 and the terms of this Agreement. 

7.3.6. Limits on JSC Authority. Notwithstanding any provision of this Section 7 to the contrary, (a) each
Party will retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless such delegation or vesting of rights is expressly provided for in this
Agreement or the Parties expressly so agree in writing, (b) except with respect to modifications to the Research and Development Plan or Manufacturing Plan permitted as set forth in Section 7.3.4.5, the JSC will not have the power to amend
this Agreement or otherwise modify or waive compliance with this Agreement in any manner and (c) neither Party will require the other Party to (i) breach any obligation or agreement that such other Party may have with or to a Third Party
to the extent such obligation or agreement existed prior to the Effective Date or (ii) perform any activities that are materially different or greater in scope or more costly than those provided for in the Research and Development Plan then in
effect. For avoidance of doubt, a joint committee will be formed under the Commercialization Agreement to provide operational and strategic oversight of the Commercialization. 

7.3.7. JSC Term. The JSC will be dissolved upon expiration of the Term. 

7.4. Materials and Permitted Activities. 

7.4.1. Transfer. From time to time during the Term, Pfizer shall provide BioNTech with tangible chemical or biological
materials (the “Pfizer Materials”) and BioNTech may provide Pfizer with BioNTech Materials for the other Party’s use in accordance with binding parts of the Research and Development Plan. The Party providing its Materials
represents and warrants to the other Party that, as of the date of delivery of the Material (a) [***], (b) [***] and (c) [***]. [***]. 

  
 38 

 7.4.2. Title to Materials. All right, title and interest in and to
the providing Party’s Materials (including any modifications or progeny thereof) will remain the sole and exclusive property of such Party notwithstanding the transfer to and use by other Party of the same. 

7.4.3. Permitted Activities. Notwithstanding anything to the contrary in this Agreement save for each Party’s
exclusivity obligations and restrictions (including those at Sections 3.1 and 3.10), nothing in this Agreement shall be deemed to prevent or restrict in any way the ability of either Party or its Affiliates to conduct any activities in the
Territory, which activities would be allowed under any safe harbor, research exemption, government or executive declaration of urgent public health need, or similar right available in law or equity if conducted by a Third Party. 

7.4.4. Return of Proprietary Materials. Upon termination or expiration of the Term, each Party receiving the other
Party’s Materials hereunder shall, either destroy or return all unused Materials to the providing Party. 
  

	8.	 MANUFACTURING 

8.1. Development of Manufacture Process. BioNTech and Pfizer shall jointly Develop a scalable process for Manufacture of Candidates and
Products in the Field in the Territory in accordance with the binding parts of the Research and Development Plan and the Manufacturing Plan. 

8.2. Manufacture of Candidates and Products. Each Party will use Commercially Reasonable Efforts to perform its obligations and
activities identified under the binding parts of the Manufacturing Plan or as allocated to it by the JSC in a professional manner in accordance with any target dates set forth in the Manufacturing Plan. Further, each Party will perform its
obligations under the binding parts of the Manufacturing Plan or as allocated to it by the JSC in compliance with all Laws applicable to its activities under the Manufacturing Plan. Pfizer and BioNTech will collaborate in the build-up of Manufacturing capacity for the Manufacturing of Candidates and Products for clinical and commercial purposes in accordance with the binding parts of the Manufacturing Plan and the terms and conditions
set forth in this Section 8. The Manufacturing Plan may be modified by unanimous consent of the JSC pursuant to Section 7. Unless otherwise agreed in the Manufacturing Plan, at a minimum Pfizer will be responsible for the build-up of its Manufacturing site(s) in the USA for quantities of Product to be agreed as part of the Manufacturing Plan and the commercial supply agreement for such site, and at a minimum BioNTech will be
responsible for the extension of its Manufacturing sites in Mainz and Idar-Oberstein for quantities of Product to be agreed as part of the Manufacturing Plan and the commercial supply agreement for such sites. [***] The Manufacturing Plan may also
consider one or both Parties engaging Third Party contract manufacturing organizations as a source of Manufacturing. In addition, promptly after the Effective Date, the Parties will agree on a technology transfer plan and continue to perform the
technology transfer that the Parties have already started prior to the Effective Date to enable Manufacturing by Pfizer. For the avoidance of doubt, to the extent the technology transferred under this Agreement is identical to the technology to be
transferred pursuant to the Flu Collaboration License, the Parties shall cooperate to minimize any duplication of technology transfer efforts under the Flu Collaboration License that unreasonably would be duplicative, wasteful or unnecessary. 

  
 39 

 8.3. Quality Requirements. Each Party that undertakes or subcontracts any
Manufacturing activities in respect of the Candidates or Products, whether for the purposes of this Agreement, the Clinical Trials or pursuant to the commercial supply agreements shall ensure that all Manufacturing activities are undertaken in
accordance with (a) applicable GxP standards, applicable Laws, and other regulatory and manufacturing good practice (including record and sample keeping, deviation reporting, testing and quality requirements); and (b) the requirements of
the applicable Quality Agreement. 
 8.4. Manufacturing Agreements. 

8.4.1. Clinical Supply. Within [***] following the Effective Date, the Parties shall enter into an agreement for
clinical supply, as required to ensure the Clinical Trials planned can proceed on the timelines set forth in the binding parts of the Research and Development Plan. All clinical supply of Candidates and Products shall be charged at the Manufacturing
Costs. In addition, the Parties will negotiate in good faith and mutually agree on a Quality Agreement with respect to such clinical supply agreement. 

8.4.2. Commercial Supply. Furthermore, the Parties will negotiate in good faith and mutually agree on one or more
commercial supply agreement(s) and Quality Agreement(s) simultaneously with the negotiation of the Commercialization Terms. The commercial supply agreement(s) shall be in accordance with the following commercial terms: 

 

	 	8.4.2.1.	 The Manufacturing Party shall be entitled to charge the Transfer Price for each batch of Product delivered in
accordance with the relevant commercial supply agreement. Such Transfer Price shall be invoiced by the Manufacturing Party upon delivery of the Products and shall be payable by the other Party within [***] from receipt of such invoice.

  

	 	8.4.2.2.	 The Transfer Price shall be adjusted on a yearly basis for all commercial supply agreements in accordance with
relevant cost developments. 

  

	 	8.4.2.3.	 The Parties will work together, subject to and observing applicable Laws, and agree the volumes of Product
Materials to be purchased from Third Party suppliers for the purposes of this Agreement and to [***] of either Party to source the other Party’s requirements for such Product Materials for its Manufacturing activities pursuant to this Agreement
and the Commercialization Agreement, which sourced Product Materials shall then be sold, at cost, to that other Party [***]. 

  

	 	8.4.2.4.	 [***] 

  
 40 

 8.4.3. The supply agreements to be entered into between the Parties pursuant
to Sections 8.4.1 and 8.4.2, or the Commercialization Agreements if more appropriate, shall include appropriate accounting mechanisms to allow for true-up payments in respect of (i) Manufacturing Costs,
including to account for any mark up on the Manufacturing Costs of Product Materials where permitted in the definition of Manufacturing Costs, and (ii) Manufacturing Variances. 

8.5. Allocation of Responsibilities. Section 6.3.1 and Sections 6.3.4 to 6.3.6 shall apply mutatis mutandis in respect of
each Party’s responsibilities under the Manufacturing Plan. 
  

	9.	 DEVELOPMENT, REGULATORY AND PHARMACOVIGILANCE.  

9.1. Development Matters. 

9.1.1. Allocation of Development and Regulatory Responsibility. The Development of Candidates and Products shall be
conducted by the Parties, under the direction and oversight of the JSC (and, as applicable, the Joint Development Committee), in accordance with the applicable Research and Development Plan and Development Budget. Pursuant to the initial Research
and Development Plan, the Parties shall identify a strategy for Development of the Candidates and Products in the Territory that identifies the Party that is leading the clinical Development of the Candidates or Products in a country in the
Territory (the “Lead Development Party”). Notwithstanding the foregoing, the Parties have agreed that (a) Pfizer shall lead the clinical aspects of Development of Candidates and Products in the USA, and (b) BioNTech shall
lead the clinical aspects of Development of Candidates and Products in the EU. BioNTech shall be the sponsor and IND/CTA holder for all Clinical Trials in the Territory, in each case, subject to a mutually agreeable strategy with respect to the
Development of Candidates and Products. For any Clinical Trial for which Pfizer is the Lead Development Party (but is not the sponsor of such Clinical Trials), BioNTech shall have delegated to Pfizer operational and day-to-day Development activities, decision-making authority and responsibility for such Clinical Trial, including those activities described in Schedule 9.1.1, subject to a protocol approved by unanimous
consent by the JSC. For avoidance of doubt, the Lead Development Party shall conduct its Development activities in collaboration with and with active review of the other Party. 

9.1.2. Appointment of Lead Development Party for Future Clinical Trials. At any time during the term of this Agreement,
the JSC may determine by mutual consent that additional clinical Development of the Candidate and Product are warranted and, in such event, unless otherwise agreed by the JSC, (a) Pfizer shall be the Lead Development Party for each additional
Clinical Trial in the USA, (b) BioNTech shall be the Lead Development Party for each additional Clinical Trial in the EU and (c) the JSC shall mutually agree on the appointment of one of the Parties to be the Lead Development Party for
each additional Clinical Trial on a Clinical Trial-by-Clinical Trial basis in a country or region in the Territory other than the USA and EU (“ROW”), and subject to the mutually agreed upon
strategy. 
 9.1.3. Clinical Trials. In respect of Clinical Trials for the Candidates or Products pursuant to this
Agreement, the following shall apply: 
  

	 	9.1.3.1.	 GxP Standards. Subject to Section 9.1.3.7, BioNTech as the sponsor for any Clinical Trial in
respect of any Candidate or Product pursuant to this Agreement shall ensure the Clinical Trial is conducted in accordance with GxP and all applicable Laws, and will provide to the other Party any significant GxP or
non-compliance issues relating to the protocol for such Clinical Trial, which arise or may be identified through monitoring, 

  
 41 

	 	9.1.3.2.	 Monitoring Plans. A high-level strategy for monitoring Clinical Trials in respect of any Candidate or
Product pursuant to this Agreement will be agreed by the JSC within [***] following the Effective Date. The Lead Development Party of the Clinical Trial will notify the other Party if there are any amendments required to such monitoring plan, and
provide such other Party with an opportunity to review and comment on any such amendments, and any amendments shall only be made following approval by the JSC. 

 

	 	9.1.3.3.	 IRB/IEC Approval. BioNTech as the sponsor and Regulatory Approval holder of the Clinical Trials shall
ensure that the Clinical Trial is approved by and subject to continuing oversight by an appropriate Institutional Review Board (IRB) or Independent Ethics Committee (IEC), except that BioNTech shall delegate this responsibility to Pfizer for any
Clinical Trial for which Pfizer is the Lead Development Party. The Lead Development Party shall provide documentation of both the initial IRB/IEC approval of the final protocol to the other Party and annual renewals of that approval if such renewals
are required. To the extent a Party receives notice of any withdrawal or suspension of IRB/IEC approval during the term of this Agreement, it will promptly inform the other Party 

 

	 	9.1.3.4.	 Informed Consent. BioNTech as the sponsor and Regulatory Approval holder for each applicable Clinical
Trial will obtain informed consent for each Clinical Trial subject in accordance with the applicable informed consent document and applicable Law and will inform and obtain express consent from each Clinical Trial subject that the data arising from
such Clinical Trial may be used in accordance with the terms of this Agreement (including its export from the European Union and its processing by Pfizer or other Third Parties in accordance with the terms of this Agreement and Law), provided
however, that BioNTech shall delegate this responsibility to Pfizer for those Clinical Trials for which Pfizer is the Lead Development Party. Notwithstanding the foregoing, the Lead Development Party will share the informed consent document with the
other Party for such other Party’s review and comment prior to its use in a Clinical Trial in a country in the Territory. 

  

	 	9.1.3.5.	 Sponsorship. Where the Lead Development Party (or its Affiliate or designee) is not the sponsor of a
Clinical Trial or Regulatory Approval holder, such Lead Development Party shall not represent to any Third Party, including any Clinical Trial subjects, that the Lead Development Party or its Affiliates are a sponsor. 

 

	 	9.1.3.6.	 Reporting. BioNTech is solely responsible for any and all safety reporting and regulatory obligations
associated with the conduct of the Clinical Trial for which it is the sponsor, including, but not limited to, obtaining and maintaining Regulatory Approvals for the conduct of the Clinical Trials, provided, however, that BioNTech shall delegate the
safety reporting and regulatory obligations associated with the conduct of each Clinical Trial in the Territory to Pfizer subject to Section 9.3. 

  
 42 

	 	9.1.3.7.	 Delegation. Notwithstanding the responsibilities of BioNTech as IND/CTA holder or sponsor of Clinical
Trials, where Pfizer is the Lead Development Party for a Clinical Trial Pfizer shall conduct its activities in compliance with GxP and applicable Law with respect to each of the activities which have been delegated to Pfizer pursuant to Schedule
9.1.1. 

 9.2. Regulatory Matters. 

9.2.1. Lead Development Party. The JSC shall agree on a strategy to allocate operational responsibility for regulatory
activities relating to each Candidate or Product to a Lead Development Party by reference to the country or region within the Territory for which that Party is to act as the Lead Development Party in respect of a Clinical Trial for one or more
Candidates or Products. The JSC’s initial allocation shall be that Lead Development Party for regulatory activities relating to each Candidate or Product in the EU shall be BioNTech, and the Lead Development Party for regulatory activities
relating to each Candidate or Product in the USAshall be Pfizer. Subject to the JSC’s mutual consent to seek Regulatory Approval in one or more countries or regions in the ROW, Pfizer shall be the Lead Development Party for regulatory
activities relating to each Candidate or Product in such country or region in the ROW. If the JSC cannot agree on whether Regulatory Approval shall be sought for any country or region in the ROW, the Party that wishes to seek Regulatory Approval in
such country or region shall be entitled to be the Lead Development Party for regulatory activities relating to each Candidate or Product in such country or region and seek such Regulatory Approval at its own cost. The JSC may vary from the
foregoing allocations by mutual consent. The other Party shall cooperate with the Lead Development Party, at its reasonable request, with respect to any regulatory matters for which the Regulatory Approval holder is responsible or to whom regulatory
matters have been delegated.  
 9.2.2. Regulatory Communications and Filings. Pfizer shall prepare, file in
BioNTech’s name, diligently prosecute to grant, and maintain all applications for Regulatory Approvals (“Marketing Authorization Applications”) and all Regulatory Approvals obtained therefrom in respect of any Candidates or
Products in USA and, subject to Section 9.2.1, the ROW. BionTech shall prepare, file in BioNTech’s name, diligently prosecute to grant, and maintain all applications for Marketing Authorization Applications and all Regulatory Approvals
obtained therefrom in respect of any Candidates or Products in EU. The JSC may vary from the foregoing allocations by mutual consent. In accordance with Section 9.2.1, each Party shall cooperate with the other Party with respect to any and all
regulatory matters for which the other Party is responsible pursuant to this Agreement or the Research and Development Plan. Unless exigent action is required with respect to a given filing before a Regulatory Authority concerning a Candidate or
Product, or a material communication with a Regulatory Authority concerning the same, the Party submitting such Marketing Authorization Application shall provide the other Party with copies of all filings relating to such Marketing Authorization
Application prior to submission within a reasonable amount of time (but not less than [***] Business Days) to allow such Party to review and comment on such filings, and the Party submitting such Marketing Authorization Application shall
consider all comments and proposed revisions from the other Party in good faith prior to submission. The Party responsible for filing such Regulatory Approvals shall consult with the other Party regarding, and keep the other Party informed of, the
status of the preparation of all Marketing Authorization Applications and the prosecution thereof, including any material communications 

  
 43 

 
that it receives with respect to the same. Upon request of the other Party, the Lead Development Party responsible for filing applications for such Regulatory Approvals shall provide to the other
Party copies of all final Marketing Authorization Applications and filings relating thereto that it submits. The foregoing provisions of this Section 9.2.2 shall also apply to material and substantive communications with Regulatory Authorities.

 9.2.3. Regulatory Meetings. The Lead Development Party shall consult with the other Party reasonably in advance of
the date of any anticipated meeting with a Regulatory Authority relating to any Marketing Authorization Applications or Regulatory Approvals in respect of any Candidate or Product and shall consider any timely and reasonable recommendations made by
the other Party in preparation for such meeting. The Parties agree that Pfizer, as the Lead Development Party for the regulatory activities in the USA and ROW shall lead interactions with the Regulatory Authority in the USA and ROW, while BioNTech
as the Lead Development Party for the EU, shall lead interactions with the Regulatory Authority in Germany and the EU. The Parties agree that the Party who has been appointed by the JSC as the Lead Development Party shall lead interactions with
respect to countries or regions in the Territory. Upon the request of the other Party, and to the extent legally permissible and not opposed by the relevant Regulatory Authority, the Lead Development Party shall permit the other Party to attend any
and all meetings with the applicable Regulatory Authority concerning the Candidate or Product. [***] 
 9.2.4.
Manufacturing Matters. Where Pfizer is the Lead Development Party and responsible for preparing the filings for Regulatory Approval, BioNTech shall provide all reasonable assistance to Pfizer in such filings, including preparation of the CMC
portions of the Common Technical Document in English and supporting ancillary cGMP documents and analytical data as required to meet specific regulatory filing and approval requirements. Each Party shall promptly provide the other with copies of
material written correspondence as reasonably necessary to permit each Party to comply with its relevant regulatory obligations described in the Agreement or as otherwise reasonably requested.  

9.2.5. Ownership of Regulatory Filings, Market Authorization Approvals and Pricing and Reimbursement Approvals. Unless
otherwise required under applicable Law or determined by unanimous consent of the JSC (or the JCC with respect to Commercialization Agreement, as applicable), all Regulatory Approvals directed to a Candidate or Product in a country in the Territory
and all applications therefor shall be made or held in the name of and owned by BioNTech. Notwithstanding the foregoing BioNTech may, upon giving reasonable notice to Pfizer, elect to transfer to Pfizer or any of its Affiliates one or more
Regulatory Approvals in the Territory directed to a Candidate or Product and Pfizer will not withhold its agreement to such transfer if Pfizer or any of its Affiliates is already Commercializing a Pfizer vaccine product in such country and is
permitted to hold Regulatory Approvals in such country. Recognizing that the transfer of the foregoing responsibilities or the responsibilities described in 9.2.1 and 9.2.2 and Regulatory Approvals as the case may be requires time, coordination and
effort, the Parties will agree a reasonable transition plan for each such transfer and during the transfer period BioNTech shall continue to perform its obligations as Lead Development Party or owner of the Regulatory Approval. 

  
 44 

 9.2.6. Notice of Regulatory Investigation or Inquiry. If any
Regulatory Authority (i) contacts a Party with respect to the alleged improper Development, Manufacture, or Commercialization of a Candidate or Product in the Territory, (ii) conducts, or gives notice of its intent to conduct, an
inspection at a Party’s facilities used in the Development or Manufacturing of a Candidate or Product, or (iii) takes, or gives notice of its intent to take, any other regulatory action with respect to any activity of a Party that could
reasonably be expected to adversely affect any Development, Manufacture or Commercialization activities with respect to a Candidate or Product in the Territory, then such Party shall promptly notify the other Party of such contact, inspection or
notice. The inspected Party shall provide such other Party with copies of all pertinent information and documentation issued by any such Regulatory Authority within [***] Business Days of receipt, and, to the extent practicable, the JSC or
appropriate subcommittee. Such other Party shall have the right to (a) be present at any such inspection, and (b) review and comment upon in advance any responses of the inspected Party that pertain to a Candidate or Product or a
Party’s activities hereunder. 
 9.2.7. Pharmacovigilance and Pharmacovigilance Agreement. 

 

	 	9.2.7.1.	 As soon as practicably possible following the Signing Date the Parties shall form a Joint Safety Committee to
(a) review and approve each investigator’s brochure for the clinical Development of Candidates and Products, (b) review and approve all aggregated data Drug Safety Update Reports, annual IND reports, and other period reports to
Governmental Authorities information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products, (c) review, discuss and agree the outputs of each Party’s periodic Candidate and
Product related benefit/risk analysis, and (d) such other patient safety-related activities as the Parties may delegate to it from time to time. 

  

	 	9.2.7.2.	 So long as BioNTech holds the necessary INDs/CTAs/Regulatory Approvals and is acting as sponsor in a country or
region in the Territory, BioNTech may initiate clinical Development of the Candidates and Products in the EU prior to the Parties entering into a pharmacovigilance agreement. In such circumstances BioNTech shall be responsible for collecting,
monitoring, evaluating, sharing and reporting to applicable Governmental Authorities in the EU information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products. BioNTech shall be
responsible for maintaining a suitable safety database. 

  

	 	9.2.7.3.	 By no later than the approval of the Investigational New Drug (IND) for Candidate(s) with FDA, the Parties
shall have entered into a pharmacovigilance agreement (“Pharmacovigilance Agreement”) reflecting the terms set forth in Section 9.3 and Schedule 9.2.7. 

 

	 	9.2.7.4.	 Following the filing of the IND for Candidate(s) with FDA: 

  
 45 

	 	(a)	 should BioNTech require Pfizer to take over certain activities in relation to collecting, monitoring,
evaluating, sharing and reporting to applicable Governmental Authorities, but excluding Ethics Committees, information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or Products in the EU,
the Parties shall agree and execute an amendment to the Pharmacovigilance Agreement to (i) reflect the additional activities and responsibilities the Parties have agreed Pfizer will perform in the EU, and (ii) set out the procedures the
Parties have agreed upon to allow for the reconciliation of BioNTech’s safety database with Pfizer’s safety database. The effectiveness of the amendment shall be conditional upon BioNTech delivering to Pfizer (x) confirmation from the
relevant Governmental Authorities in the EU that they have accepted an amendment to the clinical trial protocol for any on-going clinical trial of Candidates or Product in the EU to reflect the necessary
changes (as agreed with Pfizer) in responsibilities and contact information for collecting, monitoring, evaluating, sharing and reporting of information regarding patient safety (including adverse drug) experiences, and (y) written confirmation
from BioNTech that it has amended the relevant clinical trial agreements to reflect the change in pharmacovigilance provider and trained the investigators on the new reporting procedures; and, 

 

	 	(b)	 BioNTech through their Agreement with Fosun shall ensure that Fosun, via BioNTech, deliver to Pfizer (x) a
copy of a due diligence report on Fosun’s safety data reporting system reasonably acceptable to Pfizer in terms of findings made, (y) a copy of the pharmacovigilance agreement between BioNTech and Fosun which, inter alia, provides for
delivery to Pfizer of fully assessed, translated (into English) CIOMS forms for all SAEs: Death / life threatening SUSARs – 5 Business Days from Day 0 (Day 0 being receipt by Fosun from the clinical investigator), or 10 days for all other SAEs,
[***] and (z) details of the quality management system used with Fosun to ensure that if late inbound reports are received BioNTech can request root cause analysis and implementation of corrective and preventive actions by Fosun. The Parties
agree that prior to Fosun’s commencement of clinical activities by Fosun, BioNTech shall have entered into a written agreement with Fosun, reflecting the foregoing. 

 

	 	9.2.7.5.	 The Pharmacovigilance Agreement and each amendment to it from time to time shall set forth the responsibilities
and procedures for (i) collecting, monitoring, evaluating, sharing and reporting to applicable Governmental Authorities information regarding patient safety (including adverse drug) experiences that are or may be associated with Candidates or
Products in the countries covered by that agreement and (ii) providing regulatory information to and support of the other Party 

  
 46 

	 	
with regard to regulatory obligations, provided, that, each such agreement shall include the following guiding principles: acting as BioNTech’s delegate for regulatory interactions, Pfizer
shall primarily control the regulatory process and regulatory interactions in the countries covered by that agreement, provided, however that the Parties shall work together collaboratively to further the purposes of the collaboration and the
activities described in this Agreement. Subject to the proviso in the foregoing sentence, to the extent there is any conflict between the terms and conditions of the Pharmacovigilance Agreement (as amended from time to time) and this Agreement with
respect to safety or regulatory matters, the Pharmacovigilance Agreement shall control. 

 9.2.8. Audits.
Each Party shall have the right, at its sole cost and expense, to perform audits of the other Party’s pharmacovigilance, regulatory, and environmental, health and safety activities concerning any Candidates or Products under this Agreement,
including each Party’s oversight of any Third Party contracted to perform pharmacovigilance, regulatory or environmental health and safety activities as outlined in this Agreement and in compliance with applicable Laws, which audit right is
exercisable at any time during the Term. Upon request, BioNTech shall provide Pfizer with a copy if its latest audit report on Fosun’s pharmacovigilance activities. 

9.3. Global Safety Database and Safety Reporting. Subject to Section 9.2.7, Pfizer shall maintain the global safety database for
the Candidates and Products pursuant to this Agreement and the Commercialization Agreement. Provided that (a) BioNTech (subject to Section 9.1) will be the Lead Development Party with respect to Clinical Trials conducted in the EU,
(b) BioNTech will hold a safety database to meet its sponsor responsibilities and regulatory responsibilities in the EU and to hold safety data reports received from China; (c) information shall be exchanged between Pfizer and BioNTech as
described in the Pharmacovigilance Agreement to ensure alignment of information between the databases and (d) BioNTech will delegate its responsibilities for the collection, processing, assessment and safety reporting to Regulatory Authorities
for all Clinical Trial(s) conducted pursuant to the Research and Development Plan in the Territory upon the approval of the IND for Candidate(s) with FDA. Notwithstanding the foregoing, such responsibility can only be delegated to and Pfizer can
only accept this responsibility if the Clinical Trial sites for the Candidates and Products are reporting the safety data, including all individual Serious Adverse Events, translated into English, to Pfizer and for so long as Pfizer has access to
all safety data, including all individual Serious Adverse Events, translated into English for any and all active Clinical Trials for the Candidates and Products, including products identical to Candidates or Products conducted under the terms and
conditions of the Fosun Agreement (or subsequent agreements with other development partners) to allow Pfizer to meet its regulatory obligations as Lead Development Party in the Territory. 

9.4. Product Complaints and Returns. The Parties’ rights and obligations with respect to
non-conformance and returns of Products shall be governed by, as and to the extent applicable, the applicable supply agreement, the global Quality Agreement, or the Pharmacovigilance Agreement. 

9.5. Clinical Trial Register. BioNTech shall, in accordance with Law and its internal policies, register, and publish the summaries and
results of, Clinical Trials relating to the Candidate or Product on a clinical trial register maintained by it (or an equivalent register), or as otherwise required by Law. If Pfizer is the Lead Development Party for a Clinical Trial, Pfizer shall
prepare such summaries and results in accordance with its internal policies and in a timely manner so as to allow the summaries and results to be published within the mandatory time period, and provide such summaries and results to BioNTech for
review and comment. Pfizer will give reasonable consideration to any such comments. BioNTech shall publish such summaries and results on a clinical trial register maintained by it (or an equivalent register), within the mandatory time period. 

  
 47 

 9.6. Regulatory Exclusivity. The JSC shall oversee the process of applying for and
securing exclusivity rights that may be available under the Law of countries in the Territory, including any data or market exclusivity periods such as those periods listed in the FDA’s Orange Book or Purple Book (as applicable) or periods
under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 (including any pediatric exclusivity extensions or other forms of regulatory exclusivity that may be available), and all international equivalents. 

9.7. Liability. Subject to Pfizer and its Affiliates compliance with the obligations set forth in Section 9.1.3.7 above, Pfizer
and its Affiliates, employees, agents or representatives will not be liable to BioNTech or its Affiliates in respect of any act, omission, default or neglect on the part of Pfizer, its Affiliates, or their respective employees, agents or
representatives in connection with the activities undertaken as a Lead Development Party where such activities are undertaken in good faith, unless liability arises from Pfizer’s or its Affiliates, employees, agents or representatives gross
negligence or willful misconduct. 
 9.8. Objection Right. Notwithstanding any other provision of this Section 9, as Regulatory
Approval holder, BioNTech shall have the right to object to and oppose any intended action of Pfizer as Lead Development Party if BioNTech reasonably believes Pfizer’s intended action to be contrary to applicable Law. 

9.9. Personal Data. To the extent the Parties shall be required to share Personal Data in connection with this Agreement or the
Commercialization Agreement, the Parties shall enter into a legally binding written agreement governing the Parties relationship and their processing activities as required by Applicable Data Protection Law. 

 

	10.	 INTELLECTUAL PROPERTY 

10.1. Patent Committee. Within the first [***] following the Effective Date, or as otherwise agreed by the Parties, the Parties
will establish a patent committee (the “Patent Committee”), comprised of at least one (1) representative of BioNTech and at least one (1) representative of Pfizer (which representative may be replaced by either Party at
any time through written notice to the other Party). The Patent Committee shall coordinate all activities in relation to Patent Rights applicable to the terms of this Agreement. In particular, the Patent Committee shall: 

10.1.1. coordinate all activities in relation to the filing and prosecution of Patent Rights relating to this Agreement
pursuant to Sections 10.2.1 and 10.3.1 of this Agreement, 
 10.1.2. discuss any actual, potential or suspected infringement
of such Patent Rights pursuant to Section 10.4.1, and 
 10.1.3. regularly review which BioNTech Patent Rights may be
relevant to Candidates and Products. 
 10.1.4. The Patent Committee shall meet (either
in-person or by audio or video conference) as often as determined by the Patent Committee as well as upon the reasonable request of either Party. It is acknowledged that particularly in the case of any
Enforcement Action the Patent Committee may need to meet at very short notice and be required to expedite and make decisions very quickly and the Parties shall procure that the Patent Committee shall meet urgently

  
 48 

 
as quickly as reasonably required in connection with any Enforcement Action. The Patent Committee will be chaired by a Patent Committee member chosen by mutual agreement. The Patent Committee
shall operate in good faith and acting reasonably. Sections 7.3.2 and 7.3.3, unless otherwise mutually agreed between the Parties, shall apply mutatis mutandis. The Patent Committee will use good faith efforts to reach agreement on all
matters properly brought before it. If, despite such good faith efforts, the Patent Committee is unable to reach unanimous agreement on a particular matter, such matter shall be escalated to the JSC for final resolution and decisions of the JSC in
this regard must be made by unanimous consent. 
 10.2. Ownership of Intellectual Property. 

10.2.1. Ownership of Product Technology. [***] 

10.2.2. Ownership of BioNTech Improvements and Pfizer Improvements. As between the Parties, (a) BioNTech will own
all BioNTech Improvements and (b) Pfizer will own all Pfizer Improvements. 
 10.2.3. Ownership of other Research and
Development Program Technology. Except for BioNTech Improvements, Pfizer Improvements and [***] the ownership of other Research and Development Program Technology, will be allocated based on inventorship as defined under the Laws of the United
States. Notwithstanding the foregoing, during the Term, and without prejudice to Section 10.3 the Parties (through the Patent Committee) shall cooperate and discuss in good faith with respect to the timing, scope and filing of any Patent Rights
claiming or disclosing any Research and Development Program Technology. 
 10.2.4. Ownership of Joint Technology.
Subject to Section 10.2.1, 10.2.2 and 10.2.3, the Parties will jointly own any Joint Technology. Subject to (a) the grant of licenses or sublicenses under Section 3, (b) BioNTech’s representations, warranties and covenants
under Section 12 and (c) the Parties’ other rights and obligations under this Agreement (including Section 3.10), each Party will be free to exploit, either itself or through the grant of licenses to Third Parties (which Third
Party licenses may be further sublicensed), Joint Technology throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any
payment of any compensation to the other Party. 
 10.2.5. Ownership of Other Intellectual Property. Except as set
forth in Sections 10.2.1, 10.2.4, 10.2.2 and 10.2.1, each Party will own all right, title and interest in and to any and all Know-How, Patent Rights or other Intellectual Property Rights that such Party owns
as of the Effective Date or otherwise acquires during the Term. For the purposes of determining ownership under this Agreement, as applicable, inventorship will be determined in accordance with United States patent laws. 

10.3. Patent Rights. 

10.3.1. Filing, Prosecution and Maintenance of Patent Rights.  

 

	 	10.3.1.1.	 Prosecution by BioNTech. BioNTech will have the first right, and a Commercially Reasonable Efforts
obligation, to file, prosecute and maintain the BioNTech Patent Rights owned by BioNTech or its Affiliates [***] and Patent Rights claiming BioNTech Improvements (together the “BioNTech Prosecution Patent 

  
 49 

	 	
Rights”) at BioNTech’s sole expense using counsel of its own choice reasonably acceptable to Pfizer in Australia, Canada, the member states of the European Patent Convention
including the Major EU Market Countries, Japan, the United States, Brazil, Russia, India, Mexico and South Korea (“Key Patent Jurisdictions”). Upon request of Pfizer, BioNTech shall file one or more BioNTech Prosecution Patent
Rights in one or more jurisdictions other than the Key Patent Jurisdictions (“Additional Patent Jurisdictions”), and BioNTech will have the first right, and a Commercially Reasonable Efforts obligation, to file, prosecute and
maintain such BioNTech Prosecution Patent Rights in such Additional Patent Jurisdictions at Pfizer’s sole expense (until such time as Pfizer elects not to maintain such Patent Rights in such Additional Patent Jurisdictions whereupon BioNTech
can elect to abandon or surrender the same or to continue the prosecution and maintenance of such Patent Rights at its own expense) using counsel of its own choice reasonably acceptable to Pfizer. BioNTech will keep Pfizer advised on the status of
the preparation, filing, prosecution, and maintenance of the Patent Rights included within BioNTech Prosecution Patent Rights in all the jurisdictions where filed. Further, in respect of any jurisdiction, BioNTech will (a) allow Pfizer a
reasonable opportunity and reasonable time to review and provide comments to BioNTech’s patent counsel regarding relevant substantive communications to BioNTech and drafts of any responses or other proposed substantive filings by BioNTech
before any applicable filings are submitted to any relevant patent office (or Governmental Authority) with respect to any BioNTech Prosecution Patent Rights and (b) reflect any reasonable and timely comments offered by Pfizer in any final
filings submitted by BioNTech to any relevant patent office (or Governmental Authority) with respect to any BioNTech Prosecution Patent Rights. If BioNTech elects not to file a Patent Right included in the BioNTech Prosecution Patent Rights in any
Key Patent Jurisdiction or Additional Patent Jurisdiction or elects to cease the prosecution or maintenance of one or more Patent Rights included in the BioNTech Prosecution Patent Rights in any Key Patent Jurisdiction or Additional Patent
Jurisdiction and, as relevant, no Third Party has agreed to continue the prosecution or maintenance of such Patent Rights under agreements concluded before the Effective Date, BioNTech will provide Pfizer with written notice of its decision not to
file, prosecute or maintain not less than [***] before any action is required to avoid abandonment or lapse. In the event of any such notice, if Pfizer elects to file or continue such prosecution or maintenance in the name of BioNTech at
Pfizer’s sole expense, (x) Pfizer shall be entitled to do so and take all steps in such prosecution and maintenance at its sole discretion; (y) BioNTech will reasonably cooperate to promptly transfer the necessary files and execute
the necessary forms regarding such transfer and (z) Pfizer will keep BioNTech advised on the status of such filing, prosecution and maintenance and will reasonably consider any comments made by BioNTech in connection therewith. If Pfizer elects
not to file or continue such prosecution or maintenance, then BioNTech may immediately abandon, allow to lapse, or omit to prosecute such Patent Right, as the case may be. BioNTech will promptly, and no later than [***] after written request by
Pfizer, by written notice to Pfizer update Schedule 12.3.4 to identify all BioNTech Patent Rights to be added thereto. 

  
 50 

	 	10.3.1.2.	 Other Patent Rights. Except as provided in Section 10.3.1.1, each Party will have the sole right,
but not the obligation, to file, prosecute and maintain the Research and Development Program Patent Rights or other Patent Rights that it solely owns under this Agreement or to which it otherwise has control of prosecution rights in its sole
discretion, provided that at a Party’s reasonable request, the other Party will provide status or other requested information for any Research and Development Program Patent Right and will consider in good faith any recommendations made by such
Party in regard to the filing, prosecution or maintenance of any such Patent Right. 

  

	 	10.3.1.3.	 Reference of Research and Development Program Know-How. If a
Party chooses to file, and thereafter prosecute and maintain, Patent Rights after the expiration of the Term, including any extension to the Term, that Party may use or incorporate Research and Development Program
Know-How in the filing or prosecution of such Patent Rights filed after the Term, if it determines in its sole discretion that it is necessary or useful to use or incorporate such Research and Development
Program Know-How. 

 10.3.2. Joint Patent Rights. In
the event the Parties make any Joint Know-How, the Parties will promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Joint
Patent Right without mutual consent. Unless otherwise agreed between the Parties, if the Parties decide to seek patent protection for any Joint Know-How: (a) BioNTech will have the first right, but not
the obligation, to prepare, file, prosecute and maintain any Joint Patent Right predominantly relating to the RNA Technology or RNA Process Technology throughout the world, and (b) Pfizer will have the first right, but not the obligation, to
prepare, file, prosecute and maintain any other Joint Patent Right throughout the world, in each case of (a) and (b) with the respective provisions of Section 10.3.1.1 to apply mutatis mutandis except as provided in this
Section 10.3.2. The non-filing Party will reimburse the filing Party for 50% of the costs reasonably incurred by the filing Party in preparing, filing, prosecuting and maintaining such Joint Patent
Rights, which reimbursement will be made pursuant to, and within 75 days of, invoices (including supporting documentation) submitted by the filing Party to the non-filing Party no more often than once per
Pfizer Quarter. The non-prosecuting Party will cooperate with the prosecuting Party in taking reasonable measures to control costs and non-prosecuting Party shall be
responsible for 100% of (x) any fees or costs related to any correspondence of outside counsel with or instructions to outside counsel by such Party (or any of such Party’s Representatives) which is independent of joint prosecution
efforts, or (y) any patent office fees, and associated counsel/agent fees and costs, for extensions which are not incurred at the request of, and not due to the actions of, the prosecuting Party. If, once the Parties have agreed to prepare and
file an application of Joint Patent Rights, either Party (the “Declining Party”) at any time thereafter declines to participate in the preparation, filing, prosecution or maintenance of any Joint Patent Right or share in the costs
of filing, prosecuting and maintaining any Joint Patent Right, on a country-by-country basis, the Declining Party will provide the other Party (the “Continuing
Party”) with 30 days prior written notice to such effect, in which event, the Declining Party will (A) have no responsibility with respect to the filing, prosecution or maintenance of the applicable Joint Patent Right after the end of
such 30 day period, (B) have no responsibility for any expenses incurred in connection with such Joint Patent Right after the end of such 30 day period and (C) if 

  
 51 

 
the Continuing Party elects to continue filing, prosecution or maintenance, the Declining Party, upon the Continuing Party’s request, will execute such documents and perform such acts, at
the Continuing Party’s expense, as may be reasonably necessary (1) to assign to the Continuing Party all of the Declining Party’s right, title and interest in and to such Joint Patent Right and (2) to permit the Continuing Party
to file, prosecute and maintain such Joint Patent Right at its sole expense. Where such Joint Patent Right is assigned to Pfizer as the Continuing Party, BioNTech will retain a non-exclusive, sublicensable,
perpetual, irrevocable, royalty-free, fully paid-up worldwide right and license to practice and exploit such Patent Right for any and all purposes excluding, during the Term, in the Field; and where such Joint
Patent Right is assigned to BioNTech as the Continuing Party, it will be excluded from the definition of BioNTech Patent Rights, and Pfizer will retain a non-exclusive, sublicensable, perpetual, irrevocable,
royalty-free, fully paid-up worldwide right and license to practice and exploit such Joint Patent Right for any and all purposes. 

10.3.3. Prosecution by Third Party Licensors. Except in the ordinary course of filing continuation applications,
BioNTech shall not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under any BioNTech Third Party Agreement in any Key Patent Jurisdiction (or other country to the extent doing so may result in
BioNTech’s loss of license to such Patent Right in such country), to the extent BioNTech is obligated to pay for, or has the right to participate in, such filing, prosecution or maintenance, that is included in the BioNTech Patent Rights and
that, in Pfizer’s reasonable opinion, covers any Candidate, Product or [***] in the Field in the Territory, and the loss of which would result in loss of right to or would materially diminish the overall protection of such Candidate or Product,
without Pfizer’s prior written consent, not to be unreasonably withheld or delayed. 
 10.3.4. Patent Term
Restoration and Extension. Upon the request of either Party, the Parties will (through the Patent Committee) reasonably discuss patent term extension and supplemental protection certificate strategies in relation to Patent Rights Covering
Candidates or Products at any time. Notwithstanding the above, within the time period specified by applicable Law upon receiving Regulatory Approval for a Product in any country in the Territory, [***]. [***] 

10.3.5. Clarifications. For clarity, prosecution under this Section 10.3 includes opposition,
revocation and post-grant review proceedings before the granting patent office or other patent office proceedings (“Prosecution Proceeding”). If such Prosecution Proceedings are concurrent with Third Party litigation under
Section 10.4 and are applicable to or part of a coordinated enforcement of such rights, the prosecuting Party and the enforcing Party shall work together and closely align their prosecution and enforcement strategy in accordance with
Section 10.5 (including the right for one Party to have final control as stipulated in Section 10.5). 
 10.3.6.
Liability. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right or otherwise exercising its rights under this Section 10.3, such Party, and its Affiliates, employees, agents or representatives, will
not be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. 

  
 52 

 10.3.7. Recording. If either Party deems it necessary or useful to
register or record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority(ies) in one or more jurisdictions, the other Party will reasonably cooperate to execute and deliver to such Party any
documents accurately reflecting or evidencing this Agreement that are necessary or useful, in such Party’s reasonable judgment, to complete such registration or recordation. 

10.3.8. Joint Research Agreement. This Agreement shall be understood to be a joint research agreement under 35
U.S.C. § 103(c)(3) for pre-AIA Patent Rights and 35 U.S.C. § 100(h) for post-AIA Patent Rights entered into for the purpose of researching, identifying and
Developing Candidates and Products. 
 10.4. Enforcement of Patent Rights. 

10.4.1. Notification of Infringement and Decision about Enforcement Actions. Each Party will promptly notify the other
(through the Patent Committee) in the event of any actual, potential or suspected infringement of a patent under the BioNTech Patent Rights or Research and Development Program Patent Rights by any Third Party. In the event of any such notification,
the Parties will (through the Patent Committee) discuss in good faith the relevant actual, potential and suspected infringement and the risks and chances of success as well as chances of settlement connected with the institution of any litigation or
other step to remedy infringement (any such steps, or threat of or assertion or enforcement of a Patent Right being an “Enforcement Action”) taking into account the possible uses of the relevant Patent Rights by each Party, its
respective Affiliates or its or their licensees and the revenues relating to or impacted by such Patent Rights, with the goal to agree on whether or not any Enforcement Action should be taken and, if yes, to closely coordinate so far as reasonably
possible their respective efforts and strategies. The Parties acknowledge that time shall be of the essence in connection with any Enforcement Action and each shall move urgently and expeditiously to discuss and seek agreement on any actual or
proposed Enforcement Action. 
 10.4.2. Enforcement of BioNTech Patent Rights and Product Patent Rights. Subject to
Section 10.4.1, and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, BioNTech shall have the first right, but
not the obligation, to institute any Enforcement Action in connection with the BioNTech Patent Rights [***] in the Field in the Territory (the “BioNTech Enforcement Patent Rights”), and any such Enforcement Action will be at
BioNTech’s expense including BioNTech indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates consent to join any such Enforcement Action upon BioNTech’s request,
or where required by Law or where Pfizer or its Affiliates are enjoined by the counterparty. BioNTech shall not name as a party Pfizer or its Affiliates in any Enforcement Action without Pfizer’s prior written consent. In any event, BioNTech
will not, without the prior written consent of Pfizer, enter into any compromise or settlement relating to such litigation that (a) admits the invalidity or unenforceability of any BioNTech Enforcement Patent Right or (b) requires BioNTech
to abandon any BioNTech Enforcement Patent Right. Upon the request of BioNTech, Pfizer shall have the sole discretion to decide whether or not to join as a party in any such Enforcement Action, and where it elects to do so it shall, at
BioNTech’s expense, join and cooperate with BioNTech in such Enforcement Action. Pfizer will have the right to consult with, and provide comments to, BioNTech about such Enforcement Action (irrespective of Pfizer or its Affiliate being a party
to such Enforcement 

  
 53 

 
Action), and to participate in and be represented by independent counsel in such Enforcement Action at Pfizer’s own expense, and BioNTech shall take into account any reasonable comments
provided by Pfizer in such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party’s indemnification obligation pursuant to Section 15) as a consequence of any Enforcement Action
initiated or pursued pursuant to this Section 10.4 or any unfavorable decision resulting therefrom, including any decision holding any BioNTech Enforcement Patent Rights invalid or unenforceable. Any infringement recoveries resulting from such
litigation or steps relating to a claim of Third Party infringement, after deducting BioNTech’s out of pocket expenses (including counsel fees and expenses including any adverse cost award) in pursuing such claim, will be treated as Gross
Profits for the purposes of the Commercialization Agreement. 
 10.4.3. Pfizer’s Enforcement Rights. In respect
of an infringement of any BioNTech Enforcement Patent Right in the Field in the Territory in connection with a Competitive Product (“Competitive Product Infringement”), if, following (a) discussion of any potential Enforcement
Action pursuant to Section 10.4.1 and (b) a subsequent written request by Pfizer to initiate any Enforcement Action in connection with such Competitive Product Infringement, BioNTech does not initiate any Enforcement Action in connection
with such Competitive Product Infringement within thirty (30) days following receipt of such notices, or as soon as possible and in any event no later than ten (10) Business Days if preliminary injunction proceedings are a potential or
likely recourse to remedy the infringement), or ten (10) days before the time limit, if any, set forth in the applicable Laws for the filing of such actions, Pfizer shall have the right, but not the obligation, in place of BioNTech to institute
any Enforcement Action in connection with such Competitive Product Infringement and any such Enforcement Action will be at Pfizer’s expense and the provisions set forth in the first paragraph of this Section 10.4.2 shall apply mutatis
mutandis. Pfizer’s rights with respect to an Enforcement Action for BioNTech Enforcement Patent Rights other than Product Patent Rights shall be limited to (i) Major Market Countries; (ii) Enforcement Actions in countries in which
a Competitive Product (or part thereof) reasonably believed to be designated for any Major Market Country is Manufactured; and (iii) Enforcement Actions in Belgium, Ireland or the Netherlands that are in parallel with Enforcement Actions in any
of the Major EU Market Countries. [***] 
 10.4.4. BioNTech Enforcement outside the Field and/or outside the
Territory. Subject to Section 10.4.1 and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, BioNTech shall
have the sole right, but not the obligation, to institute any Enforcement Action outside the Field and/or outside the Territory in connection with any BioNTech Enforcement Patent Rights), and any such Enforcement Action will be at BioNTech’s
expense including BioNTech indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates consent to join any such Enforcement Action upon BioNTech’s request, where required
by Law or where Pfizer or its Affiliates are enjoined by the counterparty. BioNTech shall not name as a party Pfizer or its Affiliates in any Enforcement Action without Pfizer’s prior written consent. In any event, BioNTech will not, without
the prior written consent of Pfizer, enter into any compromise or settlement relating to such Enforcement Action that (i) admits the invalidity or unenforceability of any BioNTech Enforcement Patent Rights or (ii) requires BioNTech to
abandon any BioNTech Enforcement Patent Rights. Upon the request of BioNTech, Pfizer shall have the sole discretion to decide whether or not to join as a party in any such Enforcement Action, and where it elects to do so it shall, at BioNTech’s
expense, join and cooperate with BioNTech in such Enforcement Action. 

  
 54 

 
Pfizer will have the right to consult with, and provide comments to, BioNTech about such Enforcement Action (irrespective of Pfizer or its Affiliate being a party to such Enforcement Action), and
to participate in and be represented by independent counsel in such Enforcement Action at Pfizer’s own expense, and BioNTech shall take into account any reasonable comments provided by Pfizer in such Enforcement Action. Neither Party will incur
any liability to the other Party (other than that related to a Party’s indemnification obligation pursuant to Section 15 or otherwise in this sub-section) as a consequence of any Enforcement Action
initiated or pursued pursuant to this Section 10.4.3 or any unfavorable decision resulting therefrom, including any decision holding any BioNTech Enforcement Patent Rights invalid or unenforceable. 

10.4.5. Pfizer Patent Rights. Pfizer shall have the sole right, but not the obligation, to institute litigation or take
other steps to remedy infringement in connection with any field in respect of any Patent Rights that it solely owns including any Pfizer Patent Right. In the event that any such Patent Rights are based on inventions made or created solely or jointly
by BioNTech, its Affiliates or its Representatives acting on BioNTech’s behalf, BioNTech shall provide reasonable assistance to Pfizer at Pfizer’s expense in connection with such litigation. 

10.4.6. Biosimilar Notices. 
  

	 	10.4.6.1.	 BioNTech Cooperation. Upon Pfizer’s request, BioNTech and Pfizer will use Commercially Reasonable
Efforts to assist and cooperate with each other in (A) establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and (B) preparing submissions responsive to any Biosimilar
Notices received by Pfizer or BioNTech; provided that BioNTech will make the final decisions with respect to such strategy and any such responses. 

  

	 	10.4.6.2.	 Compliance with Biosimilar Notices. The MA Holder will have the sole right in its discretion to comply
with the applicable provisions of 42 U.S.C. § 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in the United States, or any similar
statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received from any Third Party regarding any Product that is
being Commercialized in the Field in the Territory in the applicable jurisdiction, and the exchange of information between any Third Party and such MA Holder pursuant to such requirements; provided that, prior to any submission of information
by MA Holder to a Third Party, the other Party will have the right to review the patent information included in such proposed submission, and to make suggestions as to any changes to such patent information that Pfizer reasonably believes to be
necessary; provided further that MA Holder will determine the final content of any such submission. In the case of a Product approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United
States, any similar Law), to the extent permitted by applicable Law, the MA Holder, as the sponsor of the application for the Product, will be the “reference product sponsor” under the PHS Act. The MA Holder will give written notice to the
other Party of receipt of a Biosimilar Notice received by MA Holder with respect to a Product, and MA Holder will consult with the other Party 

  
 55 

	 	
with respect to the selection of any Patent Rights to be submitted pursuant to 42 U.S.C. § 262(l) (or any similar law in any country of the Territory outside the United States);
provided that the MA Holder will have final say on such selection of Patent Rights. Such other Party agrees to be bound and will cause its Affiliates and use Commercially Reasonable Efforts to cause all Third Party Licensors to be bound by
the confidentiality provisions of 42 U.S.C. § 262(l)(1)(B)(iii). In connection with any action brought by such other Party under this Section 10.4.6, such other Party, upon the MA Holder’s request, will reasonably cooperate and will
cause its Affiliates and use Commercially Reasonable Efforts to cause all Third Party Licensors to reasonably cooperate with MA Holder in any such action, including timely commencing or joining in any action brought by MA Holder under this
Section 10.4.6. 

 10.4.7. Unified Patent Court. In respect of BioNTech Enforcement Patent Rights,
for each and every such Patent Right having effect anywhere within any member state that was or is, from time to time, a signatory to the UPC Agreement, BioNTech shall have the sole discretion to decide whether to (a) opt in or opt out (and to
opt in again), pursuant to Article 83 of the UPC Agreement, of the Unified Patent Court system; and (b) elect if such Patent Rights should, during their prosecution, be designated as a Unitary Patent or a European Patent. The other Party shall
promptly do all things necessary and execute all documents and make all necessary elections required to give effect to such decision(s) or election(s). 

10.4.8. Settlement Cross-Licensing. If pursuant to a bona fide settlement of any Enforcement Action or Infringement
Claim controlled by Pfizer, Pfizer, with BioNTech’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, grants to a Third Party (that was a party to the Enforcement Action or Infringement Claim) any
sublicense to any of the Patent Rights licensed to Pfizer under this Agreement in respect of that Third Party’s Competitive Product, then Pfizer shall pay to BioNTech (a) at a minimum, if such sublicense includes any of the rights granted
to Pfizer under a Current License or future BioNTech Third Party Agreement (subject to Sections 3), all royalties due by BioNTech to the relevant Third Party for such sublicense under any Current License and Future BioNTech Third Party Agreement in
respect of licensed sales of such Third Party Competitive Product and (b) all other royalties received by Pfizer shall be deemed Gross Profits. For the avoidance of doubt, should the Third Party as part of the same agreement grant any
cross-license to Pfizer (sublicensable to BioNTech for the purposes of this Agreement) for any Candidates or Products, such cross-license shall not be deemed “non-cash” consideration for the purpose
of the Net Sales definition. 
 10.5. Other Actions by Third Parties. Separate from Prosecution Proceedings, each Party will promptly
notify the other Party in the event of any legal action by any Third Party involving any BioNTech Enforcement Patent Rights of which it becomes aware, including any nullity, revocation, declaratory judgment, interference, inter partes
reexamination, reexamination or compulsory license proceeding. The right to defend against any such action shall be with the Party controlling the filing, prosecution and maintenance of the affected Patent Right (as determined in accordance with
Section 10.3.1), and the provisions of Section 10.3.1 shall apply mutatis mutandis in respect of such defense. If any such action has been instituted by any Third Party in response to, or in connection with, any Enforcement Action
pursuant to Section 10.4, or any Enforcement Action is to be pursued as a consequence of such action being instituted by any Third Party, the Party controlling the Enforcement Action and the Party controlling the defense shall work together and
closely align their enforcement and defense strategy, which may include the (joint) appointment of the same patent counsel for all concurrent Third Party litigation and patent office proceedings taking into account the impact on enforcement and
potential for revenues relating to such 

  
 56 

 
Patent Rights, and in the absence of agreement, the enforcing Party shall have the final say over the Prosecution Proceedings in so far as the Prosecution Proceeding will adversely impact the
ongoing enforcement of such right, subject to having given good faith consideration to the comments and suggestions of the prosecuting Party. Further details of such joint proceeding may be agreed between the Parties from time to time. 

10.6. Purple Book Listings. To the extent of any BioNTech Enforcement Patent Rights, the Parties shall cooperate with each other to
enable BioNTech to make filings with Regulatory Authorities, as required or allowed in connection with (a) in the United States, the FDA’s Purple Book and the Biologics Price Competition and Innovation Act and (b) outside the United
States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents thereof within the Territory. Pfizer shall consider BioNTech’s reasonable requests in connection therewith, including
meeting any submission deadlines, in each case, to the extent required or permitted by applicable Law. 
 10.7. Allegations of
Infringement and Right to Seek Third Party Licenses. 
 10.7.1. Notice. If either Party becomes aware that the
Development, Manufacture, Commercialization or use of any Candidate or Product, the practice of any BioNTech Technology or Research and Development Program Technology in the Field, or the exercise of any other right granted by BioNTech to Pfizer or
any of its Affiliates or Sublicensees hereunder (collectively, the “Licensed Activities”) is alleged by a Third Party to infringe, misappropriate or otherwise violate such Third Party’s Patent Rights or other Intellectual
Property Rights or either Party otherwise identifies any Third Party Patent Rights or other Intellectual Property Rights that may be relevant to such Licensed Activities (collectively, an “FTO Action”), such Party will, as soon as
reasonably practicable, notify the other Party in writing and the Parties will discuss the FTO Action in good faith to determine and agree upon a resolution of the same. 

10.7.2. Option to Negotiate. If the Parties determine that to resolve the FTO Action it is necessary or useful to obtain
a license under one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party, then [***]; will negotiate and enter into a license or other agreement with such Third Party in close coordination with the other Party. If
the Parties do not agree that a license from a Third Party is necessary or useful to resolve the FTO Action, the Party who considers a license is necessary or useful to resolve the FTO Action shall be entitled to negotiate and enter into a license
or other agreement with such Third Party, but shall do so keeping the other Party reasonably informed. [***] [***]. 

  
 57 

 10.8. Third Party Infringement Suits. Each of the Parties will promptly notify the
other in the event that any Third Party files any suit or brings any other action alleging patent infringement by Pfizer or BioNTech or any of their respective Affiliates or Sublicensees with respect to the Development, Manufacture,
Commercialization or use of any Candidate or Product or the practice of any BioNTech Technology or Research and Development Program Technology (any such suit or other action referred to herein as an “Infringement Claim”). In the
case of any Infringement Claim against Pfizer (including its Affiliates or Sublicensees) alone, or against both Pfizer and BioNTech (including their respective Affiliates), Pfizer will have the right, but not the obligation, to control the defense
of such Infringement Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. BioNTech, upon request of Pfizer, agrees to cooperate with Pfizer at Pfizer’s expense. BioNTech
will have the right to consult with Pfizer concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation in which BioNTech is a party at BioNTech’s own expense. If Pfizer elects
to control the defense of any Infringement Claim and BioNTech is obligated under Section 15.3 to indemnify Pfizer (including any Pfizer Indemnified Party) with respect to such Infringement Claim, then (a) Pfizer will bear 100% of its own
attorneys’ fees incurred in investigating, preparing or defending such Infringement Claim notwithstanding the provisions of Section 15.3 and (b) BioNTech will otherwise indemnify Pfizer and any applicable Pfizer Indemnified Parties to
the full extent provided for under Section 15.3, provided that Pfizer shall not enter into any compromise or settlement with the Third Party in respect of such Infringement Claim without BioNTech’s prior written consent (such consent not
to be unreasonably withheld, conditioned or delayed) where such compromise or settlement requires the payment of monetary penalty or damages that are indemnified by BioNTech under this Agreement. In the case of any Infringement Claim against
BioNTech alone, Pfizer will have the right to consult with BioNTech concerning such Infringement Claim and Pfizer, upon request of BioNTech, will reasonably cooperate with BioNTech at BioNTech’s expense. Neither Party will enter into any
compromise or settlement in respect of an Infringement Claim admitting or implying that the Development, Manufacture, Commercialization or use of any Candidate or Product or the practice of any BioNTech Technology or Research and Development
Program Technology infringes Third Party patents without the other Party’s written consent. 
  

	11.	 CONFIDENTIALITY 

11.1. Confidentiality. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and
for [***] years thereafter (except to the extent a longer period is required by a Current License applicable for such Confidential Information disclosed pursuant to that Current License), each Party (the “Receiving Party”)
receiving any Confidential Information of the other Party (the “Disclosing Party”) hereunder will: (a) keep the Disclosing Party’s Confidential Information confidential; (b) not disclose, or permit the disclosure of,
the Disclosing Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose other than as expressly permitted under the terms of this Agreement (including
under any license or right of use granted hereunder). 
 11.2. Authorized Disclosure.  

11.2.1. Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 11.1, the
Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s Representatives who (a) have a need to know such Confidential Information in connection with the performance of the Receiving
Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use
provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 10.1. 

  
 58 

 11.2.2. Disclosure to Third Parties. Notwithstanding the foregoing
provisions of Section 11.1, each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary: 
  

	 	11.2.2.1.	 to Governmental Authorities to the extent useful, to (a) obtain or maintain Regulatory Approvals for any
Candidate or Product within the Territory; or (b) obtain or maintain Regulatory Approvals for a product comprising a Candidate in the Field outside of the Territory; and (c) in order to respond to inquiries, requests or investigations
(i) relating to Candidates or Products or this Agreement within the Territory; or (ii) relating to any product comprising a Candidate in the Field outside of the Territory; provided, however, that BioNTech may not disclose any
Pfizer Confidential Information to Fosun or its Affiliates without the prior written consent of Pfizer, other than to the extent necessary for Fosun or its Affiliates (or such other collaboration partner in or for China) to undertake fill/finish of
a product identical to any Product in China or to comply with information requirements of the China National Medical Products Administration relating to such product required under applicable Law, in each case so far as such use is licensed under
Sections 3.4.2(b) or 3.4.4(b); 

  

	 	11.2.2.2.	 to outside consultants (including any professional advisor), potential acquisition partners (including any
potential successors in interest), private investors or financing sources, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent
useful to develop, register or market any Candidate or Product within the Territory; provided that the Receiving Party will obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar
types of confidential information; 

  

	 	11.2.2.3.	 in connection with filing or prosecuting Research and Development Program Patent Rights, Product Patent Rights
or Trademark rights as permitted by this Agreement; 

  

	 	11.2.2.4.	 in connection with any prosecution or litigation actions or defenses undertaken pursuant to Section 10 or
any other litigation directly related to a Candidate or Product in the Field in the Territory; 

  

	 	11.2.2.5.	 subject to the provisions of Section 11.5.2, in connection with or included in scientific presentations
and publications relating to Candidates or Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; 

 

	 	11.2.2.6.	 by either Party in respect of Confidential Information belonging to the other Party (including the terms of the
Agreement) to any bona fide or potential subcontractor under this Agreement in connection with the Development of the Candidate or Product in the Territory, in each case who has agreed in writing to
non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 10.1; and

  
 59 

	 	11.2.2.7.	 to the extent necessary or useful in order to enforce its rights under this Agreement. 

Notwithstanding anything herein to the contrary, each Party acknowledges and agrees that the use by a Party of the other
Party’s Confidential Information disclosed under the Flu Collaboration License in the performance of this Agreement is not a breach of the confidentiality obligations under this Agreement or the Flu Collaboration License, and vice versa. If a
Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to clause (a) or any of clauses (c) through (e) of this Section 11.2.2, then the Disclosing Party will to the extent
possible give reasonable advance written notice of such disclosure to the other Party and take such measures to ensure confidential treatment of such information as is reasonably required by the other Party, at the other Party’s expense. 

11.3. SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement and make any other public written
disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) applicable Law, including the rules and regulations
promulgated by the United States Securities and Exchange Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in any country. Before disclosing this Agreement or any of the terms hereof pursuant
to this Section 11.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the Party disclosing pursuant to this Section 11.3 providing as much advance notice as is
feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 11.3, such Party will, at its own expense,
seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party and limit its disclosure of such Confidential Information to only that required to comply with
applicable Law. 
 11.4. Residual Knowledge Exception. Notwithstanding any provision of this Agreement to the contrary,
Residual Knowledge will not be considered Confidential Information for purposes of this Section 10.1; provided that, for clarity, a Party’s rights to Residual Knowledge hereunder shall not include the right to practice any Patent
Right owned or Controlled by the other Party that claims such Residual Knowledge unless otherwise expressly granted in another provision of this Agreement or in another agreement between the Parties. 

11.5. Public Announcements; Publications. 

11.5.1. Announcements. Except as may be expressly permitted under Section 11.3, neither Party will make any public
announcement regarding this Agreement without the prior written approval of the other Party. The Parties agree that the Parties will issue a mutually agreed upon joint press release regarding the signing of this Agreement following the Signing Date.

 11.5.2. Publications. During the Term, each Party will submit to the other Party for review and approval (such
approval not to be unreasonably withheld, delayed or conditioned) any proposed publication or public presentation proposed by a Party or its Affiliates or any of their respective Representatives that relates to the activities conducted under this
Agreement, including the Research and Development Plan ; provided that notwithstanding the requirement for approval (a) neither Party shall be prevented from submitting any publication or making a presentation in respect of a Clinical
Trial for which the Party is either the IND holder or the Lead Development Party to 

  
 60 

 
the extent such publication or presentation is required under applicable Law or such Party’s internal publication policies, but such publishing Party shall not disclose the other
Party’s confidential information in respect of its technology and Intellectual Property Rights, and shall take on board and reasonably consider any reasonable requests of the other Party with respect to such proposed publication or
presentation; (b) the Party whose approval is sought shall not unreasonably withhold or condition such approval; and (c) nothing shall prohibit a Party from making any press release or statement where required pursuant to applicable Law or
stock exchange rule, subject to such publishing Party shall take on board and reasonably consider any reasonable requests of the other Party with respect to such proposed publication or presentation. Each Party’s review and
approval will be conducted only for the purposes of identifying if confidential information should be modified or deleted so as to preserve the value of the technology owned by such Party or its Affiliates and the rights granted to each Party
hereunder. Written copies of such proposed publication or presentation required to be submitted hereunder will be submitted as soon as practically possible before submission for publication or presentation (the “Review Period”). The
reviewing Party will provide its comments with respect to such publications and presentations within 7 Business Days of its receipt of such written copy. The Review Period may be extended for an additional 10 Business Days in the event a Party can,
within 7 Business Days of receipt of the written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. Each Party will comply with standard academic practice regarding authorship of
scientific publications and recognition of contribution of other parties in any publication governed by this Section 11.5.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions. 

11.6. Non-Disclosure in China. For the avoidance of doubt, nothing in this Agreement authorizes
or permits BioNTech to disclose to Fosun, its Affiliates or any other collaboration partner in or for China any Pfizer Confidential Information without the prior written consent of Pfizer other than to the extent necessary for Fosun or its
Affiliates (or such other collaboration partner in or for China) to undertake fill/finish of a product identical to any Product in China or to comply with information obligations required by the China National Medical Products Administration
relating to such product in accordance with applicable Law, in each case so far as such use is licensed under Sections 3.4.2(b) or 3.4.4(b). 

11.7. Obligations in Connection with Change of Control. If a Party is subject to a Change of Control or if a Party or any of its
Affiliates acquires or merges with a Third Party during the Term (“Change of Control Party”), such Change of Control Party will, and it will cause its Representatives to, ensure that no Confidential Information of the other Party is
released to (a) any Affiliate of the Change of Control Party that becomes an Affiliate of the Change of Control Party as a result of the Change of Control or (b) any other Representatives of the Change of Control Party (or of the relevant
surviving entity of such Change of Control) who become Representatives of the Change of Control Party as a result of the Change of Control, unless such Affiliate or other Representatives, as applicable, have signed individual confidentiality
agreements which include equivalent obligations to those set out in this Section 11. Upon occurrence of a Change of Control, the Change of Control Party will promptly notify the other Party, share with the other Party the policies, procedures
and technical and organizational measures it plans to implement in order to protect the confidentiality of the other Party’s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are
reasonably requested by the other Party. 

  
 61 

	12.	 REPRESENTATIONS AND WARRANTIES 

12.1. Mutual Representations and Warranties. Each of BioNTech and Pfizer hereby represents and warrants to the other Party that:

 12.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
organization; 
 12.1.2. the execution, delivery and performance of this Agreement by such Party has been duly authorized by
all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests; 

12.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

12.1.4. this Agreement has been duly executed and is a legal, valid and binding obligation on each Party, enforceable against
such Party in accordance with its terms; and 
 12.1.5. the execution, delivery and performance by such Party of this
Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. 

12.2. Mutual Covenants. In addition to the covenants made by the Parties elsewhere in this Agreement, each of BioNTech and
Pfizer hereby covenants to the other Party that, from the Effective Date until expiration or termination of this Agreement it will perform its obligations under this Agreement in compliance with applicable Laws. 

12.3. Representations and Warranties of BioNTech. BioNTech hereby represents and warrants to Pfizer that, unless otherwise
disclosed in Schedule 12.3 (or otherwise as accepted to have been disclosed between BioNTech’s external counsel and Pfizer’s external counsel other than in writing), and provided that those provisions of the Current Licenses set
forth in Schedule 1.36 shall be deemed disclosed against the representations and warranties given by BioNTech at sections 12.3.1, 12.3.2, 12.3.4, 12.3.10 and 12.3.11 of this Agreement and provided further that all disclosures made under the
Flu Collaboration License shall be deemed disclosed also under this Agreement: 
 12.3.1. as of the Signing Date, except with
respect to BioNTech Technology Controlled by BioNTech pursuant to a Current License, BioNTech or its Affiliates are the sole and exclusive owner of the BioNTech Technology, and all BioNTech Technology is free and clear of any claims, liens, charges
or encumbrances; 
 12.3.2. as of the Signing Date, BioNTech has, and to its knowledge will have, the full right, power and
authority to (a) grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer, Pfizer’s Affiliates or Pfizer’s Sublicensees under this Agreement and (b) perform its obligations
under this Agreement; 
 12.3.3. Schedule 1.17 sets forth a true and complete list of all Candidates relevant to the
Field discovered, developed or Controlled by BioNTech or its Affiliates on or prior to the Signing Date; 
 12.3.4. as of the
Signing Date, (a) Schedule 12.3.4 sets forth a true and complete list of all Patent Rights (i) owned or otherwise Controlled by BioNTech or its Affiliates or (ii) to which BioNTech or its Affiliates have been granted or
otherwise transferred any right to practice under, in each case of (i) and (ii), that relate to the Candidates, the Products, the BioNTech Technology, or the Parties’ activities in the Research and Development Program, (b) each such
Patent Right is in full force and effect and, so far as BioNTech is aware, valid and enforceable, (c) BioNTech or 

  
 62 

 
its Affiliates have timely paid, or caused the appropriate Third Parties to pay, all filing and renewal fees payable with respect to such Patent Rights; (d) BioNTech Controls all Patent
Rights listed in Schedule 12.3.4; and (e) other than those licensed hereunder, there are no other Patent Rights owned or Controlled by BioNTech that Candidates or Products would infringe; 

12.3.5. as of the Signing Date, BioNTech is not aware of any material adverse event, or medical or scientific concern or doubt
regarding the safety, contraindications or effectiveness of the use of the BioNTech Technology or the Candidates that have not previously been disclosed in writing to Pfizer; 

12.3.6. to BioNTech’s knowledge as of the Signing Date, (a) no Third Party (i) is infringing any BioNTech Patent
Right or (ii) has challenged or threatened in writing to challenge the ownership, scope, validity or enforceability of, or BioNTech’s or any Current Licensor’s rights in or to, any BioNTech Patent Right (including, by way of example,
through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

12.3.7. as of the Signing Date, BioNTech has independently developed all BioNTech
Know-How and BioNTech Materials or otherwise has a valid right to use, and to permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, the BioNTech
Know-How and BioNTech Materials for all permitted purposes under this Agreement; 

12.3.8. except with respect to BioNTech Technology Controlled by BioNTech pursuant to a Current License, BioNTech or its
Affiliates have obtained from all inventors of BioNTech Technology existing as of the Signing Date, valid and enforceable agreements assigning to BioNTech or its Affiliates each such inventor’s entire right, title and interest in and to all
such BioNTech Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology automatically vests in BioNTech or its Affiliates by operation of law); 

12.3.9. in respect of BioNTech Technology solely or jointly owned by BioNTech existing as of the Signing Date, neither BioNTech
nor its Affiliates are subject to any funding agreement with any government or Governmental Authority; 
 12.3.10. as of the
Effective Date (a) there are no BioNTech Third Party Agreements other than the Current Licenses set forth in Schedule 1.36, (b) true and complete copies of each Current License (other than the Fosun Agreement) have been provided to
Pfizer, (c) except as provided in the Current Licenses, no Third Party has any right, title or interest in or to, or any license under, any BioNTech Technology in the Field, (d) no rights granted by or to BioNTech or its Affiliates under
any Current License conflict with any right or license granted to Pfizer or its Affiliates hereunder and (e) BioNTech and its Affiliates are in compliance in all material respects with all Current Licenses; 

12.3.11. as of the Signing Date, to BioNTech’s knowledge, the use by BioNTech or Pfizer (or their respective Affiliates or
Sublicensees) of the BioNTech Technology in accordance with this Agreement, and the Development, Manufacture or Commercialization of those Candidates listed in Schedule 1.17 or Products incorporating such Candidates in accordance with this
Agreement (a) does not and will not infringe any Patent Right of any Third Party or (b) will not infringe the claims of any published Third Party pending Patent Right when and if such claims issue; 

  
 63 

 12.3.12. as of the Effective Date, there is no (a) written claim,
demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to BioNTech’s knowledge, made or threatened (irrespective of whether or not in writing)
against BioNTech or any of its Affiliates or (b) judgment or settlement against or owed by BioNTech or any of its Affiliates, in each case in connection with the BioNTech Technology, the Current Licenses, any Candidate or Product or relating to
the transactions contemplated by this Agreement; 
 12.3.13. as of the Signing Date, BioNTech and its Affiliates
(a) have claimed and remunerated all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA; and (b) are entitled to unrestrictedly claim all rights to employee
inventions of their employees comprised within the GEIA Technology; 
 12.3.14. as of the Signing Date, BioNTech has obtained
all necessary assignment documents for the BioNTech Technology inventions in its files and maintains written track records of the proper claiming of any inventions made by employees of BioNTech, its Affiliates or Third Parties included in BioNTech
Technology or Research and Development Program Technology by the employer and/or the proper assignment of the inventors of their rights in the invention, including the right to claim priority to said invention, to the employer; 

12.3.15. as of the Signing Date, BioNTech has no knowledge of (a) any inequitable conduct or fraud on any patent office
with respect to any of the BioNTech Patent Rights or (b) any Person (other than Persons identified in the applicable patent applications or patents, as inventors of inventions disclosed in the BioNTech Patent Rights) who claims to be an
inventor of an invention disclosed in the BioNTech Patent Rights; 
 12.3.16. as of the Signing Date, BioNTech and its
Affiliates are not, and to BioNTech’s knowledge, no Current Licensor or Representative of BioNTech (in each case, as applicable) is, debarred by any Regulatory Authority or the subject of debarment proceedings by any Regulatory Authority and,
in the course of the discovery or pre-clinical development of any Candidate or Product, BioNTech and its Affiliates have not and, to the knowledge of BioNTech, no Current Licensor or Representative of BioNTech
(in each case, as applicable) have used any employee or consultant that is debarred by any Regulatory Authority or, to the knowledge of BioNTech, is the subject of debarment proceedings by any Regulatory Authority; 

12.3.17. BioNTech, its Affiliates, and to BioNTech’s knowledge, all third parties and Representatives acting on
BioNTech’s behalf, have and will comply in all material respects with all applicable Law and accepted pharmaceutical industry business practices in connection with this Agreement, including, to the extent applicable, the FD&C Act (21 U.S.C.
§ 301, et seq.), the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. § 1320a-7a), the False Claims Act (31 U.S.C.
§ 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA, consistent with the ‘Compliance Program Guidance for Pharmaceutical Manufacturers’ published by
the Office of Inspector General, U.S. Department of Health and Human Services; 
 12.3.18. with respect to any Candidates,
Products, or payments or services provided under this Agreement, BioNTech, its Affiliates, and to its knowledge all third parties and Representatives acting on BioNTech’s behalf, have not taken and will not during the Term take any action
directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper
advantage, and has not accepted, and will not accept in the future such payment; 

  
 64 

 12.3.19. BioNTech, its Affiliates, and to its knowledge all third parties
and Representatives acting on BioNTech’s behalf, have and will continue to comply with the laws and regulations of the countries where it operates, including Anti-Corruption Laws, accounting and record keeping laws, and laws relating to
interactions with HCPs, Governments and Government Officials; 
 12.3.20. BioNTech has implemented policies and procedures,
including but not limited to anti-corruption policies and procedures, commensurate with its current risk profile, and shall review said policies from time to time setting out rules governing interactions with HCPs and Government Officials,
engagement of Third Parties, including, where appropriate, due diligence (“Policies”), and its Policies will mandate a robust set of internal controls, including accounting controls, designed to ensure the making and keeping of fair and
accurate books, records and accounts, on its operations around the world and apply worldwide to all its employees, subsidiaries, and Third Parties acting on its behalf to provide reasonable assurance that BioNTech, its subsidiaries and such Third
Parties will comply with Laws, including but not limited to Anti-Corruption Laws to the extent required by such Laws. BioNTech will reasonably monitor its operations and the operations of its Affiliates with the purpose of ensuring its Policies are
effective at the reasonable assurance level and make necessary changes from time to time, in particular as its business activities expand; 

12.3.21. the Impf Group does not own or Control any Intellectual Property Rights used by BioNTech or that BioNTech may
reasonably require or be useful to exploitation of any of the RNA Technology. 
 12.4. Accuracy of Representations and Warranties.

 12.4.1. BioNTech will take no action which would render any representation or warranty made by BioNTech and contained in
Section 12.1 or Section 12.2 inaccurate or untrue; provided that such covenant shall not apply to representations and warranties expressly given as of the Effective Date; 

12.4.2. BioNTech will promptly notify Pfizer of any lawsuits, claims, administrative actions, regulatory inquiries or
investigations, or other proceedings asserted or commenced against BioNTech or its Representatives involving in any material way the ability of BioNTech to deliver the rights, licenses and sublicenses granted herein; and 

12.4.3. BioNTech will promptly notify Pfizer in writing of any facts or circumstances which come to its attention and which
cause, or through the passage of time may cause, any of the representations and warranties contained in Section 12.1, Section 12.2, Section 16.10 or otherwise in this Agreement to be untrue or misleading in any material respect at any
time during the Term; and in addition to the foregoing, with regard to any of the representations under Section 16.10, BioNTech will suspend all affected activities (including making any related payments) under this Agreement, unless and until
Pfizer determines that such activities may be resumed; provided that such covenant shall not apply to representations and warranties expressly given as of the Effective Date. 

  
 65 

 12.5. BioNTech Covenants. In addition to the covenants made by BioNTech
elsewhere in this Agreement, BioNTech hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement: 

12.5.1. BioNTech will not, and will cause its Affiliates not to (a) license, sell or assign (other than in a connection
with a permitted assignment of this Agreement by BioNTech pursuant to Section 16.1) or otherwise transfer to any Person (other than Pfizer or its Affiliates or Sublicensees pursuant to the terms of this Agreement) any BioNTech Technology or
Research and Development Program Technology (or agree to do any of the foregoing) or (b) incur or permit to exist, with respect to any BioNTech Technology or Research and Development Program Technology, any lien, encumbrance, charge, security
interest, mortgage, liability, assignment, grant of license or other Binding Obligation, in each case of (a) and (b) that is inconsistent with the licenses and other rights granted (or that may be granted) to Pfizer or its Affiliates under this
Agreement; 
 12.5.2. Except as explicitly permitted under this Agreement, BioNTech will not (a) take, or omit to take,
any action that diminishes the rights under the BioNTech Technology or Research and Development Program Technology granted (or that may be granted) to Pfizer or Pfizer’s Affiliates under this Agreement or (b) take, or omit to take, any
action that is reasonably necessary to avoid diminishing the rights under the BioNTech Technology or Research and Development Program Technology granted (or that may be granted) to Pfizer or Pfizer’s Affiliates under this Agreement (for the
avoidance of doubt, BioNTech shall not be in breach of the covenants set forth in this Section 12.5.2 due to any reasonable act or position taken in connection with the filing, prosecution, maintenance, defense or enforcement of BioNTech
Technology or Research and Development Program Technology as permitted in Section 10); 
 12.5.3. BioNTech will
(a) not enter into any BioNTech Third Party Agreement that adversely affects (i) the rights granted (or that may be granted) to Pfizer, Pfizer’s Affiliates or Sublicensees hereunder or (ii) BioNTech’s ability to fully
perform its obligations hereunder; (b) not amend or otherwise modify any BioNTech Third Party Agreement (including any Current License) or consent or waive rights with respect thereto in any manner that (A) adversely affects the rights
granted (or that may be granted) to Pfizer or Pfizer’s Affiliates or Sublicensees hereunder or (B) BioNTech’s ability to fully perform its obligations hereunder; (c) promptly furnish Pfizer with true and complete copies of all
(1) amendments to the Current Licenses and (2) BioNTech Third Party Agreements and related amendments executed following the Effective Date (in each case with redactions only in respect of sensitive information which is not relevant for
the purposes of this Agreement); (d) remain, and cause its Affiliates to remain, in compliance in all material respects with all BioNTech Third Party Agreements; and (e) furnish Pfizer with copies of all notices received by BioNTech or its
Representatives relating to any alleged breach or default by BioNTech or its Representatives under any BioNTech Third Party Agreement within ten (10) Business Days after receipt thereof (in each case with redactions only in respect of sensitive
information which is not relevant for the purposes of this Agreement); and 
 12.5.4. BioNTech will not enter into or
otherwise allow itself or its Representatives to be subject to any agreement or arrangement, other than the Current Licenses, which limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer
or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any Intellectual Property Right or material (including any Patent Right, Know-How or
other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned (or that may be licensed or assigned) to Pfizer or its Affiliates pursuant to this Agreement 

  
 66 

 12.5.5. BioNTech and its Affiliates will maintain or obtain valid and
enforceable agreements with or from all inventors of BioNTech Technology or Research and Development Program Technology who are employed by or otherwise acting on behalf of BioNTech or its Affiliates assigning to BioNTech or its Affiliates each such
inventor’s entire right, title and interest in and to all such BioNTech Technology or Research and Development Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech
Technology or Research and Development Program Technology automatically vests in BioNTech or its Affiliates by operation of law). 

12.5.6. BioNTech will unrestrictedly claim and remunerate (and procure that its Affiliates will unrestrictedly claim and
remunerate) all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA. 

12.5.7. In respect of GEIA Technology created after the Effective Date to which Pfizer shall obtain a license hereunder,
BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to conclude agreements with BioNTech employee inventors regarding the respective inventions by which the respective
inventors: (a) waive the employer’s obligation to release the employee invention and to enable the employee inventor upon request to apply for foreign Intellectual Property Rights for such foreign countries in which it does not intend to
apply for Intellectual Property Rights (Sec. 14 GEIA); and (b) waive the employer’s obligation to notify the employee inventor and to transfer the right in the invention to the employee inventor at the latter’s request and expense, if
it does not intend to pursue the application for the grant on an Intellectual Property Right for the invention any further or if it does not want to maintain the Intellectual Property Right granted for the
job-related invention (Sec. 16 GEIA); and (c) waive the employer’s obligation to acknowledge protectability of the invention in case the employer decides not to file a registration, but to keep the
invention secret (Sec. 17 GEIA); 
 12.5.8. To the extent BioNTech Technology or Research and Development Program Technology
is created after the Effective Date by inventors employed by or acting on behalf of BioNTech’s or its Affiliates’ Third Party subcontractors, BioNTech will (a) use Commercially Reasonable Efforts (and will procure that its Affiliates
use Commercially Reasonable Efforts) to obtain valid and enforceable agreements with their respective Third Party subcontractors imposing on their Third Party subcontractors the obligation to claim the rights in the invention in accordance with
applicable Law and to conclude agreements with its employee inventors assigning to the respective Third Party subcontractor each such inventor’s entire right, title and interest in and to all such BioNTech Technology or Research and Development
Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology or Research and Development Program Technology automatically vests in the Third Party subcontractor by operation
of law) and, (b) to the extent GEIA applies to such BioNTech Technology or Research and Development Program Technology, use Commercially Reasonable Efforts to obtain a waiver of inventor in his rights in Sec. 14, 16 and 17 GEIA; 

12.5.9. with respect to any BioNTech Technology or Research and Development Program Technology to which Pfizer shall obtain a
license hereunder that is made after the Effective Date in the jurisdiction of the GEIA by an inventor on behalf of BioNTech or its Affiliates who is employed by a university pursuant to Sec. 42 GEIA (e.g. university professors, research
assistants), BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to obtain valid and enforceable trifold agreements with such inventor and the respective university by which
the university (a) waives its entire right, title and interest in and to that BioNTech Technology or Research and Development Program Technology made by the 

  
 67 

 
inventor, (b) the inventor assigns its rights, title and interest in and to that BioNTech Technology or Research and Development Program Technology to BioNTech or its Affiliates,
(c) the inventor waives its rights pursuant to Sec. 14, 16 and 17 GEIA as well as (d) waives its negative publication right (Sec. 42 Nr. 2 GEIA) vis-a-vis
BioNTech or its Affiliates; 
 12.5.10. with respect to animals used in conducting activities under this Agreement, BioNTech
will, and will cause its Affiliates and permitted subcontractors to, comply with its policies on animal care and use which shall be no less strict than Pfizer’s Corporate Policy regarding Animal Care and Use, attached hereto as Exhibit C
(except where in conflict with applicable Law); 
 12.5.11. with respect to Human Material used, including collection or
transfer, by BioNTech, its Affiliates or permitted subcontractors in conducting activities under this Agreement, (a) such use shall be in accordance with the binding part of the Research and Development Plan and shall be within the scope of and
consistent with its ethical approval policies, (b) BioNTech will, and will cause its Affiliates or permitted subcontractors to, handle and use the Human Material in accordance with all applicable Laws and the ICF, which shall permit Pfizer to
use the Human Material for the research purposes contemplated by this Agreement, (c) BioNTech will provide the ICF to Pfizer upon request by Pfizer, (d) the Human Material will be used for research purposes only and not be used for
treatment of or administration to humans and (e) if BioNTech procures any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material and the use of the Human Material for
purposes of the Research and Development Plan is in accordance with all applicable Laws and recognized international standards for the protection of human research subjects; 

12.5.12. BioNTech shall, at all times, maintain and enforce a compliance and ethics program containing adequate systems,
policies and procedures for the detection, investigation, documentation, and remediation of any allegations, reports or findings related to a potential violation of applicable Law, including Anti-Corruption Laws, with respect to the Candidates,
Products, payments and services under this Agreement, which policies shall be not less strict than Pfizer’s Anti-Bribery and Anti-Corruption Principles attached hereto as Exhibit B. Such policies and procedures should set out rules governing
interactions with HCPs, Government Officials, the engagement of Third Parties, and where appropriate, conducting due diligence, and the investigation, documentation and remediation of any allegations, reports or findings related to a potential
violation of applicable Laws, and BioNTech shall, upon Pfizer’s request, require any persons acting on behalf of BioNTech in connection with this Agreement to complete anti-corruption compliance training provided by Pfizer, and will notify
Pfizer of any persons that require or may require such training during the Term of this Agreement; 
 12.5.13. if BioNTech
finds, following an investigation, credible evidence of a violation of any applicable policies and procedures that are designed to ensure compliance with any applicable Laws, including any criminal, civil or administrative laws or regulations, or
violations of policies or procedures related to scientific misconduct or data integrity, BioNTech shall promptly inform Pfizer of the occurrence and the steps taken by BioNTech to remediate the occurrence; and 

12.5.14. in it undertaking, sponsoring, or having regulatory oversight over any Clinical Trials, BioNTech shall ensure and
procure that all documentation for such Clinical Trials shall comply with, and take advantage of, any applicable Laws that serve to limit product liability claims and losses having regard to the pandemic status of
COVID-19, including any requirements under any declarations pursuant to the Public Readiness and Emergency Preparedness (PREP) Act in the USA or any equivalent, similar or comparable legislation in the
Territory. 

  
 68 

 12.6. Pfizer Covenants. In addition to the covenants made by Pfizer elsewhere in this
Agreement, Pfizer hereby covenants to BioNTech that, from the Effective Date until expiration or termination of this Agreement, 

12.6.1. Pfizer and its Affiliates maintain or will obtain valid and enforceable agreements with or from all inventors of Pfizer
Improvements or Research and Development Program Technology who are employed by or otherwise acting on behalf of Pfizer or its Affiliates valid and enforceable agreements assigning to Pfizer or its Affiliates each such inventor’s entire right,
title and interest in and to all such Pfizer Improvements or Research and Development Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such Pfizer Improvements or Research and Development
Program Technology automatically vests in Pfizer or its Affiliates by operation of law), and Pfizer and its Affiliates have made or will make any payments owing to any such inventors in respect of any Pfizer Improvements or Research and Development
Program Technology or any other Person that is required in connection with the creation or exploitation of or transfer of rights to such Pfizer Improvements or Research and Development Program Technology; 

12.6.2. with respect to Human Material used, including collection or transfer, by Pfizer, its Affiliates or permitted
subcontractors in conducting activities under this Agreement, (a) such use shall be within the scope of and consistent with its ethical approval policies, (b) Pfizer will, and will cause its Affiliates or permitted subcontractors to,
handle and use the Human Material in accordance with all applicable Laws and the ICF, (c) Pfizer will provide the ICF to BioNTech upon request by BioNTech, (d) the Human Material will be used for research purposes only and not be used for
treatment of or administration to humans and (e) if Pfizer procures any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material and the use of the Human Material for
purposes of the Research and Development Plan is in accordance with all applicable Laws and recognized international standards for the protection of human research subjects; and 

12.6.3. Pfizer will comply with the provisions of the Current Licenses set forth in Schedule 1.36 in respect of
BioNTech Technology sublicensed to Pfizer under the respective Current Licenses insofar as Pfizer is using such BioNTech Technology; 

12.6.4. Pfizer shall comply with its Anti-Bribery and Anti-Corruption Principles attached hereto as Exhibit B and its
Corporate Policy regarding Animal Care and Use, attached hereto as Exhibit C; and 
 12.6.5. in it undertaking,
sponsoring, or having regulatory oversight over any Clinical Trials, Pfizer shall ensure and procure that all documentation for such Clinical Trials shall comply with, and take advantage of, any applicable Laws that serve to limit product liability
claims and losses having regard to the pandemic status of COVID-19, including any requirements under any declarations pursuant to the Public Readiness and Emergency Preparedness (PREP) Act in the USA or any
equivalent, similar or comparable legislation in the Territory. 
 12.7. Notifications. During the Term. BioNTech will
promptly notify Pfizer in writing or orally in the event that it learns of: 
 12.7.1. any prior art or other facts that
BioNTech believes would result in the invalidity or unenforceability of any of the claims included in any of the BioNTech Patent Rights or Research and Development Program Patent Rights; or 

  
 69 

 12.7.2. any inequitable conduct or fraud on the patent office with respect
to any of the BioNTech Patent Rights or Research and Development Program Patent Rights; or 
 12.7.3. any Person (other than
Persons identified as inventors of inventions disclosed in the BioNTech Patent Rights or Research and Development Program Patent Rights) who claims to be an inventor of an invention disclosed in the BioNTech Patent Rights or Research and Development
Program Patent Rights; and 
 12.7.4. any lawsuits, claims, administrative actions, government inquiries or investigations,
or other proceedings related to the activities contemplated under this Agreement. 
 12.8. Representation by Legal Counsel.
Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement,
the Parties agree that no presumption will exist or be implied against the Party which drafted such terms and provisions. 
 12.9.
BioNTech’s knowledge. All references in this Section 12 to BioNTech’s knowledge (or equivalent) shall refer to the actual knowledge after reasonable internal inquiry of BioNTech’s management comprising those
individuals set forth in Schedule 12.9. 
 12.10. Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH
PARTY ARE IN LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND
DISCLAIMED. 
  

	13.	 GOVERNMENT APPROVALS; TERM AND TERMINATION 

13.1. Government Approvals. Each of BioNTech and Pfizer will cooperate with the other Party and to make all
registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other
things necessary or useful for the consummation of the transactions as contemplated hereby including the collection of Human Material. 

13.2. Term. The term of this Agreement (the “Term”) will commence on the Effective Date and
shall continue, unless terminated earlier in accordance with this Section 13, until the later of (a) completion of all Development and Manufacturing obligations of each Party set out herein; and (b) the termination or expiry of the
Commercialization Agreement or, in the absence of a Commercialization Agreement, Pfizer ceasing to pursue Commercialization activities pursuant to the Commercialization Terms. 

13.3. Termination for Cause by a Party. Either Party may terminate this Agreement for cause, at any time
during the Term, by giving written notice to the other Party in the event that such other Party commits a material breach of its obligations under this Agreement and such material breach remains uncured for at least 90 days, in each case measured
from the date written notice of such material breach is given to Pfizer; provided, however, that if any breach is not reasonably curable within [***] and if the Party accused of breach is making a bona fide effort/using Commercially
Reasonable Efforts to cure such breach, such termination will be delayed for a time period to be agreed by both Parties in order to permit the Party accused of a breach a reasonable period of time to cure such breach. If the alleged material breach
relates to non-payment of any amount due under this Agreement, the cure period will be tolled pending resolution of any bona fide dispute between the Parties as to whether such payment is due. 

  
 70 

 13.4. Termination by Pfizer Convenience. [***], Pfizer may terminate
this Agreement for convenience upon [***] prior written notice (which notice period may be shortened by BioNTech in BioNTech’s sole discretion through written notice to Pfizer at any time after BioNTech’s receipt of such termination
notice) without any liability to BioNTech. 
 13.5. Termination by Pfizer for [***] 

13.6. Effects of Termination. 

13.6.1. Termination for Cause by a Party. In the event that a Party terminates this Agreement for cause pursuant to
Section 13.3, all rights and obligations of each Party hereunder will cease (including all rights and licenses and sublicenses granted by either Party to the other Party hereunder, and all sublicenses granted to Affiliates or Third Parties
under the rights granted hereunder), except as otherwise expressly provided herein. 
 13.6.2. Termination for
Pfizer’s Convenience. Upon Pfizer’s termination pursuant to Section 13.4 (a) [***]; and (b) [***]. 

13.6.3. No Effect on Related Agreements. Unless explicitly agreed otherwise, termination or expiration of this Agreement
shall not affect any other agreements concluded hereunder, including the Commercialization Agreement or any Manufacturing agreements pursuant to Article 8. 

13.6.4. Continuation of Pfizer Licenses. Except in the event of Pfizer’s termination pursuant to Section 13.3
or 13.7.1, (a) [***], (b) [***], (c) [***], and (d) [***]. 

  
 71 

 13.6.5. Exclusivity. In the event of Pfizer’s termination
pursuant to Section 13.3 or 13.7, the Parties’ obligations pursuant to Section 3.10.3 shall survive the termination or expiration of this Agreement for a period of [***] years provided that BioNTech shall not be prevented from
using the Product within the Field. In the event of Pfizer’s termination pursuant to Section 13.4 or 13.5, Pfizer shall not be entitled to enter into any collaboration or license agreement with any Third Party to Develop or Commercialize
in the Territory an immunogenic composition comprising mRNA in the Field for a period of [***] months commencing on the date of the termination notice served by Pfizer, provided that such obligation shall not (i) restrict Pfizer’s or
its Affiliates’ right to work as contract manufacturer for a Third Party, (ii) prohibit Pfizer or its Affiliate from acquiring any Third Party, or being acquired by any Third Party, that at the time of acquisition is active in the
Development or Commercialization of an immunogenic composition comprising mRNA in the Field, or (iii) prohibit Pfizer or its Affiliate from undertaking non-clinical research work. 

13.6.6. Accrued Rights. Expiration or termination of this Agreement for any reason will be without prejudice to any
right which will have accrued to the benefit of either Party prior to such termination, including damages arising from any breach under this Agreement. Expiration or termination of this Agreement will not relieve either Party from any obligation
which is expressly indicated to survive such expiration or termination. 
 13.6.7. Survival Period. The
following sections, together with any sections that expressly survive, will survive expiration or termination of this Agreement for any reason: Sections 1 (Definitions), 3.5 (additional licenses), 5.4.2(a) through (d) only (Repayment of
BioNTech Deferred Development Costs) (except in the event of a termination by Pfizer pursuant to Section 13.4), 5.6 (Records and Accounting Principles), 5.7.1 (Withholding Taxes), 5.10 (Audits), 5.10.1 (Underpayments/Overpayments), 5.10.2
(Confidentiality), 7.4.2 (Title to Pfizer Materials and BioNTech Materials), 7.4.4 (Return of Proprietary Materials), 9.2.5, first sentence only (Ownership of Regulatory Filings), 9.7 (Liability), 10.2 (Ownership of Intellectual Property), 10.3.1.2,
10.3.1.3 and 10.3.2 (Filing, Prosecution and Maintenance of Patent Rights), 11 (Confidentiality), 13.6 (Effects of Termination), 13.7 (Provision for Insolvency), 15.1 (No Consequential Damages), 15.2 (Indemnification by Pfizer), 15.3
(Indemnification by BioNTech), 15.4 (Procedure), 16 (Miscellaneous) and, to the extent an Enforcement Action or Infringement Claim is active, live or pending at the time of expiry or termination, Sections 10.4 or 10.8, as applicable. 

13.7. Provision for Insolvency. 

13.7.1. Termination Right. BioNTech will be deemed a “Debtor” under this Agreement if, at any time
during the Term (a) a case is commenced by or against BioNTech under the Bankruptcy Code, (b) BioNTech files for or is subject to the institution of bankruptcy, reorganization, liquidation or receivership proceedings (other than a case
under the Bankruptcy Code), (c) BioNTech assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for BioNTech’s business or (e) a substantial portion of BioNTech’s
business is subject to attachment or similar process; provided, however, that in the case of any involuntary case under the Bankruptcy Code, BioNTech will not be deemed a Debtor if the 

  
 72 

 
case is dismissed within 60 days after the commencement thereof. If BioNTech is deemed a Debtor, then Pfizer may terminate this Agreement by providing written notice to BioNTech. If Pfizer
terminates this Agreement pursuant this Section 13.7.1, then: (i) all licenses granted to Pfizer under this Agreement will become irrevocable and perpetual, and Pfizer will have no further obligations to BioNTech under this Agreement other
than (A) those obligations that expressly survive termination in accordance with Section 13.6.7 and (B) an obligation to pay royalties with respect to Net Sales of Products in an amount equal to 100% of the amount that would otherwise
have been payable under this Agreement, such amount to be paid in accordance with and subject to the other terms of this Agreement governing the payment of royalties; (ii) such termination will not be construed to limit BioNTech’s right to
receive payments that accrued before the effective date of such termination; (iii) Pfizer will have the right to offset, against any payment owing to BioNTech as provided for under clause (i), above, any damages found or agreed by the Parties
to be owed by BioNTech to Pfizer; and (iv) nothing in this Section 13.7.1 will limit any other remedy Pfizer may have for any breach by BioNTech of this Agreement. 

13.7.2. Rights to Intellectual Property. All rights and licenses now or hereafter granted by BioNTech to Pfizer under or
pursuant to any Section of this Agreement, including Sections3.1.1, 3.2.1, 3.3, 3.4.1 and 3.5.1 and Section 10 hereof, are rights to “intellectual property” (as defined in the Bankruptcy Code). The Parties hereto acknowledge and
agree that the payments provided for under Sections 5 and all other payments by Pfizer to BioNTech hereunder or under the Commercialization Agreement do not constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or
relate to licenses of intellectual property hereunder. If (a) a case under the Bankruptcy Code is commenced by or against BioNTech, (b) this Agreement is rejected as provided in the Bankruptcy Code and (c) Pfizer elects to retain its
rights hereunder as provided in Section 365(n) of the Bankruptcy Code, then BioNTech (in any capacity, including debtor-in-possession) and its successors and
assigns (including any trustee) will provide to Pfizer all Intellectual Property Rights licensed hereunder, and agrees to grant and hereby grants to Pfizer and its Affiliates a right to access and to obtain possession of and to benefit from and, in
the case of any chemical or biological material or other tangible item of which there is a fixed or limited quantity, to obtain a pro rata portion of, each of the following to the extent related to any Candidate or Product, or otherwise related to
any right or license granted under or pursuant to this Agreement: (i) copies of pre-clinical and clinical research data and results; (ii) all of the following (to the extent that any of the following
are so related): BioNTech Materials, cell lines, antibodies, assays, reagents and other biological materials; (iii) samples or Candidates and Products; (iv) BioNTech Technology, Product Technology, and RNA Technology, (v) laboratory
notes and notebooks; (vi) Candidate and Product data or filings, and (vii) rights of reference in respect of filings for and Regulatory Approvals, all of which constitute “embodiments” of intellectual property pursuant to
Section 365(n) of the Bankruptcy Code, and (viii) all other embodiments of such intellectual property, whether any of the foregoing are in BioNTech’s possession or control or in the possession and control of any Third Party but which
BioNTech has the right to access or benefit from and to make available to Pfizer. BioNTech will not interfere with the exercise by Pfizer or its Affiliates of rights and licenses to Intellectual Property Rights licensed hereunder and embodiments
thereof in accordance with this Agreement and agrees to use Commercially Reasonable Efforts to assist Pfizer and its Affiliates to obtain such Intellectual Property Rights and embodiments thereof in the possession or control of Third Parties as
reasonably necessary or useful for Pfizer or its Affiliates or Sublicensees to exercise such rights and licenses in accordance with this Agreement. 

13.7.3. No Limitation of Rights. All rights, powers and remedies of Pfizer provided in this Section 13.7 are
in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at Law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code involving
BioNTech. To the extent 

  
 73 

 
equivalent rights exist under the Bankruptcy Code existing from time to time in the jurisdiction where BioNTech is established the foregoing provisions shall be interpreted in accordance with
such equivalent rights, and where such equivalent rights to not exist Pfizer shall be entitled to avail of itself all remedies and rights available to it as a creditor and licensee of Intellectual Property Rights under such local Bankruptcy Code.

  

	14.	 CHANGE OF CONTROL 

14.1. Change of Control. If a Change of Control occurs with respect to a Party and a Third Party during the Term, or if a Party or any
of its Affiliates acquires or merges with a Third Party during the Term, (in either case such Party being the “Affected Party”): 

14.1.1. if such Third Party is, at the time of such Change of Control or acquisition or merger, conducting activities that
would cause the Affected Party or one of its Affiliates to violate Section 3.10.1 (such activities, a “Acquisition Program”), then such Affected Party or such Third Party shall be permitted to continue such Acquisition Program
and such continuation will not constitute a violation of Section 3.10.1; 
 14.1.2. the provisions of Section 11.7
shall apply and no Confidential Information of the other Party or its Affiliates may be disclosed to the Third Party and shall not be used in any Acquisition Program (if any) and the Affected Party shall implement and maintain, in accordance with
such Affected Party’s internal commercially reasonable practices, an information and personnel barrier between the working teams involved in the day to day conduct of such Affected Party’s internal program of Development and Manufacture of
Candidates and Products under this Agreement, and any activities of the Third Party, including under any Acquisition Program; and 

14.1.3. if BioNTech is the Affected Party then: 
  

	 	14.1.3.1.	 [***]; 

  

	 	14.1.3.2.	 [***]; 

  

	 	14.1.3.3.	 [***]; 

  
 74 

	 	14.1.3.4.	 [***]; and 

  

	 	14.1.3.5.	 [***]. 

14.2. Effects of Change of Control. In the event of a Change of Control of BioNTech by during the Term, the following provisions of
this Section 14 shall also apply: 
 14.2.1. BioNTech Intellectual Property. All BioNTech Technology and Research
and Development Program Technology, Controlled by BioNTech immediately prior to such BioNTech Change of Control shall continue to be BioNTech Technology and Research and Development Program Technology licensed to Pfizer for purposes of this
Agreement. 
 14.2.2. Existing Acquirer Intellectual Property. Patent Rights and
Know-How that were Controlled by the entity acquiring BioNTech or such entity’s Affiliates that were not Affiliates of BioNTech prior to such BioNTech Change of Control (collectively, the
“Acquirer”) shall not be included within the licenses granted to Pfizer hereunder. 
 14.2.3. Independent
Intellectual Property. Patent Rights and Know-How that, following such BioNTech Change of Control, are developed, made or otherwise acquired or Controlled by the Acquirer outside of the Research and
Development Plan or the Manufacturing Plan and without use of Pfizer’s Technology, Pfizer’s Confidential Information, Research and Development Program Technology, BioNTech Improvements or BioNTech Technology shall not be included within
the Research and Development Program Technology or BioNTech Technology or BioNTech Third Party Agreements (it being understood, however, for the avoidance of doubt, that all BioNTech Technology, Research and Development Program Technology, and
Intellectual Property Rights developed by BioNTech or the Acquirer in the course of, or used by BioNTech or the Acquirer under the Research and Development Plan or used in the Manufacture of the Candidates or Products by BioNTech shall be licensed
to Pfizer pursuant to the licenses set forth in this Agreement). 
 14.2.4. Research and Development Program
Technology. No Research and Development Program Technology Controlled by Pfizer including Pfizer Improvements shall be licensed or sub-licensable to the Acquirer, and no Confidential Information of Pfizer
or its Representatives shall be disclosed to the Acquirer, in each case without the prior written consent of Pfizer. 

14.2.5. Effect on Certain Agreement Provisions. From and after the effective date of a BioNTech Change of Control by a
Specified Person, the Acquirer shall not be considered an “Affiliate” for the purposes of this Agreement, provided that the Acquirer does not engage in any activities otherwise restricted under Section 3.10 using any Research and
Development Program Technology, Pfizer Technology, Pfizer Improvements or Confidential Information of Pfizer. 
  

	15.	 LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE 

15.1. No Consequential Damages. Except with respect to liability arising from a breach of Sections 10 or 10.1, from any willful
misconduct or intentionally wrongful act, or to the extent such Party may be required to indemnify the other Party under this Section 15, in no event will either Party or its Representatives be liable under this Agreement for any special (only
as related to indirect, incidental or 

  
 75 

 
consequential damages), indirect, incidental, consequential or punitive damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of indirect profits
or revenue suffered by the other Party or any of its Representatives. Without limiting the generality of the foregoing, “consequential damages” will be deemed to include, and neither Party will be liable to the other Party or any of such
other Party’s Representatives or stockholders for any damages based on or measured by loss of projected or speculative future sales of the Products, any development, regulatory, launch or sales threshold milestone payments due or any other
unearned, speculative or otherwise contingent payments provided for in this Agreement. 
 15.2. Indemnification by Pfizer.
Pfizer will indemnify, defend and hold harmless BioNTech, each of its Affiliates, and each of its and its Affiliates’ employees, officers, directors and agents (each, a “BioNTech Indemnified Party”) from and against any and all
claims, causes, or allegations (whether threatened or pending), judgments, expenses, damages, liabilities, obligations, fees (including the reasonable fees of attorneys and other consulting or testifying professionals), costs and losses
(collectively, “Liabilities”) that the BioNTech Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of (a) use of the Pfizer Technology, Pfizer Materials, and/or Pfizer Know-How disclosed by or on behalf of Pfizer in accordance with the rights licensed under this Agreement, (b) use of the Pfizer name or logo in accordance with the rights licensed under this Agreement or
(c) the material breach by Pfizer of any of its representations, warranties or covenants set forth in Section 7.4.1, Section 12.1 or Section 12.2 or Section 12.6; except, in each case, to the extent caused by the negligence,
recklessness or intentional acts of BioNTech or any BioNTech Indemnified Party. 
 15.3. Indemnification by BioNTech. BioNTech
will indemnify, defend and hold harmless Pfizer, its Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and
against any and all Liabilities that the Pfizer Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of (a) use of the BioNTech Technology [***], BioNTech Materials, and/or BioNTech Know-How disclosed by or on behalf of BioNTech in accordance with the rights licensed under this Agreement, (b) the Candidates or Products in accordance with the rights licensed under this Agreement, save to
the extent the Liabilities are in respect of (i) the exploitation of Pfizer Technology infringing a Third Party Patent Right or (ii) [***]; (c) use of the BioNTech name or logo in accordance with the rights licensed under this
Agreement, (d) rights or obligations under the GEIA relating to inventions made by employees of BioNTech or its Affiliates or Third Party Licensors in relation to BioNTech Technology or Research and Development Program Technology used in any
Candidate or Product; or (e) the material breach by BioNTech or any of its Representatives of any of its representations, warranties or covenants set forth in Section 9, Section 12.1, Section 12.2, Section 12.3, or
Section 12.5 except to the extent caused by the negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party. 

15.4. Procedure. 

15.4.1. Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which
indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”) is
entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party will promptly notify the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced
thereby. 

  
 76 

 15.4.2. Control. Subject to either Party’s right to control any
actions described in Section 10 (even where the other Party is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within ten Business Days after receipt of notice from the
Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim
solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of
the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the
Indemnifying Party and the Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the
“Litigation Conditions”). Within ten Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party will give notice to the
Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until
such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel
selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will cooperate, and will cause its
Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings,
hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s
intent to defend any Third Party Claim within ten Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying
Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the
Indemnified Party, as the case may be, will have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any
Third Party Claim that the other party is defending as provided in this Agreement. 
 15.4.3. Settlement. The
Indemnifying Party will not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole
and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but
will not have the right to settle such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not
make any admission of liability in respect of any Third Party Claim without the prior written consent of the other party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

  
 77 

 15.5. Insurance. Each Party further agrees to obtain and maintain, during the
Term, commercial general liability insurance, including products liability insurance (or clinical trials insurance, if applicable), with minimum “A-” A.M. Best rated insurance carriers to cover its
indemnification obligations under Section 15.2 or Section 15.3, as applicable, in each case with limits of not less than $[***] ([***] U.S. Dollars) per occurrence and in the aggregate. All deductibles and retentions will be the
responsibility of the named insured. Within [***] days of the Effective Date, BioNTech will amend its existing insurance policies in such a way that (a) Pfizer Inc. and its Affiliates will be indemnified as principal on BioNTech’s
commercial general liability and products liability policies (or clinical trials insurance, if applicable) and (b) Pfizer Inc. and its Affiliates will be provided a waiver of subrogation on BioNTech’s commercial general liability and
products liability policies (or clinical trials insurance, if applicable). For U.S. exposures, additional insured status on BioNTech’s commercial general liability and products liability policies shall be via form CG20101185 or its equivalent.
Products liability coverage shall be maintained for three years following termination of this Agreement. To the extent of its culpability or negligence, all coverages of BioNTech will be primary and
non-contributing with any similar insurance, carried by Pfizer. Notwithstanding any provision of this Section 15.5 to the contrary, Pfizer may meet its obligations under this Section 15.5
through self-insurance. Neither Party’s insurance will be construed to create a limit of liability with respect to its indemnification obligations under this Section 15. 

 

	16.	 MISCELLANEOUS 

16.1. Assignment. Neither this Agreement nor any interest hereunder will be assignable by a Party without the prior written
consent of the other Party, except as follows: (a) subject to the provisions of this Agreement in respect of Change of Control, as applicable, a Party may assign its rights and obligations under this Agreement by way of sale of itself or the
sale of the portion of its business to which this Agreement relates, through merger, sale of assets and/or sale of stock or ownership interest, provided that the assignee will expressly agree to be bound by such Party’s obligations under
this Agreement and that such sale is not primarily for the benefit of its creditors, (b) such Party may assign its rights and obligations under this Agreement to any of its Affiliates, provided that the assignee will expressly agree to
be bound by such Party’s obligations under this Agreement and that such Party will remain liable for all of its rights and obligations under this Agreement. In addition, Pfizer may assign its rights and obligations under this Agreement to a
Third Party where Pfizer or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition,
provided that the assignee will expressly agree to be bound by Pfizer’s obligations under this Agreement. Each Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section 16.1. This
Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry
out the intent of this Agreement. Any assignment not in accordance with this Section 16.1 will be void. 
 16.2. Further
Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

16.3. Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to the extent that
such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and
the nonperforming Party takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, “force majeure” will include conditions beyond the control of the Parties, including an act of God, voluntary or
involuntary compliance with any regulation, Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers,
destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

  
 78 

 16.4. Interpretation. Except where the context expressly requires otherwise,
(a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include”, “includes”
and “including” will be deemed to be followed by the phrase “without limitation”, (c) the word “will” will be construed to have the same meaning and effect as the word “shall”, (d) any definition of
or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein”, “hereof” and
“hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, Exhibits or Schedules will be construed to refer
to Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and will include
notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or
the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (excluding e-mail or instant messaging, but a
signed PDF document being acceptable), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or
regulation thereof, and (k) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or”. 

16.5. Notices. Any notice or notification required or permitted to be provided pursuant to the terms and conditions of this
Agreement (including any notice of force majeure, breach, termination, change of address, etc.) will be in writing and will be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), and upon delivery if
mailed by registered or certified mail or courier. Where delivery occurs outside normal working hours, notice will be deemed given at the start of normal working hours on the next Business Day. Notice shall be given to the Parties at the following
addresses or facsimile numbers (or at such other address or facsimile number for a Party as will be specified by like notice, provided, however, that notices of a change of address will be effective only upon receipt thereof): 

All correspondence to Pfizer will be addressed as follows: 

Pfizer Inc. 
 Notices: [***] 

with a copy to: 
 Pfizer Inc.

 Notices: Pfizer Legal Division 

[***] 

  
 79 

 [***] 

To help expedite Pfizer’s awareness and response, copies of notices may be provided to Pfizer by email but must be supplemented by
one of the following methods: (a) personal delivery, (b) first class certified mail with return receipt requested, or (c) next-day delivery by major international courier, with
confirmation of delivery. Electronic copies may be sent via email to [***]. 
 All correspondence to BioNTech will be
addressed as follows: 
 BioNTech SE 

[***] 
 16.6.
Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

16.7. Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party will not be
construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 
 16.8.
Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this
Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained
in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable Law. 

16.9. Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or
effect in construing or interpreting any of the provisions of this Agreement. 
 16.10. Global Trade Control Laws. The Parties
acknowledge that certain activities covered by or performed under this Agreement may be subject to laws, regulations or orders regarding economic sanctions, import controls or export controls (“Global Trade Control Laws”). Each of
the Parties will perform all activities under this Agreement in compliance with all applicable Global Trade Control Laws. Furthermore, with respect to the activities performed under this Agreement, each of the Parties represents, warrants and
covenants that: 
 16.10.1. Each Party will not, for activities under this Agreement, (a) engage in any such activities
in a Restricted Market; (b) involve individuals ordinarily resident in a Restricted Market; or (c) include companies, organizations, or Governmental Authorities from or located in a Restricted Market. “Restricted Market”
for purposes of this Agreement means the Crimean Peninsula, Cuba, the Donbass Region, Iran, North Korea, Sudan, and Syria, or any other country or region sanctioned by the United States or European Union. 

  
 80 

 16.10.2. Each Party represents and warrants that it is not a Restricted
Party and is not owned or controlled by a Restricted Party. With respect to activities performed under this Agreement, neither Party will engage or delegate to any Restricted Parties for any activities under this Agreement. Each Party will screen
all relevant Third Parties involved by such Party in the activities under this Agreement under the relevant Restricted Party Lists. “Restricted Parties” for purposes of this Agreement means any individual or entity on any of the
following “Restricted Party Lists”: the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List of the U.S. Treasury Department’s Office of
Foreign Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List of the U.S. Department of Commerce; entities subject to restrictive measures and the Consolidated List of Persons, Groups and Entities Subject
to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign & Security Policy; the List of Excluded Individuals / Entities published by the U.S. Health and Human Services’ Office of Inspector General; any lists of prohibited
or debarred parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of parties suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties maintained by the Governmental
Authorities of the countries that have jurisdiction over the activities conducted under this Agreement. 
 16.10.3. Neither
Party will knowingly transfer to the other Party any goods, software, technology or services that are (a) controlled under the U.S. International Traffic in Arms Regulations or at a level other than EAR99 under the U.S. Export Administration
Regulations; or (b) specifically identified as an E.U. Dual Use Item or on an applicable export control list of another country. 

16.11. Dispute Resolution. If any dispute or disagreement arises between Pfizer and BioNTech in respect of this Agreement, they
will follow the following procedures in an attempt to resolve the dispute or disagreement: 
 16.11.1. The Party claiming
that such a dispute exists will give notice in writing (“Notice of Dispute”) to the other Party of the nature of the dispute. 

16.11.2. Within 30 days of receipt of a Notice of Dispute and in advance of any meeting pursuant to Section 16.11.3, the
receiving Party will provide a written response to the other Party’s claims regarding the dispute. 
 16.11.3. Within 45
days of receipt of a Notice of Dispute, the Chief Scientific Officer, Vaccine Research and Development of Pfizer and the Chief Scientific Officer of BioNTech AG will meet at a mutually agreed-upon time and location for the purpose of resolving such
dispute to discuss the dispute or disagreement. 
 Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate
litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this
Section 16.11 will survive for five years from the date of termination or expiration of this Agreement. 
 16.12. Governing
Law. This Agreement is governed by, and all disputes arising under or in connection with this Agreement shall be resolved in accordance with, laws of England and Wales, without regard to conflict of law principles thereof. 

  
 81 

 16.13. Consent to Jurisdiction and Venue. The Parties irrevocably
submit to the exclusive jurisdiction of the courts of England and Wales as regards any claim, dispute or matter (whether contractual or non-contractual) arising out of or in connection with this Agreement
(including its formation). Notwithstanding the foregoing, this clause shall not prevent either Party from being entitled to seek urgent interim or emergency relief (such as a preliminary injunction) before any other court of competent jurisdiction
in respect of any claim, dispute or matter (whether contractual or non-contractual) arising out of or in connection with this Agreement (including its formation). 

16.14. Entire Agreement. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement
of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof, including (a) that certain
[***] (which is hereby terminated effective as of the Effective Date, provided that such Confidential Disclosure Agreement will continue to govern the treatment of Confidential Information disclosed by the Parties prior to the Effective Date
in accordance with its terms), (b) that certain [***] (which is hereby terminated effective as of the Effective Date, provided that the terms of this Agreement shall also apply to all activities made under the [***] (which is hereby
terminated effective as of the Effective Date). 
 16.15. Flu Collaboration. Except as provided in Section 8.2, nothing in this
Agreement varies, amends or otherwise supersedes or replaces the provisions and rights under the Flu Collaboration License, and the Flu Collaboration License and this Agreement shall be treated as separate arm’s length transactions. 

16.16. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained will be
deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act
of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever.

 16.17. Counterparts. This Agreement may be executed in two (2) counterparts, each of which will be an original and
both of which will constitute together the same document. Counterparts may be signed and delivered by facsimile or digital (e.g., PDF) file, each of which will be binding when received by the applicable Party. 

16.18. No Third Party Rights or Obligations. No provision of this Agreement will be deemed or construed in any way to result in
the creation of any rights or obligation in any Person not a Party to this Agreement, and this Agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement. However, Pfizer
may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer will remain liable hereunder for the performance by any such Affiliates of any such obligations.

 (Signature page follows) 

  
 82 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this
Agreement as of the Effective Date to be effective as of the Effective Date. 
  

									
	PFIZER INC.	 		 	BIONTECH SE
					
	By	 	 	 		 	By	 	 
					
	Name:	 		 		 	Name:	 	
					
	Title:	 		 		 	Title:	 	
					
		 		 		 	By	 	 
					
		 		 		 	Name:	 	
					
		 		 		 	Title:	 	

 [Signature page to Collaboration Agreement] 

 Exhibit A 

Research and Development Plan 
 To be
agreed by the Parties in accordance with Section 2.2 and added after the Signing Date. 

  
 84 

 Exhibit B 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRINCIPLES 

Pfizer has a longstanding corporate policy that prohibits colleagues or anyone acting on our behalf from providing any payment or benefit to any person or
entity in order to improperly influence a government official or to gain an unfair business advantage. Pfizer is committed to performing with integrity, and acting ethically and legally in accordance with all applicable laws and regulations,
including, but not limited to, anti-bribery and anti-corruption laws. We expect the same commitment from the consultants, agents, representatives or other companies and individuals acting on our behalf (“Business Associates”), as well as
those acting on behalf of Business Associates, in connection with work for Pfizer. 
 Bribery of Government Officials 

Most countries have laws that forbid making, offering or promising any payment or anything of value (directly or indirectly) to a government official when the
payment is intended to influence an official act or decision to award or retain business. Under Pfizer’s policies, “government official” is broadly interpreted and includes: (i) any elected or appointed government official (e.g.,
a member of a ministry of health); (ii) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function; (iii) any political party, candidate for public office, officer,
employee, or person acting for or on behalf of a political party or candidate for public office; or (iv) an employee or person acting for or on behalf of a public international organization (e.g., the United Nations). “Government” is
meant to include all levels and subdivisions of governments (i.e., local, regional, or national and administrative, legislative, or executive). Because this definition of “government official” is so broad, it is likely that Business
Associates will interact with a government official in the ordinary course of their business on behalf of Pfizer. For example, doctors employed by government-owned hospitals would be considered “government officials” under Pfizer’s
policies. 
 The U.S. Foreign Corrupt Practices Act of 1977 (the “FCPA”) prohibits making, promising, or authorizing the making of a payment or
providing anything of value to a non-U.S. government official to improperly or corruptly induce that official to make any governmental act or decision to assist a company in obtaining or retaining business, or
to otherwise obtain an improper advantage. The FCPA also prohibits a company or person from using another company or individual to engage in any of the foregoing activities. As a U.S. company, Pfizer must comply with the FCPA and could be held
liable as a result of acts committed anywhere in the world by a Business Associate. 
 Anti-Bribery and Anti-Corruption Principles Governing Interactions
with Governments and Government Officials 
 Business Associates must communicate and abide by the following principles with regard to their interactions
with governments and government officials: 
  

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any government official to induce that government official to make any governmental act or decision to help Pfizer obtain or retain business.
Business Associates, and those acting on their behalf in connection with work for Pfizer, may never make a payment to or offer a government official any item or benefit, regardless of value, as an improper inducement for such government official to
approve, reimburse, prescribe, or purchase a Pfizer product, to influence the outcome of a clinical trial, or otherwise improperly to benefit Pfizer’s business activities. 

 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, need to understand
whether local laws, regulations, or operating procedures (including requirements imposed by government entities such as government-owned hospitals or research institutions) impose any limits, restrictions, or disclosure requirements on compensation,
financial support, donations, or gifts that may be provided to government officials. Business Associates, and those acting on their behalf in connection with work for Pfizer, must take into account and comply with any applicable restrictions in
conducting their Pfizer-related activities. If a Business Associate is uncertain as to the meaning or applicability of any identified limits, restrictions, or disclosure requirements with respect to
interactions with government officials, that Business Associate should consult with his or her primary Pfizer contact before undertaking their activities. 

  
 85 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, are not permitted to
offer facilitation payments. A “facilitation payment” is a nominal, unofficial payment to a government official for the purpose of securing or expediting the performance of a routine,
non-discretionary governmental action. Examples of facilitation payments include payments to expedite the processing of licenses, permits or visas for which all paperwork is in order. In the event that a
Business Associate, or someone acting on their behalf in connection with work for Pfizer, receives or becomes aware of a request or demand for a facilitation payment or bribe in connection with work for Pfizer, the Business Associate shall report
such request or demand promptly to his or her primary Pfizer contact before taking any further action. 

 Commercial Bribery 

Bribery and corruption can also occur in non-government, business to business relationships. Most countries have laws
which prohibit offering, promising, giving, requesting, receiving, accepting, or agreeing to accept money or anything of value in exchange for an improper business advantage. Examples of prohibited conduct could include, but are not limited to, the
provision of inappropriate gifts or hospitality, kickbacks, or investment opportunities offered to improperly induce the purchase of goods or services. Pfizer colleagues are not permitted to offer, give, solicit or accept bribes, and we expect our
Business Associates, and those acting on their behalf in connection with work for Pfizer, to abide by the same principles. 
 Anti-Bribery and
Anti-Corruption Principles Governing Interactions with Private Parties and Pfizer Colleagues 
 Business Associates must communicate and abide by the
following principles with regard to their interactions with private parties and Pfizer colleagues: 
  

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any person to induce that person to provide an unlawful business advantage for Pfizer. 

 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly, solicit, agree to accept, or receive a payment or anything of value as an improper inducement in connection with their business activities performed for Pfizer. 

 

	 	•	 	 Pfizer colleagues are not permitted to receive gifts, services, perks, entertainment, or other items of more than
token or nominal monetary value from Business Associates, and those acting on their behalf in connection with work for Pfizer. Moreover, gifts of nominal value are only permitted if they are received on an infrequent basis and only at appropriate
occasions. 

 Reporting Suspected or Actual Violations 

Business Associates, and those acting on behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these
International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer’s Compliance Group, by e-mail at corporate.compliance@pfizer.com or by phone at 1-212-733-3026. 

  
 86 

 Exhibit C 

Pfizer’s Corporate Policy regarding Animal Care and Use (v. 1.2, June 18, 2017) 

BACKGROUND 
 Pfizer is dedicated to helping people and
animals live longer, healthier lives through the discovery and development of breakthrough medicines and therapies. Animal-based biomedical research in the pharmaceutical industry remains a vital component of the discovery, evaluation and regulatory
processes, which lead to the development of products that save or improve human lives throughout the world. Pfizer’s Animal Care and Use policy reflects our absolute commitment that all animals used by our business are treated humanely. This
means that any research involving animals is conducted only after appropriate ethical consideration and review. This review ensures that we provide a high level of care to all animals used, and that a scientifically appropriate and validated
alternative to the use of animals is not available. 
 Why We Conduct Animal-based Biomedical Research 

Pfizer is ethically and legally obliged to rigorously evaluate potential new medicines and therapies. Many of these evaluations can be, and are, accomplished
by techniques that do not require the use of animals. However, given the present state of scientific knowledge, testing potential new medicines and therapies in animals is frequently critical to their evaluation, and is required by regulatory
authorities worldwide to ensure the quality, efficacy and safety of the medicines we discover. 
 Pfizer’s Commitment to Ethical and Humane
Treatment of Animals 
 Pfizer accepts its responsibility to use animals in a humane and ethical manner and expects all Colleagues to treat animals with
respect. We approach the use of animals in our business with a high level of humane and ethical concern for those animals. All use is carefully planned and conducted in such a way as to minimize or avoid pain, distress, or discomfort to the animals.
Every proposed use is thoroughly evaluated before being undertaken as the health and well-being of all animals under our care is a primary concern. Similarly, we expect any Third Party organization we engage to conduct animal-based research on our
behalf to adhere to this Policy and to comply with all applicable laws and regulations. 
 Pfizer’s Commitment to Alternatives to Animal-based
Biomedical Research 
 Pfizer is fully committed to the development and use of scientifically validated alternative testing methods that are acceptable
to regulatory authorities and do not compromise patient safety or the effectiveness of our medicines. Pfizer continues to engage and lead cross-industry efforts aimed at developing and refining new in-vitro
testing and predictive informatics-based systems that hold promise for future reduction of animal usage. Pfizer works directly with regulators and through pharmaceutical trade organizations to increase the recognition and acceptance of alternative
models where such alternatives can be used appropriately. 
 POLICY 

For as long as it remains necessary to use animals in the discovery, development, evaluation and production of new medicines, we commit to maintaining high
standards in the humane treatment of these animals. Significantly, we embrace the principles known as the “3Rs” of animal research first proposed in 1959 by Russell and Burch to describe the use of alternatives in animal research. These
are: 
 Replacement of animal experiments with non-animal experiments such as mathematical models, computer
simulations, and in-vitro biological systems wherever appropriate; and where animals must be used; 
 Reduction
of the numbers of animals used in each study, and of the number of studies involving animals, to the absolute minimum necessary to obtain valid results and achieve our research objectives; and 

Refinement of procedures involving animals to minimize the potential for pain and distress. 

  
 87 

 In addition to the 3R’s, and to further assure we maintain high standards for our animals, we have
adopted the following guidelines: 
  

	 	•	 	 When animal experimentation is necessary, great care is taken to choose the most appropriate animal species for
the research and to optimize the study design to ensure that the results will be as meaningful as possible. 

  

	 	•	 	 Non-human primates will only be used when scientifically justified, for
example in cases where other species will not provide sufficiently close analogues to the biological pathways and responses expected in humans. 

  

	 	•	 	 All studies are carefully designed to gain the maximum information from the fewest number of animals possible.

  

	 	•	 	 Each proposed use of animals is reviewed and approved by a panel of objective experts prior to performing any
experiments to ensure that the use of the animals is consistent with sound scientific practices and ethical considerations. 

  

	 	•	 	 Our standards of animal care and welfare meet or exceed those required by applicable local, national, or
international laws and regulations. 

  

	 	•	 	 We regularly monitor our animals for signs of ill health or distress and take prompt action wherever appropriate.
We make veterinary care available to our animals at all times. 

  

	 	•	 	 Our veterinarians and scientists evaluate every proposed animal procedure with an emphasis on eliminating or
minimizing any potential for pain or distress which may be experienced by the animals. 

  

	 	•	 	 We train all Colleagues involved in the care, welfare and use of animals to ensure (a) that they are
competent in the care of the animals and in the procedures required to complete the proposed work; (b) that they are aware of the ethical issues involved in the use of animals; and (c) that they demonstrate respect and humane treatment
towards the animals in their care. 

  

	 	•	 	 We expect our contract research organizations, collaborators and vendors to maintain similar high standards.
Parties conducting animal based research for Pfizer at their facilities are required to adhere to this Policy and to comply with all applicable laws and regulations. We perform welfare audits of Third Party facilities in accordance with our quality
assurance policies. 

  

	 	•	 	 Because respect is a key tenant in our use of animals, we have also established standards regarding the use of
animals in the marketing of Pfizer products. If advertisements featuring animals are used, any animal shown should be healthy and in a natural or appropriate setting. Non-human primates should not be used in
the advertising of Pfizer products, and other wild animals will also not be used unless they are shown in their natural setting or portrayed through animation or computer-generated graphics. 

This Policy represents Pfizer’s commitment to high-quality animal care and welfare throughout our business, and to the replacement, reduction and
refinement of the use of animals in research. We are equally committed to bringing important and safe new medicines to patients. 

  
 88 

 Schedule 1.17 

Candidates 
  

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 89 

 Schedule 1.36 

Current Licenses 
 [***] 

  
 90 

 Schedule 1.40 

Developing Countries List 
  

			
	 [***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
	  	 [***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

[***]
 [***]

  
 91 

 Schedule 1.41 

Initial Development Budget 
 To be agreed
by the Parties in accordance with Section 2.2 and added after the Signing Date. 

  
 92 

 Schedule 1.77 

Initial Manufacturing Plan 
 To be agreed
by the Parties in accordance with Section 2.2 and added after the Signing Date. 

  
 93 

 Schedule 4.1 

Commercialization Agreement Term Sheet 

[***] 
  

			
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

  
 94 

			
		  	[***]
		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]

  
 95 

			
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

  
 96 

			
		  	 [***]
  

[***]
  

[***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]
  

[***]

  
 97 

			
		  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 98 

			
		
		  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 99 

			
		  	 [***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 100 

			
		
		  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 101 

			
		  	 [***]

		
	 [***]
	  	 [***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]
  

[***]

  
 102 

			
		  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 103 

			
		
		  	 [***]
  

[***]
  

[***]
  

[***]

  
 104 

			
		  	 [***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]
  

[***]

  
 105 

			
	 [***]
	  	[***]
		
	 [***]
	  	 [***]
  

[***]

		
	 [***]
	  	 [***]
  

[***]

		
	 [***]
	  	[***]

  
 106 

			
		  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

  
 107 

 ANNEX A 

ABAC Compliance Certification 
 [I/I
on behalf of Party] hereby certify: 
  

	1.	 [I have/Party has] communicated our International Anti-Bribery and Anti-Corruption Principles to all
persons acting on [my/its] behalf in connection with work under this Agreement, including any agents, contractors, or subcontractors; 

  

	2.	 With respect to any [Products], payments, or [Services] provided under this Agreement, [Party] has not taken
any action directly or indirectly to (i) offer, promise, provide, or authorize the offer or provision of money or anything of value, in order to improperly or corruptly seek to influence any Government Official or any other person in order to
obtain or retain business or any other improper business advantage; (ii) request or accept any such improper payment; or (iii) cause a violation of any applicable Anti-Corruption Law. For example, this includes providing any inducement for
such Government Official or person to approve, reimburse, prescribe, or purchase a [Product], to influence the outcome of a clinical trial, or otherwise to benefit [Counterparty]’s business activities improperly; 

 

	3.	 [Party] has ensured that it and every agent, contractor, or subcontractor performing [Services] in connection
with the Agreement has agreed to comply with and be bound by the provisions of the Agreement; 

  

	4.	 [Party has] met all relevant disclosure obligations required under the Agreement; and 

 

	5.	 To the extent requested by Pfizer, any persons acting on behalf of [me/Party] in connection with the Agreement,
have completed anti-corruption compliance training provided by Pfizer. 

 COMPANY NAME: ___________________________ 

NAME: ___________________________ 
 TITLE:
____________________________ 
 DATE: ____________________________ 

  
 108 

 Schedule 5.5 

Potential Third Party Funders 

[***] 

	 	

	 	

	 	

	 	

  
 109 

 Schedule 7.3.5 

Decision-Making Rights 
  

							
	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***]

				
	 [***] 
	  	 [***] 
	  		  	
	
	 [***]

				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
				
	 [***] 
	  	 [***] 
	  	[***]	  	[***]
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]

  
 110 

							
	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]

				
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 

				
	[***]	  	 [***] 
	  	 [***] 
	  	
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	
				
	[***]	  	 [***] 
	  	 [***] 
	  	[***]
				
	[***]	  	 [***] 
	  	 [***] 
	  	[***]
				
	[***]	  	 [***] 
	  	 [***] 
	  	
				
	[***]	  	 [***] 
	  	 [***] 
	  	

  
 111 

							
	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***]

				
	[***]	  	 [***] 
	  	 [***] 
	  	
				
	 [***] 
	  		  		  	
				
	 [***] 
	  		  		  	
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	
				
	 [***] 
	  	 [***] 
	  	 [***] 
	  	
	
	 [***] 

  
 112 

 Schedule 9.1.1 

Responsiblities delegated to Pfizer in the USA or other countries in the Territory where it is the Lead Development Party 

Subject to the Agreement, the activities delegated to Pfizer will be managed within Pfizer’s quality systems including: 

[***] 

	 	

	 	

  
 113 

 Schedule 9.2.7 

Pharmacovigilance Agreement Term Sheet 

[***] 

  
 114 

 Schedule 12.3 

Disclosures 
 [***] 

 
 [***] 

[***] 
  

[***] 
  

[***] 
  

[***] 
  

											
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

						
	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]
						
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

  
 115 

											
						
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 

						
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 

						
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]	  	[***]
						
	 [***] 
	  	 [***]
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 

						
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

 [***] 
  

[***] 

  
 116 

 Schedule 12.3.4 

BioNTech Patent Rights existing as of the Effective Date 

  
 117 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 118 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 119 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  		  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 120 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 121 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 122 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 123 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 124 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

  
 125 

																	
									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 126 

																	
									
		  	 [***]
	  		  		  		  		  		  		  	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***] 

	  	 [***] 

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***] 

	  	 [***] 

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	 [***]

  
 127 

																	
									
		  	 [***]
	  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***] 

	  	 [***] 

	  	 [***] 

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  		  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

	  	 [***]

	  	 [***]

  
 128 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  	[***]
	  	 [***]

	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

  
 129 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 130 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 131 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 132 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

  
 133 

																	
	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

  
 134 

																	
	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  	[***]
	  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  		  		  	 [***]

	  	 [***]

	[***]	  	[***]	  	[***]	  	[***]	  	 [***]
	  	[***]
	  	[***]
	  		  	 [***]

	  	 [***]

  
 135 

																	
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 136 

																	
									
	 [***]
	  	[***]	  	 [***] 
	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
	  	[***]
									
	[***]	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
	  	[***]
									
	 [***] 
	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
	  	[***]
									
	[***]	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
	  	[***]
									
	[***]	  	[***]	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]
	  	[***]
									
	[***]	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]
	  	[***]
									
	 [***] 
	  	[***]	  	 [***]
	  	 [***]
	  	 [***] 
	  		  		  		  	[***]
	  	[***]
									
	 [***] 
	  	[***]	  	 [***] 
	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  		  	[***]
	  	[***]
									
	 [***] 
	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  		  		  	[***]
	  	[***]
									
	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***] 
	  		  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***] 
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***] 
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***]
									
	 [***]
	  	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***] 

									
	 [***] 
	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 
	  		  	[***]
									
	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***]
									
	 [***] 
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	[***] 

  
 137 

															
								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

								
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 

								
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 

								
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 

	  	 [***] 

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 138 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]

  
 139 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]

  
 140 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]

  
 141 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	    	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

  
 142 

																	
		  	[***]	  		  		  		  		  		  		  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	    	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  	    	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	    	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	    	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	    	  	 [***]

  
 143 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

  
 144 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

									
		  		  		  		  		  		  		  		  	 [***]

  
 145 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]

  
 146 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]

  
 147 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  		  	 [***]

	  	[***]
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

  
 148 

															
		  	 [***]
	  		  		  		  		  		  	
								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

								
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

	  	 [***]

								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	  	[***]
								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]
								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	  	[***]
								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	  	[***]
								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  		  	[***]
	  	[***]
								
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 149 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	[***]	  	 [***]

  
 150 

																	
		  	[***]	  		  		  		  		  		  		  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 151 

																	
									
		  	 [***]
	  		  		  		  		  		  		  	
	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

  
 152 

																	
									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]

  
 153 

																	
									
		  		  		  		  		  		  		  		  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***] 

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***] 

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***] 

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	 [***]

	  	 [***]

									
	 [***]
	  	 [***]
	  	 [***]
	  	 [***]
	  	[***]	  	 [***]
	  	[***]	  	 [***]
	  	 [***]

	  	 [***]

  
 154 

																	
									
	 [***]
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]	  	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 

	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***]
	  	[***]	  	 [***]
	  		  		  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]	  	 [***]
	  		  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 
	  		  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 
	  		  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 
	  		  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  		  		  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  		  		  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  	 [***] [***]
	  	 [***]

									
	[***]	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	[***]	  		  		  	 [***]

									
	[***]	  	 [***]
	  	 [***] 
	  	 [***] 
	  	 [***] 
	  	 [***]
	  		  		  	 [***]

  
 155 

 Schedule 12.9 

BioNTech Management with Knowledge 
 [***]

  
 156EX-10.46

 Exhibit 10.46 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT
MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 Contract number (FI No): [***] 

Contract number (FI No): [***] 

Serapis No: [***] 
 ANTIVIRAL
VACCINE RDI 
 Finance Contract 

between the 
 European
Investment Bank 
 and 

BioNTech SE 

							
	 WHEREAS:
	  	 	6	 
		
	 ARTICLE 1
	  	 	7	 
			
	 1.1
	  	 INTERPRETATION
	  	 	7	 
			
	 1.2
	  	 DEFINITIONS
	  	 	7	 
		
	 ARTICLE 2
	  	 	16	 
			
	 2.1
	  	 AMOUNT OF CREDIT
	  	 	16	 
			
	 2.2
	  	 DISBURSEMENT PROCEDURE
	  	 	16	 
			
	 2.2.1
	  	 TRANCHES
	  	 	16	 
	 2.2.2
	  	 DISBURSEMENT OFFER
	  	 	16	 
	 2.2.3
	  	 DISBURSEMENT ACCEPTANCE
	  	 	17	 
			
	 2.3
	  	 DISBURSEMENT ACCOUNT
	  	 	17	 
			
	 2.4
	  	 CURRENCY OF DISBURSEMENT
	  	 	17	 
			
	 2.5
	  	 CONDITIONS OF DISBURSEMENT
	  	 	17	 
			
	 2.5.1
	  	 INITIAL DOCUMENTARY CONDITIONS
PRECEDENT
	  	 	17	 
	 2.5.2
	  	 TRANCHE B – ADDITIONAL CONDITIONS
PRECEDENT
	  	 	17	 
	 2.5.3
	  	 ALL TRANCHES - DOCUMENTARY CONDITIONS
PRECEDENT
	  	 	18	 
	 2.5.4
	  	 ALL TRANCHES – OTHER
CONDITIONS
	  	 	18	 
			
	 2.6
	  	 CANCELLATION
	  	 	18	 
			
	 2.7
	  	 FEE FOR CANCELLATION OF AN ACCEPTED TRANCHE
	  	 	19	 
			
	 2.8
	  	 CANCELLATION AFTER EXPIRY OF THE CREDIT
	  	 	19	 
			
	 2.9
	  	 STANDBY FEE
	  	 	19	 
			
	 2.10
	  	 SUMS DUE UNDER ARTICLE 2
	  	 	19	 
		
	 ARTICLE 3
	  	 	19	 
			
	 3.1
	  	 AMOUNT OF LOAN
	  	 	19	 
			
	 3.2
	  	 CURRENCY OF REPAYMENT, INTEREST AND OTHER CHARGES
	  	 	19	 
		
	 ARTICLE 4
	  	 	20	 
			
	 4.1
	  	 CASH INTEREST FIXED RATE
	  	 	20	 
			
	 4.2
	  	 DEFERRED INTEREST FIXED RATE
	  	 	20	 
			
	 4.3
	  	 PROFIT PARTICIPATION
	  	 	20	 
			
	 4.4
	  	 INTEREST ON OVERDUE SUMS
	  	 	21	 
		
	 ARTICLE 5
	  	 	22	 
			
	 5.1
	  	 NORMAL REPAYMENT
	  	 	22	 
			
	 5.2
	  	 VOLUNTARY PREPAYMENT
	  	 	22	 
			
	 5.2.1
	  	 PREPAYMENT OPTION
	  	 	22	 
	 5.2.2
	  	 PREPAYMENT FEE
	  	 	22	 
	 5.2.3
	  	 PREPAYMENT MECHANICS
	  	 	23	 
			
	 5.3
	  	 COMPULSORY PREPAYMENT
	  	 	23	 
			
	 5.3.1
	  	 COST REDUCTION
	  	 	23	 
	 5.3.2
	  	 CHANGE EVENTS
	  	 	23	 
	 5.3.3
	  	 ILLEGALITY
	  	 	23	 
	 5.3.4
	  	 DISPOSALS
	  	 	23	 
	 5.3.5
	  	 EXPIRY OF GUARANTEE AGREEMENT
	  	 	24	 
	 5.3.6
	  	 PARI PASSU TO NON-EIB FINANCING
	  	 	24	 
	 5.3.7
	  	 PREPAYMENT FEE
	  	 	24	 
	 5.3.8
	  	 PREPAYMENT MECHANICS
	  	 	24	 

  
 2 

							
			
	 5.4
	  	 GENERAL
	  	 	24	 
		
	 ARTICLE 6
	  	 	25	 
			
	 6.1
	  	 DAY COUNT CONVENTION
	  	 	25	 
			
	 6.2
	  	 TIME AND PLACE OF PAYMENT
	  	 	25	 
			
	 6.3
	  	 NO SET-OFF BY THE BORROWER
	  	 	25	 
			
	 6.4
	  	 DISRUPTION TO PAYMENT SYSTEMS
	  	 	25	 
			
	 6.5
	  	 APPLICATION OF SUMS RECEIVED
	  	 	26	 
			
	 6.5.1
	  	 GENERAL
	  	 	26	 
	 6.5.2
	  	 PARTIAL PAYMENTS
	  	 	26	 
	 6.5.3
	  	 ALLOCATION OF SUMS RELATED
TO TRANCHES
	  	 	26	 
		
	 ARTICLE 7
	  	 	26	 
		
	 ARTICLE 8
	  	 	26	 
			
	 8.1
	  	 TAXES, DUTIES AND FEES
	  	 	26	 
			
	 8.2
	  	 OTHER CHARGES
	  	 	27	 
			
	 8.3
	  	 INCREASED COSTS, INDEMNITY AND SET-OFF
	  	 	27	 
		
	 ARTICLE 9
	  	 	27	 
			
	 9.1
	  	 RIGHT TO DEMAND REPAYMENT
	  	 	27	 
			
	 9.2
	  	 OTHER RIGHTS AT LAW
	  	 	29	 
			
	 9.3
	  	 PREPAYMENT FEE
	  	 	29	 
			
	 9.4
	  	 NON-WAIVER
	  	 	29	 
		
	 ARTICLE 10
	  	 	29	 
			
	 10.1
	  	 GOVERNING LAW
	  	 	29	 
			
	 10.2
	  	 JURISDICTION
	  	 	29	 
			
	 10.3
	  	 PLACE OF PERFORMANCE
	  	 	29	 
			
	 10.4
	  	 EVIDENCE OF SUMS DUE
	  	 	30	 
			
	 10.5
	  	 THIRD PARTY RIGHTS
	  	 	30	 
			
	 10.6
	  	 ENTIRE AGREEMENT
	  	 	30	 
			
	 10.7
	  	 INVALIDITY
	  	 	30	 
			
	 10.8
	  	 AMENDMENTS
	  	 	30	 
			
	 10.9
	  	 COUNTERPARTS
	  	 	30	 
			
	 10.10
	  	 ASSIGNMENT AND TRANSFER BY THE BANK
	  	 	31	 
		
	 ARTICLE 11
	  	 	31	 
			
	 11.1
	  	 NOTICES
	  	 	31	 
			
	 11.1.1
	  	 FORM OF NOTICE
	  	 	31	 
	 11.1.2
	  	 ADDRESSES
	  	 	32	 
	 11.1.3
	  	 DEMAND AFTER NOTICE TO
REMEDY
	  	 	32	 
			
	 11.2
	  	 ENGLISH LANGUAGE
	  	 	32	 
			
	 11.3
	  	 CONCLUSION OF THIS CONTRACT (VERTRAGSSCHLUSS)
	  	 	33	 
		
	 SCHEDULE A
	  	 	35	 
		
	 INVESTMENT SPECIFICATION AND REPORTING
	  	 	35	 
		
	 SCHEDULE B
	  	 	37	 

  
 3 

					
		
	 DEFINITION OF EURIBOR
	  	 	37	 
		
	 SCHEDULE C
	  	 	38	 
		
	 FORM OF DISBURSEMENT OFFER/ACCEPTANCE
	  	 	38	 
		
	 SCHEDULE D
	  	 	40	 
		
	 FORM OF DRAWDOWN CERTIFICATE
	  	 	40	 
		
	 SCHEDULE E
	  	 	41	 
		
	 FORM OF COMPLIANCE CERTIFICATE
	  	 	41	 
		
	 SCHEDULE F
	  	 	42	 
		
	 CONDITIONS PRECEDENT
	  	 	42	 
		
	 SCHEDULE G
	  	 	45	 
		
	 REPRESENTATIONS AND WARRANTIES
	  	 	45	 
		
	 SCHEDULE H
	  	 	48	 
		
	 GENERAL UNDERTAKINGS
	  	 	48	 
		
	 SCHEDULE I
	  	 	58	 
		
	 INFORMATION AND VISITS
	  	 	58	 
		
	 SCHEDULE J
	  	 	62	 
		
	 EXISTING INDEBTEDNESS
	  	 	62	 
		
	 SCHEDULE K
	  	 	63	 
		
	 EXISTING SECURITY
	  	 	63	 

  
 4 

 THIS CONTRACT IS MADE ON 10 JUNE 2020 BETWEEN: 

 

			
	The European Investment Bank having its seat at 100 blvd Konrad Adenauer, Luxembourg, L-2950 Luxembourg, represented by Donald Fitzpatrick, Head of Divission and Emma Milne, Legal
Counsel	  	 (the “Bank”)

		
	and	  	
		
	 BioNTech SE a European public limited liability company (Europäische Gesellschaft)

incorporated in Germany, having its registered office at An der Goldgrube 12, D- 55131 Mainz, Germany, registered with
the commercial register (Handelsregister) of the local court (Amtsgericht) of Mainz under HRB 48720, represented by Dr. Sierk Poetting, CFO & COO (Vorstand) and Dr. James Timothy Patrick Ryan
(Prokurist)
	  	 (the “Borrower”)

 . 

  
 5 

 WHEREAS: 
  

	 	(A)	 The Borrower has stated that it is implementing an investment programme relating to research and development
and related expenses for the development of a prophylactic vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as more particularly described in
the technical description (the “Technical Description”) set out in Schedule A (Investment Specification and Reporting) (the “Investment”). The total cost of the Investment, as estimated by the Bank, is EUR
[***] ([***] euro). 

  

	 	(B)	 The Bank, considering that the financing of the Investment falls within the scope of its functions, agreed to
provide the Borrower with a credit (including a profit participation credit (partiarisches Darlehen)) in an amount of EUR 100,000,000 (one hundred million euro) under this finance contract (the “Contract”) to partially
finance the Investment; provided that the amount of the loan hereunder shall not, in any case, exceed 50% (fifty per cent.) of the cost of the Investment. The Parties being aware of the differences between a profit participation credit
(partiarisches Darlehen) and a silent partnership (stille Gesellschaft), have consciously decided to enter into this Contract. 

  

	 	(C)	 This operation benefits from a guarantee from the European Union under the European Fund for Strategic
Investments (“EFSI”). 

  

	 	(D)	 The Credit falls under a joint initiative between the Bank and the European Commission, which is intended as a
new Bank financing instrument, to finance inter alia research projects and research infrastructure under the Horizon 2020 framework programme of the European Union for Research and Technological Development (2014-2020) (the “Horizon
2020 Framework EU Programme”) and, in particular, under the programme called “Risk Sharing for Corporate Research and Innovation Facility”. 

 

	 	(E)	 The statute of the Bank provides that the Bank shall ensure that its funds are used as rationally as possible
in the interests of the European Union; and, accordingly, the terms and conditions of the Bank’s loan operations must be consistent with relevant policies of the European Union. 

 

	 	(F)	 The financing of the Investment includes certain state subsidies or grants and the provision of such funds has
been duly authorised and will be provided in compliance with all relevant legislation of the European Union. 

  

	 	(G)	 The Bank considers that access to information plays an essential role in the reduction of environmental and
social risks, including human rights violations, linked to the projects it finances and has therefore established its transparency policy, the purpose of which is to enhance the accountability of the Bank’s group towards its stakeholders and
the citizens of the European Union in general. 

  

	 	(H)	 The processing of personal data shall be carried out by the Bank in accordance with applicable European Union
legislation on the protection of individuals with regard to the processing of personal data by the European Union institutions and bodies and on the free movement of such data. 

 

	 	(I)	 The Bank supports the implementation of international and EU standards in the field of anti-money laundering
and countering the financing of terrorism and promotes tax good governance standards. It has established policies and procedures to avoid the risk of misuse of its funds for purposes which are illegal or abusive in relation to applicable laws. The
Bank’s group statement on tax fraud, tax evasion, tax avoidance, aggressive tax planning, money laundering and financing of terrorism is available on the Bank’s website and offers further guidance to the Bank’s contracting
counterparties. 

  
 6 

 It is hereby agreed as follows: 

ARTICLE 1 

Interpretation and definitions 
  

	1.1	 Interpretation 

In this Contract: 
  

	 	(a)	 references to Articles, Recitals, Schedules and (Sub-)Paragraphs are,
save if explicitly stipulated otherwise, references respectively to articles of, and recitals, schedules and (sub-)paragraphs of schedules to, this Contract. All Recitals and Schedules form part of this
Contract; 

  

	 	(b)	 references to “law” or “laws” mean (i) any applicable law and any applicable treaty,
constitution, statute, legislation, decree, normative act, rule, regulation, judgement, order, writ, injunction, determination, award or other legislative or administrative measure or judicial or arbitral decision in any jurisdiction which is
binding or applicable case law, and (ii) EU Law; 

  

	 	(c)	 references to applicable law, applicable laws or applicable jurisdiction means (i) a law or jurisdiction
applicable to the Borrower or any other Obligor (as the context requires), its respective rights and/or obligations (in each case arising out of or in connection with the Finance Documents), its capacity and/or assets and/or the Investment; and/or,
as applicable, (ii) a law or jurisdiction (including in each case the Bank’s Statute) applicable to the Bank, its rights, obligations, capacity and/or assets; 

 

	 	(d)	 references to a provision of law are references to that provision as amended or
re-enacted; 

  

	 	(e)	 references to any Finance Document or other agreement or instrument are references to that Finance Document or
other agreement or instrument as amended, novated, supplemented, extended or restated; 

  

	 	(f)	 words and expressions in plural shall include singular and vice versa; 

 

	 	(g)	 “promptly” is to be construed as unverzüglich (without undue delay) within the meaning of
Section 121 para. 1 sentence 1 of the BGB; 

  

	 	(h)	 a Default (other than an Event of Default) is “continuing” if it has not been remedied or waived and
an Event of Default is “continuing” if it has not been waived; and 

  

	 	(i)	 terms defined in the GDPR (as defined below), including the terms “data subject”, “personal
data” and “processing” have the same meanings when used in Paragraph 25 (Data Protection) of Schedule H (General Undertakings) of, this Contract. 

This Contract is made in the English language. For the avoidance of doubt, the English language version of this Contract shall prevail over any
translation of this Contract. However, where a German translation of a word or phrase appears in the text of this Contract, the German translation of such word or phrase shall prevail. 

 

	1.2	 Definitions 

In this Contract: 

“Accepted Tranche” means a Tranche in respect of a Disbursement Offer which has been duly accepted by the Borrower in
accordance with its terms on or before the Disbursement Acceptance Deadline. 
 “acting in concert” means acting together
pursuant to an agreement or understanding (whether formal or informal). 
 “AktG” means the German stock corporation act
(Aktiengesetz). 
 “Auditor” means an independent, international and leading firm of accounts (which has at least
offices in Luxembourg and Frankfurt am Main) appointed by the Bank and accepted by the Borrower. If the Bank and the Borrower have not agreed on an Auditor within 60 (sixty) days of any such request, the Bank will have sole discretion to appoint an
Auditor. 

  
 7 

 “Authorisation” means an authorisation, permit, consent, approval,
resolution, licence, exemption, filing, notarisation or registration. 
 “Authorised Signatory” means a person authorised to
sign individually or jointly (as the case may be) Disbursement Acceptances on behalf of the Borrower and named in the most recent List of Authorised Signatories and Accounts received by the Bank prior to the receipt of the relevant Disbursement
Acceptance. 
 “BGB” means the German Civil Code (Bürgerliches Gesetzbuch). 

“Budget” has the meaning given to that term in Sub-Paragraph (b) of
Paragraph 2 (Information concerning the Borrower) of Schedule I (Information and Visits). 
 “Business
Day” means a day (other than a Saturday or Sunday) on which the Bank and commercial banks are open for general business in Luxembourg and Mainz, Germany. 

“Cancellation Fee” has the meaning given to such term in Article 1.2 (Definitions) of the Finance Fee Letter. 

“Cash Interest Fixed Rate” means a fixed rate of [***]% ([***] basis points) per annum. 

“Change in the Beneficial Ownership” means a change in the ultimate ownership or control of the Borrower according to the
definition of “beneficial owner” set out in article 3(6) of Directive 2015/849 of the European Parliament and of the Council of 20 May 2015 on the prevention of the use of the financial system for the purposes of money laundering
or terrorist financing, as amended, supplemented or restated. 

“Change-of-Control Event” means: 

 

	 	(a)	 any person or group of persons acting in concert gains Control of the Borrower or of any entity directly or
indirectly Controlling the Borrower; or 

  

	 	(b)	 the Borrower ceases to Control any Guarantor; or 

 

	 	(c)	 a Delisting of the Borrower. 

“Change-of-Law Event” means the enactment,
promulgation, execution or ratification of or any change in or amendment to any law, rule or regulation (or in the application or official interpretation of any law, rule or regulation) that occurs after the date of this Contract and which, in the
opinion of the Bank, would materially impair an Obligor’s ability to perform its obligations under the Finance Documents. 

“Clinical Study” means each of the ongoing clinical studies with references NCT04380701 and NCT04368728. 

“Compliance Certificate” means a certificate substantially in the form set out in Schedule E (Form of Compliance
Certificate). 
 “Contract Number” shall mean each Bank generated number identifying this Contract and indicated on the
cover page of this Contract after the letters “FI N°”. 
 “Control” means (i) owning (directly or
indirectly) more than 50% (fifty per cent) of the shares in an entity, (ii) the power to cast, or to control the casting of, more than 50% (fifty per cent) of the maximum number of votes that might be cast at a shareholder or general meeting of
an entity, (iii) the power to appoint or remove all, or the majority, of the directors of an entity, and/or (iv) the power to direct the management and policies of an entity, whether through the ownership of voting capital, by contract or
otherwise, and “Controlling” and “Controlled” has the corresponding meaning. 
 “COVID-19 Syndrome” means severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 

“COVID-19 Vaccine” means a vaccine against
COVID-19 Syndrome developed by the Borrower. 

“COVID-19 Vaccine Gross Profit” means the Group’s share of the aggregate amount
of: 

  
 8 

	 	(a)	 [***]; and 

  

	 	(b)	 [***], 

less such amounts applied towards reimbursement of the ‘BioNTech Deferred Development Costs’ under and as defined in section 5.4.2 of
the Pfizer Agreement as at 17 March 2020. 
 “Credit” has the meaning given to it in Article 2.1 (Amount of
Credit). 
 “Default” means an Event of Default or any event or circumstance specified in Article 9 (Events of
Default) which would (with the expiry of a grace period, the giving of notice, the making of any determination under this Contract or any combination of any of the foregoing) be an Event of Default. 

“Deferred Interest Fixed Rate” means a fixed rate of [***]% ([***] basis points) per annum [***]. 

“Delisting” means voluntary or involuntary removal of listed shares from a regulated market or revocation of admission to
trading of shares on a regulated market. 
 “Disbursement Acceptance” means a copy of the Disbursement Offer duly
countersigned by the Borrower. 
 “Disbursement Acceptance Deadline” means the date and time of expiry of a Disbursement
Offer as specified therein. 
 “Disbursement Account” means, in respect of each Tranche, the bank account set out in the
most recent List of Authorised Signatories and Accounts. 
 “Disbursement Date” means the date on which disbursement of a
Tranche is made by the Bank. 
 “Disbursement Offer” means a letter substantially in the form set out in Schedule C (Form
of Disbursement Offer/Acceptance). 
 “Dispute” has the meaning given to it in Article 10.2 (Jurisdiction).

 “Disruption Event” means either or both of: 
  

	 	(a)	 a material disruption to those payment or communications systems or to those financial markets which are, in
each case, required to operate in order for payments to be made in connection with this Contract; or 

  

	 	(b)	 the occurrence of any other event which results in a disruption (of a technical or systems-related nature) to
the treasury or payments operations of either the Bank or the Borrower, preventing that party from: 

  

	 	(i)	 performing its payment obligations under this Contract; or 

 

	 	(ii)	 communicating with other parties in accordance with the terms of this Contract, 

and which disruption (in either such case as per Paragraph (a) or (b) above) is not caused by, and is beyond the control of, the party
whose operations are disrupted. 
 “EBITDA” means, in respect of any Relevant Period, the consolidated operating profit of
the Group before taxation (excluding the results from discontinued operations): 
  

	 	(a)	 after deducting own work capitalised; 

 

	 	(b)	 before deducting any interest, commission, fees, discounts, prepayment fees, premiums or charges and other
finance payments whether paid, payable or capitalised by any Group Company (calculated on a consolidated basis) in respect of that Relevant Period; 

  

	 	(c)	 not including any accrued interest owing to any Group Company; 

 

	 	(d)	 after adding back any amount attributable to the amortisation or depreciation of assets of members of the
Group; 

  

	 	(e)	 before taking into account any Exceptional Items; 

  
 9 

	 	(f)	 after deducting the amount of any profit (or adding back the amount of any loss) of any Group Company which is
attributable to minority interests; 

  

	 	(g)	 plus or minus the Group’s share of the profits or losses (after finance costs and tax) of entities which
are not Group Companies; 

  

	 	(h)	 before taking into account any unrealised gains or losses on any financial instrument (other than any
derivative instrument which is accounted for on a hedge accounting basis); and 

  

	 	(i)	 before taking into account any gain arising from an upward revaluation of any other asset,

 in each case, to the extent added, deducted or taken into account, as the case may be, for the purposes of determining
operating profits of the Group before taxation. 
 “EIB Fee Letter” means the letter from the Bank to the Borrower dated
17 April 2020. 
 “EFSI” has the meaning given in Recital (C). 

“EFSI Regulation” means the Regulation 2015/1017 of the European Parliament and of the Council of 25 June 2015 on the
European Fund for Strategic Investments, as amended, supplemented or restated. 
 “Environment” means the following, in so
far as they affect human health or social well-being: 
  

	 	(a)	 fauna and flora; 

  

	 	(b)	 soil, water, air, climate and the landscape; and 

 

	 	(c)	 cultural heritage and the built environment, 

and includes, without limitation, occupational and community health and safety. 

“Environmental Approval” means any Authorisation required by Environmental Law. 

“Environmental Claim” means any claim, proceeding, formal notice or investigation by any person in respect of any
Environmental Law. 
 “Environmental Law” means EU Law including principles and standards, and national laws and
regulations, of which a principal objective is the preservation, protection or improvement of the Environment. 
 “Equity
Investments” mean: 
  

	 	(a)	 the investment of USD 113,000,000 (one hundred and thirteen million dollars) by Pfizer; and

  

	 	(b)	 the investment of USD 50,000,000 (fifty million dollars) by Fosun, 

for subscribed shares in the Borrower. 

“EU Directives” means the directives of the European Union. 

“EU Law” means the acquis communautaire of the European Union as expressed through the Treaties of the European Union, the
regulations, the EU Directives, delegated acts, implementing acts, and the case law of the Court of Justice of the European Union. 

“EUR” or “euro” means the lawful currency of the Member States of the European Union which adopt or have
adopted it as their currency in accordance with the relevant provisions of the Treaty on European Union and the Treaty on the Functioning of the European Union or their succeeding treaties. 

“EURIBOR” has the meaning given to it in Schedule B (Definition of EURIBOR). 

“Event of Default” means any of the circumstances, events or occurrences specified in Article 9 (Events of Default).

 “Exceptional Items” means any material items of an unusual or non-recurring
nature which represent gains or losses including those arising on: 
  

	 	(a)	 the restructuring of the activities of an entity and reversals of any provisions for the cost of restructuring;

  
 10 

	 	(b)	 disposals, revaluations, write downs or impairment of non-current
assets or any reversal of any write down or impairment; 

  

	 	(c)	 disposals of assets associated with discontinued operations; and 

 

	 	(d)	 any other examples of “exceptional items” (as such term has the meaning attributed to it in IFRS).

 “Existing EIB Finance Contract” means the finance contract entered into by the Bank and the Borrower on
12 December 2019. 
 “Existing Indebtedness” means any Indebtedness of members of the Group arising under any
arrangement listed in Schedule J (Existing Indebtedness). 
 “Existing Security” means any Security granted by
members of the Group which is listed in Schedule K (Existing Security). 
 “Fee Letters” means the EIB Finance Letter
and the Finance Fee Letter. 
 “Finance Fee Letter” means the Luxembourg law governed finance fee letter from the Bank to
the Borrower dated on or about the date hereof. 
 “Final Availability Date” means the day falling [***] ([***]) months
after the date of this Contract. 
 “Finance Documents” means this Contract, any Guarantee Agreement, the Fee Letters and
any other document designated a “Finance Document” by the Borrower and the Bank. 
 “Finance Lease” means any
lease or hire purchase contract which would, in accordance with IFRS in force prior to 1 January 2019, be treated as a finance or capital lease; it is understood between the parties to this Contract that the definition of “Finance
Lease” does not include operational lease. 
 “Fosun” means Shanghai Fosun Pharmaceutical Industrial Development, Co.,
Ltd, a company incorporated in the People’s Republic of China, and having a place of business at No. 1289 Yishan Road, Shanghai, People’s Republic of China. 

“Fosun Agreement” means the development and license agreement between Fosun and the Borrower dated 13 March 2020. 

“GAAP” means generally accepted accounting principles (Grundsätze ordnungsgemäßer
Buchführung) in Germany, including IFRS. 
 “GDPR” means General Data Protection Regulation (EU) 2016/679. 

[***] 
  

	 	[***]	 

  

	 	[***]	 

“Germany” means the Federal Republic of Germany. 

“Group” means the Group Companies, taken together as a whole. 

“Group Company” means the Borrower and its Subsidiaries. 

“Guarantee Agreement” means a guarantee and indemnity agreement in form and substance satisfactory to the Bank to be entered
into by a Guarantor as guarantor and the Bank as beneficiary. 
 “Guarantor” means: 

 

	 	(a)	 BioNTech RNA Pharmaceuticals GmbH; 

 

	 	(b)	 BioNTech Innovative Manufacturing Services GmbH; 

 

	 	(c)	 JPT Peptide Technologies GmbH; 

 

	 	(d)	 BioNTech Cell & Gene Therapies GmbH; and 

  
 11 

	 	(e)	 each Material Subsidiary which enters into a Guarantee Agreement in accordance with Sub-Paragraph (b) of Paragraph 16 (Guarantees) of Schedule H (General Undertakings). 

“Horizon 2020 Framework EU Programme” has the meaning given in Recital (D). 

“Horizon 2020 Legal Basis” means the Regulation 1291/2013 of the European Parliament and of the Council of 11 December
2013 establishing Horizon 2020 and Council Decision of 3 December 2013 establishing the specific programme implementing Horizon 2020. 

“IFRS” means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the
relevant financial statements. 
 “Illegal Activities” means any of the following illegal activities or activities carried
out for illegal purposes: tax crimes (as referred to in the directive (EU) 2015/849 of 20 May 2015), fraud, corruption, coercion, collusion, obstruction, money laundering, financing of terrorism or any illegal activity that may affect the
financial interests of the EU, according to applicable laws. 
 “Indebtedness” means any: 

 

	 	(a)	 obligations for borrowed money; 

 

	 	(b)	 indebtedness under any acceptance credit; 

 

	 	(c)	 indebtedness under any bond, debenture, note or similar instrument; 

 

	 	(d)	 instrument under any bill of exchange; 

 

	 	(e)	 indebtedness in respect of any interest rate or currency swap or forward currency sale or purchase or other
form of interest or currency hedging transaction (including without limit caps, collars and floors); 

  

	 	(f)	 indebtedness under any Finance Lease; 

 

	 	(g)	 indebtedness (actual or contingent) under any guarantee, bond security, indemnity or other agreement;

  

	 	(h)	 indebtedness (actual or contingent) under any instrument entered into for the purpose of raising finance;

  

	 	(i)	 indebtedness in respect of a liability to reimburse a purchaser of any receivables sold or discounted in the
event that any amount of those receivables is not paid; 

  

	 	(j)	 indebtedness arising under a securitisation; or 

 

	 	(k)	 other transaction which has the commercial effect of borrowing. 

“Independent Expert” means an investment bank or consultancy firm of international standing and repute, appointed by the
Borrower and accepted by the Bank. If the Bank and the Borrower have not agreed on an Independent Expert within 60 (sixty) days of any such request, the Independent Expert shall be appointed by the President of the Chamber of Industry and Commerce
Frankfurt am Main (Industrie- und Handelskammer Frankfurt am Main) upon application by either the Bank or the Borrower. 

“Initial Ownership Stake” has the meaning given to that term in Sub-Paragraph (b)(i)
of Paragraph 13 (Ownership) of Schedule H (General Undertakings). 
 “InsO” means the German Insolvency Code
(Insolvenzordnung). 
 “Intellectual Property Rights” means intellectual property rights (gewerbliche
Schutzrechte; Immaterialgüterrechte) of every designation (including, without limitation, patents, utility patents, copyrights, design rights, trademarks, software, service marks and know how) whether capable of registration or not. 

“Investment” has the meaning given to that term in Recital (A). 

“Key Contracts” means [***] and any other document designated a “Key Contract” by the Borrower and the Bank. 

  
 12 

 “Lead Organisation” means the European Union, the United Nations and
international standard setting organisations including the International Monetary Fund, the Financial Stability Board, the Financial Action Task Force, the Organisation for Economic Cooperation and Development and the Global Forum on Transparency
and Exchange of Information for Tax Purposes and any successor organisations. 
 “List of Authorised Signatories and
Accounts” means a list (signed by Authorised Signatories), in form and substance satisfactory to the Bank, setting out: (i) the Authorised Signatories, accompanied by evidence of signing authority of the persons named on the list and
specifying if they have individual or joint signing authority, (ii) the specimen signatures of such persons, and (iii) the bank account(s) to which disbursements may be made under this Contract (specified by IBAN code if the country is
included in the IBAN Registry published by SWIFT, or in the appropriate account format in line with the local banking practice), BIC/SWIFT code of the bank and the name of the bank account(s) beneficiary. 

“Loan” means the aggregate of the amounts disbursed from time to time by the Bank under this Contract. 

“Loan Outstanding” means the aggregate of the amounts disbursed from time to time by the Bank under this Contract that remains
outstanding. 
 “Material Adverse Change” means, any event or change of condition, which, in the reasonable opinion of the
Bank has a material adverse effect on: 
  

	 	(a)	 the ability of any Obligor to perform its respective obligations under the Finance Documents;

  

	 	(b)	 the business, operations, property or condition (financial or otherwise) of any Obligor or the Group as a
whole; or 

  

	 	(c)	 the legality, validity or enforceability of, or the effectiveness or ranking of, the rights or remedies of the
Bank under the Finance Documents. 

 “Material Subsidiary” means BioNTech RNA Pharmaceuticals GmbH,
BioNTech Innovative Manufacturing Services GmbH, JPT Peptide Technologies GmbH, BioNTech Cell & Gene Therapies GmbH and any Subsidiary from time to time, whose gross revenues, Total Assets or EBITDA represents more than 5% (five per cent.)
of (i) the consolidated gross revenues of the Group or, (ii) the Total Assets, or, (iii) as the case may be, the consolidated EBITDA of the Group, as calculated based on the then latest consolidated audited accounts of the Group. 

“Maturity Date” means, for each Tranche, the last Repayment Date of that Tranche as specified in the relevant Disbursement
Offer, being the date falling 6 (six) years from the respective Disbursement Date of the relevant Tranche. 
 “Milestone
Events” means collectively the Tranche A Milestone Events and the Tranche B Milestone Events. 
 “Non-EIB Financing” includes any loan (save for the Loan and any other direct loans from the Bank to the Borrower (or any other Group Company or a Guarantor)), credit bond or other form of financial
indebtedness or any obligation for the payment or repayment of money originally granted to the Borrower (or any other Group Company or a Guarantor)) for a term of more than 3 (three) years. 

“Obligor” means the Borrower and each Guarantor. 

“Payment Date” means the quarterly dates specified in the Disbursement Offer until and including the Maturity Date, save that,
in case any such date is not a Relevant Business Day, it means the following Relevant Business Day, without adjustment to the interest due under Article 4 (Interest), except for those cases where a payment is made as a single instalment
in accordance with Article 5.1 (Normal Repayment), and to the final interest payment only, when it shall mean the preceding Relevant Business Day, with adjustment to the interest due under Article 4 (Interest). 

“Permitted Disposal” means each disposal permitted in accordance with Sub-Paragraph
(b) of Paragraph 7 (Disposal of assets) of Schedule H (General Undertakings). 
 “Permitted Guarantees”
means each and every guarantee permitted in accordance with Paragraph 16 (Guarantees) of Schedule H (General Undertakings). 

  
 13 

 “Permitted Hedging” has the meaning given to such term in Paragraph 17
(Hedging) of Schedule H (General Undertakings). 
 “Permitted Indebtedness” means Indebtedness of the Borrower
and/or any Group Company which is permitted in accordance with Paragraph 15 (Indebtedness) of Schedule H (General Undertakings). 

“Permitted Security” means Security of the Borrower and/or any Group Company which is permitted in accordance with Sub-Paragraph (c) Paragraph 23 (Negative pledge) of Schedule H (General Undertakings). 

“Pfizer” means Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of
business at 235 East 42nd Street, New York, New York, 10017 United States. 
 “Pfizer Agreement” means the collaboration
agreement between the Borrower and Pfizer dated 17 March 2020. 
 “Pfizer Commercialisation Agreement” means the
definitive agreement pursuant to which Pfizer shall be licensed to commercialise the COVID-19 Vaccine in accordance with the provisions of the Pfizer Agreement. 

“Prepayment Amount” means the amount of a Tranche to be prepaid by the Borrower in accordance with Articles 5.2
(Voluntary prepayment), 5.3 (Compulsory prepayment) or 9.1 (Right to demand repayment). 
 “Prepayment
Date” means the date on which the Borrower proposes or is requested by the Bank, as applicable, to effect prepayment of a Prepayment Amount. 

“Prepayment Event” means any of the events described in Article 5.3 (Compulsory Prepayment). 

“Prepayment Fee” means, in relation to a Prepayment Amount in respect of a Tranche, a fee as follows: 

 

	 	(a)	 a fee of 4% (four hundred basis points) of the Prepayment Amount if the Prepayment Date is after the relevant
Disbursement Date but before or on the first anniversary of such Disbursement Date; 

  

	 	(b)	 a fee of 3% (three hundred basis points) of the Prepayment Amount if the Prepayment Date is after the first
anniversary of the relevant Disbursement Date but before or on the second anniversary of such Disbursement Date; 

  

	 	(c)	 a fee of 2% (two hundred basis points) of the Prepayment Amount if the Prepayment Date is after the second
anniversary of the relevant Disbursement Date but before or on the third anniversary of such Disbursement Date; 

  

	 	(d)	 a fee of 1% (one hundred basis points) of the Prepayment Amount if the Prepayment Date is after the third
anniversary of the relevant Disbursement Date but before or on the fourth anniversary of such Disbursement Date; or 

  

	 	(e)	 a fee of 0.5% (fifty basis points) of the Prepayment Amount if the Prepayment Date is after the fourth
anniversary of the relevant Disbursement Date but before the Maturity Date, 

 with such fee being payable on the
applicable Prepayment Date. 
 “Prepayment Notice” means a written notice from the Bank to the Borrower in accordance with
Article 5.2.3 (Prepayment mechanics). 
 “Prepayment Request” means a written request from the Borrower to the
Bank to prepay all or part of the Loan Outstanding, in accordance with Article 5.2.1 (Prepayment option). 
 “Profit
Participation Cap” means, at any time, an amount of EUR 25,000,000 (twenty five million euro) or any other amount agreed between the Bank and the Borrower in writing. 

“Profit Participation Payments” has the meaning given to it in Paragraph (a) of Article 4.3 (Profit
Participation). 

  
 14 

 “Profit Participation Period” means the 6 (six) year period starting with
the date on which the first sale of the COVID-19 Vaccine has occurred after regulatory approval for commercial sale has been obtained by the US Food and Drug Administration or the European Medicines Agency,
which may include a conditional or emergency approval. 
 “Relevant Business Day” means a day on which the Trans-European
Automated Real-time Gross Settlement Express Transfer payment system which utilises a single shared platform and which was launched on 19 November 2007 (TARGET2) is open for the settlement of payments in EUR. 

“Relevant Period” means each period of 12 (twelve) months ending on or about the last day of the financial year. 

“Repayment Date” shall mean the sole Payment Date specified in the Disbursement Offer for the repayment of a Tranche in
accordance with Article 5.1 (Normal repayment). 
 “Repeating Representations” means each of the representations
set out in Schedule G (Representations and Warranties) other than those Paragraphs thereof which are identified with the words “(Non-repeating)” at the end of the Paragraphs. 

“Replacement Conditions” has the meaning given to that term in Sub-Paragraph
(e) of Paragraph 14 (Acquisitions) of Schedule H (General Undertakings). 
 “Sales Milestone
Payments” means [***]. 
 “Security” means any mortgage, land charge (Grundschuld), pledge, lien, charge,
assignment, security transfer (Sicherungsübereignung), retention of title arrangements, hypothecation, or other security interest securing any obligation of any person or any other agreement or arrangement having a similar effect. 

“Semi-Annual Date” means each of 30 June and 31 December. 

“Standby Fee” has the meaning given to such term in Article 2. (Standby fee) of the Finance 

Fee Letter. 

“Subsidiary” means a subsidiary within the meaning of Sections 15 to 17 AktG and an entity of which the Borrower has direct or
indirect Control. 
 “Tax” means any tax, levy, impost, duty or other charge or withholding of a similar nature (including
any penalty or interest payable in connection with any failure to pay or any delay in paying any of the same). 
 “Technical
Description” has the meaning given to it in Recital (A). 
 “Total Assets” means the total consolidated assets
of the Group, as shown in the Borrower’s latest consolidated financial statements, as at the end of any Relevant Period. 

“Tranche” means each disbursement made or to be made under this Contract consisting of Tranche A and Tranche B. In the event
that no Disbursement Acceptance has been received, Tranche shall mean a Tranche as offered under Article 2.2.2 (Disbursement Offer). 

“Tranche A” means the first Tranche in the amount set out in Paragraph (a) of Article 2.2.1 (Tranches), in
relation to which a [***] shall be paid in accordance with Article [***] and [***] shall be paid in accordance with Article [***]. 

“Tranche A Milestone Events” has the meaning given to such term in Part A of Schedule F (Conditions Precedent). 

  
 15 

 “Tranche B” means the second Tranche in the amount set out in Paragraph
(b) of Article 2.2.1 (Tranches), in relation to which a [***] shall be paid in accordance with Article [***] and furthermore [***] to the Bank in accordance with Article [***]. 

“Tranche B Milestone Events” has the meaning given to such term in Part B of Schedule F (Conditions Precedent). 

“Upfront Payments” mean: 
  

	 	(a)	 [***]; and 

  

	 	(b)	 [***]. 

“Voluntary Non EIB Prepayment” means a voluntary prepayment by any Group Company or any Guarantor (for the avoidance of doubt,
prepayment shall include a repurchase, redemption or cancellation where applicable) of a part or the whole of any Non-EIB Financing where: 

 

	 	(a)	 such prepayment is not made within a revolving credit facility (save for the cancellation of a revolving credit
facility); or 

  

	 	(b)	 such prepayment is not made out of the proceeds of a loan or other indebtedness having a term at least equal to
the unexpired term of the Non-EIB Financing prepaid. 

 ARTICLE 2

 Credit and Disbursements 
  

	2.1	 Amount of Credit 

By this Contract, the Bank establishes in favour of the Borrower, and the Borrower accepts, a credit (including a profit participation credit
(partiarisches Darlehen)) in an aggregate amount of up to EUR 100,000,000 (one hundred million euro) for the financing of the Investment (the “Credit”). 

 

	2.2	 Disbursement procedure 

 

	2.2.1	 Tranches 

The Bank shall disburse the Credit in Euros in 2 (two) Tranches, as set out below: 

 

	 	(a)	 Tranche A, in an amount of EUR 50,000,000 (fifty million euro); and 

 

	 	(b)	 Tranche B, in an amount of EUR 50,000,000 (fifty million euro). 

 

	2.2.2	 Disbursement Offer 

Upon request by the Borrower and subject to Article 2.5 (Conditions of Disbursement), provided that no event mentioned in Sub-Paragraph (b) of Article 2.6 (Cancellation) has occurred and is continuing, the Bank shall send to the Borrower a Disbursement Offer for the disbursement of a Tranche. The latest time for
receipt by the Borrower of a Disbursement Offer is [***] ([***]) days before the Final Availability Date. The Disbursement Offer shall specify: 
  

	 	(a)	 the amount of the Tranche; 

 

	 	(b)	 the Disbursement Date, which shall be a Relevant Business Day, falling at least [***] ([***]) days after the
date of the Disbursement Offer and on or before the Final Availability Date; 

  

	 	(c)	 the interest rate basis of the Tranche, namely: 

 

	 	(i)	 the Cash Interest Fixed Rate; 

 

	 	(ii)	 if relevant, the Deferred Interest Fixed Rate; 

  
 16 

	 	(iii)	 the Payment Dates; 

  

	 	(d)	 the terms and frequency for repayment of principal (bullet); 

 

	 	(e)	 the Maturity Date; and 

 

	 	(f)	 the Disbursement Acceptance Deadline. 

 

	2.2.3	 Disbursement Acceptance 

 

	 	(a)	 The Borrower may accept a Disbursement Offer by delivering a Disbursement Acceptance to the Bank no later than
the Disbursement Acceptance Deadline. The Disbursement Acceptance shall be signed by an Authorised Signatory with individual representation rights or 2 (two) or more Authorised Signatories with joint representation rights and shall specify the
Disbursement Account to which disbursement of the Tranche should be made in accordance with Article 2.3 (Disbursement Account). 

  

	 	(b)	 If a Disbursement Offer is duly accepted by the Borrower in accordance with its terms on or before the
Disbursement Acceptance Deadline, and provided the conditions in Article 2.5.4 (All Tranches – Other Conditions) are met, the Bank shall make the Accepted Tranche available to the Borrower in accordance with the relevant Disbursement
Offer and subject to the terms and conditions of this Contract. 

  

	 	(c)	 The Borrower shall be deemed to have refused any Disbursement Offer which has not been duly accepted in
accordance with its terms on or before the Disbursement Acceptance Deadline, in which case the Tranche shall not be made available to the Borrower by the Bank, and the Credit shall not be affected. 

 

	2.3	 Disbursement Account 

 

	 	(a)	 Disbursement shall be made to the Disbursement Account specified in the relevant Disbursement Acceptance,
provided that such Disbursement Account is acceptable to the Bank in accordance with paragraph (d) of Article 6.2 (Time and place of payment). 

  

	 	(b)	 Only one Disbursement Account may be specified for each Tranche. 

 

	2.4	 Currency of disbursement 

The Bank shall disburse each Tranche in EUR. 
  

	2.5	 Conditions of Disbursement 

 

	2.5.1	 Initial Documentary Conditions Precedent 

Without prejudice to Articles 2.5.2 (Tranche B – Additional Conditions Precedent) to 2.5.4 (All Tranches – Other
Conditions), no Disbursement Offer will be provided by the Bank under this Contract unless the Bank has received all of the documents and other evidence listed in Part A of Schedule F (Conditions Precedent) in agreed form or otherwise in
form and substance satisfactory to the Bank. 
  

	2.5.2	 Tranche B – Additional Conditions Precedent 

Without prejudice to the generality of Articles 2.5.1 (Initial Documentary Conditions Precedent) to 2.5.4 (All Tranches – Other
Conditions), no Disbursement Offer will be provided by the Bank under this Contract in respect of Tranche B unless the Bank has received all of the additional documents and other evidence listed in Part B of Schedule F (Conditions
Precedent) in agreed form or otherwise in form and substance satisfactory to the Bank, including the Tranche B Milestone Events. 
  

	2.5.3	 All Tranches—Documentary Conditions Precedent 

No Disbursement Offer, including the first Disbursement Offer, will be provided by the Bank under this Contract unless the Bank has confirmed
that it has received, in form and substance satisfactory to it: 

  
 17 

	 	(a)	 a certificate from the Borrower in the form of Schedule D (Form of Drawdown Certificate), signed by an
Authorised Signatory of the Borrower and dated no earlier than the date falling 14 (fourteen) days before the respective Disbursement Date; and 

  

	 	(b)	 a certificate (signed by one or more Authorised Signatories of the Borrower as appropriate) from the Borrower
which confirms that the Borrower has sufficient resources to pay its debts as they fall due for at least [***] ([***]) months from the Disbursement Date not taking into account the disbursement of the proposed Tranche with a current extract from the
commercial register (Handelsregisterauszug) of the Borrower and an up-to-date search on www.insolvenzbekanntmachungen.de in relation to the Borrower attached.

  

	2.5.4	 All Tranches – Other Conditions 

The Bank will only be obliged to make any Accepted Tranche available to the Borrower if on the Disbursement Date for the proposed Tranche: 

 

	 	(a)	 the Repeating Representations made by the Borrower (in respect of itself and, where applicable, the other
Obligors) are correct in all respects; 

  

	 	(b)	 no event or circumstance has occurred and is continuing which constitutes or would with the expiry of a grace
period and/or the giving of notice under this Contract constitute a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction) or would, in each case, result from the disbursement of the proposed Tranche; 

 

	 	(c)	 no event or circumstance has occurred and is continuing which constitutes a Default or an Event of Default or
would, in each case, result from the disbursement of the proposed Tranche; and 

  

	 	(d)	 the Borrower complies with all preceding and already achieved Milestone Events. 

 

	2.6	 Cancellation 

 

	 	(a)	 The Borrower may send a written notice to the Bank requesting the cancellation of the undisbursed portion of
the Credit. The written notice: 

  

	 	(i)	 must specify whether the Borrower would like to cancel the undisbursed portion of the Credit in whole or in
part and, if in part, the amount of the Credit the Borrower would like to cancel; and 

  

	 	(ii)	 must not relate to an Accepted Tranche which has a Disbursement Date falling within [***] ([***]) Business Days
of the date of the written notice. 

 Upon receipt of such written notice, the Bank shall cancel the requested undisbursed
portion of the Credit with immediate effect. 
  

	 	(b)	 At any time upon the occurrence of the following events, the Bank may notify the Borrower in writing that the
undisbursed portion of the Credit shall be cancelled in whole or in part: 

  

	 	(i)	 a Prepayment Event, which in case cancellation pursuant to Article 5.3.1 (Cost Reduction) only shall be
in respect of an amount equal to the amount by which it is entitled to cancel the Credit under such Article 5.3.1 (Cost Reduction); 

  

	 	(ii)	 an Event of Default; or 

 

	 	(iii)	 an event or circumstance which would with the passage of time or giving of notice under this Contract
constitute a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction) or an Event of Default. 

 On
the date of such written notification the relevant undisbursed portion of the Credit shall be cancelled with immediate effect. 

  
 18 

	2.7	 Fee for cancellation of an Accepted Tranche 

 

	 	(a)	 If pursuant to Sub-Paragraph (a) of Article 2.6
(Cancellation) the Borrower cancels an Accepted Tranche, the Borrower shall pay to the Bank the Cancellation Fee in accordance with the terms of the Finance Fee Letter. 

 

	 	(b)	 If pursuant to Sub-Paragraph (b) of Article 2.6
(Cancellation) the Bank cancels all or part of an Accepted Tranche, the Borrower shall pay to the Bank the Cancellation Fee in accordance with the terms of the Finance Fee Letter. 

 

	 	(c)	 If an Accepted Tranche is not disbursed on the Disbursement Date because the conditions precedent set out in
Article 2.5.4 (All Tranches – Other Conditions) are not satisfied on such date, such Tranche shall be cancelled and the Borrower shall pay to the Bank the relevant Cancellation Fee in accordance with the terms of the Finance Fee Letter.

  

	2.8	 Cancellation after expiry of the Credit 

On the day following the Final Availability Date, and unless otherwise specifically agreed to in writing by the Bank, any part of the Credit in
respect of which no Disbursement Acceptance has been received in accordance with Article 2.2.3 (Disbursement Acceptance) shall be automatically cancelled, without any notice being served by the Bank to the Borrower. 

 

	2.9	 Standby fee 

 

	 	(a)	 The Borrower shall pay to the Bank the Standby Fee in accordance with the terms of the Finance Fee Letter.

  

	 	(b)	 For the avoidance of doubt, the Standby Fee payable under this Article 2.9 (Standby fee) is independent
of any other fees stipulated in this Contract. 

  

	2.10	 Sums due under Article 2 

Sums due under this Article 2 shall be payable in EUR. Sums due under this Article 2 shall be payable within [***] ([***]) days of the
Borrower’s receipt of the Bank’s demand or within any longer period specified in the Bank’s demand. 
 ARTICLE 3

 The Loan 
  

	3.1	 Amount of Loan 

The Loan shall comprise the aggregate amount of Tranches disbursed by the Bank under the Credit. 

 

	3.2	 Currency of repayment, interest and other charges 

 

	 	(a)	 Interest, Participation Payments, repayments and other charges payable in respect of each Tranche shall be made
by the Borrower in EUR. 

  

	 	(b)	 Any other payment shall be made in the currency specified by the Bank having regard to the currency of the
expenditure to be reimbursed by means of that payment. 

 ARTICLE 4 

Interest 
  

	4.1	 Cash Interest Fixed Rate 

The Borrower shall pay interest on the outstanding balance of each Tranche at the Cash Interest Fixed Rate quarterly in arrear on the relevant
Payment Dates specified in the 

  
 19 

 
Disbursement Offer, and calculated on the basis of Article 6.1 (Day count convention). If the period from the Disbursement Date to the first Payment Date is [***] ([***]) days or less then
the payment of interest accrued during such period shall be postponed to the following Payment Date. 
  

	4.2	 Deferred Interest Fixed Rate 

In addition to the interest payable pursuant to Article 4.1 (Cash Interest Fixed Rate), interest shall accrue on the outstanding balance
of Tranche A at the Deferred Interest Fixed Rate, and calculated on the basis of Article 6.1 (Day count convention), and such interest shall be due and payable on the Maturity Date of such Tranche or, where such Tranche is cancelled or
prepaid, on the date of cancellation or Prepayment Date. For the avoidance of doubt, any such interest shall not be capitalised and shall not bear interest. 
  

	4.3	 Profit Participation 

 

	 	(a)	 Subject to Paragraph (b) below and in addition to the interest payable pursuant to Article 4.1 (Cash
Interest Fixed Rate) and in consideration of the Bank making the Credit available to the Borrower in accordance with this Contract, the Borrower hereby grants and reserves for the benefit of the Bank if Tranche [***] is disbursed, the aggregate
amount of: 

  

	 	(i)	 a participation in the annual COVID-19 Vaccine Gross Profit during the
Profit Participation Period equal to: 

  

	 	(A)	 [***]% ([***]) of the annual COVID-19 Vaccine Gross Profit below USD
55,000,000 (fifty five million dollars); 

  

	 	(B)	 [***]% ([***]) of the annual COVID-19 Vaccine Gross Profit between USD
55,000,000 (fifty five million dollars) and USD 165,000,000 (one hundred and sixty five million dollars); and 

  

	 	(C)	 [***]% ([***]) of the annual COVID-19 Vaccine Gross Profit above USD
165,000,000 (one hundred and sixty five million dollars); and 

  

	 	(ii)	 [***]% (four per cent.) of the annual Sales Milestone Payments during the Profit Participation Period,

 the “Profit Participation Payments”, and hereby undertakes to pay the respective Profit Participation
Payments to the Bank subject to the terms of this Contract. For the avoidance of doubt and by way of distinction from a silent partnership (stille Beteiligung), the Bank does not participate in any loss of the Borrower or any other Group
Company. 
  

	 	(b)	 The obligation of the Borrower to make Profit Participation Payments pursuant to Paragraph (a) above shall
exist only for so long as and to the extent that a due Profit Participation Payment together with the aggregate amount of all preceding Profit Participation Payments does not exceed the Profit Participation Cap. 

 

	 	(c)	 Each Profit Participation Payment shall become due and payable on the Payment Date immediately following the
date falling [***] ([***]) months after the end of each financial year within the Profit Participation Period. 

  

	 	(d)	 The Borrower shall permit an Auditor, at reasonable times and at reasonable notice, to audit the books and
records maintained by the Borrower to ensure the accuracy of the Profit Participation Payments. The cost of this audit shall be borne by the Borrower. If any such audit concludes that additional amounts are owed to the Bank, subject to the Profit
Participation Cap the Borrower shall pay the Bank such additional amounts with interest in accordance with Article 4.4 (Interest on overdue sums) within [***] ([***]) days of the date of the completion of such audit. 

  
 20 

	 	(e)	 Upon the Bank’s written request, the Borrower shall promptly exercise its rights under clause 8.9
(Audit) (or a corresponding amended provision or replacement provision) of the Fosun Agreement or clause 5.10 (Audits) (or a corresponding amended provision or replacement provision) of the Pfizer Agreement. If any such audit concludes
that additional amounts are owed to the Borrower, Sub-Paragraph (a) above shall be re-calculated based on the figures ascertained from the audit and any additional
amounts with interest in accordance with Article 4.4. (Interest on overdue sums) shall be paid by the Borrower to the Bank within [***] ([***]) days of the date of such audit. For the avoidance of doubt, any information or document concerning
any audit under a Key Contract must be shared with the Bank in accordance with Sub-Paragraph (a)(vi) of Paragraph 2 (Information concerning the Borrower) of Schedule I (Information and Visits).

  

	 	(f)	 In case a Tranche is cancelled or prepaid pursuant to Articles 5.2 (Voluntary prepayment) or 5.3
(Compulsory prepayment) within the Profit Participation Period, the Bank shall have the right (but not the obligation) to demand from the Borrower the payment of the present value of all future Profit Participation Payments (up to the Profit
Participation Cap), as determined by an Independent Expert (the “Expert Determination”). The costs related to the Expert’s Determination shall be borne by the Borrower and the Expert’s Determination shall, in the absence
of manifest error, be conclusive and binding on all parties to this Contract as to the matters to which it relates. The Borrower shall, within [***] ([***]) Business Days of delivery of the Expert’s Determination and upon the Bank’s
demand, pay to the Bank the amount determined by the Expert Determination. 

  

	 	(g)	 For the avoidance of doubt, if Tranche [***] is disbursed then the Borrower’s obligation under this
Article 4.3 (Profit Participation) to make Profit Participation Payments shall continue regardless of: 

  

	 	(i)	 any cancellation or prepayment in respect of Tranche B within the Profit Participation Period pursuant to
Articles 5.2 (Voluntary prepayment) or 5.3 (Compulsory prepayment), or 

  

	 	(ii)	 any repayment of Tranche B in accordance with Article 5.1 (Normal repayment), 

unless the Bank has exercised its rights under Paragraph (f) of this Article 4.3 (Profit Participation) and the Borrower has made
the payment required under such Paragraph. 
  

	 	(h)	 The Borrower shall withhold any statutory withholding tax (Kapitalertragssteuer) from the Profit
Participation Payments and shall pay it to the competent tax office. 

  

	 	(i)	 Sums due under this Article 4.3 (Profit Participation) shall be payable in EUR. For the calculation of
the Profit Participation Payment, where amounts relating to such calculation are received by the Borrower in currencies other than EUR, the applicable rate published by the European Central Bank in Frankfurt on the Business Day preceding the
relevant Payment Date shall apply to determine such amounts equivalent in EUR. 

  

	4.4	 Interest on overdue sums 

 

	 	(a)	 Without prejudice to Article 9 (Events of default) and by way of exception to Article 4.1 (Cash
Interest Fixed Rate) and Article 4.2 (Deferred Interest Fixed Rate), if the Borrower fails to pay any amount (other than any interest amount) payable by it under the Contract on its due date (including any amount due in respect of a
Profit Participation Payment), interest shall accrue on any such overdue amount (other than any interest amount) from the due date to the date of actual payment at an annual rate equal to: 

 

	 	(i)	 for overdue sums related to a Tranche, the higher of (A) the Cash Interest Fixed Rate and, if applicable,
the Deferred Interest Fixed Rate plus [***]% ([***] basis points) or (B) EURIBOR plus [***]% ([***] basis points); 

  

	 	(ii)	 for overdue sums other than under Sub-Paragraph (a) of Article 4.4
(Interest on overdue sums) above, EURIBOR plus [***]% ([***] basis points), 

 and shall be payable in accordance
with the demand of the Bank. 

  
 21 

	 	(b)	 If the Borrower fails to pay any interest amount payable by it under this Contract on its due date, it shall
make a liquidated damages payment (pauschalierter Schadensersatz) from the due date up to the date of actual payment at an annual rate equal to the higher of (i) the applicable Fixed Rate plus [***]% ([***] basis points) or
(ii) EURIBOR plus [***]% ([***] basis points), provided that the Borrower shall have the right to prove that no damages have arisen, or that damages have not arisen in the asserted amount. The amount determined in accordance with this Sub-Paragraph (b) of Article 4.4 (Interest on overdue sums) shall be payable in accordance with the demand of the Bank. 

For the purpose of determining EURIBOR in relation to this Article 4.4 (Interest on overdue sums), the relevant periods within the
meaning of Schedule B (Definition of EURIBOR) shall be successive periods of one month commencing on the due date. 
 If the overdue
sum is in a currency other than the currency of the Loan, the relevant interbank rate that is generally retained by the Bank for transactions in that currency plus [***]% ([***] basis points) shall apply, calculated in accordance with the market
practice for such rate. 
 ARTICLE 5 

Repayment 
  

	5.1	 Normal repayment 

The Borrower shall repay each Tranche, together with all other amounts outstanding under this Contract in relation to that Tranche, in a single
instalment on the Maturity Date of that Tranche. 
  

	5.2	 Voluntary prepayment 

 

	5.2.1	 Prepayment option 

 

	 	(a)	 Subject to Articles 5.2.2 (Prepayment Fee), 5.2.3 (Prepayment mechanics) and 5.4
(General), the Borrower may prepay all or part of any Tranche, together with any accrued interest under Article 4.1 (Cash Interest Fixed Rate), Article 4.2 (Deferred Interest Fixed Rate), any Profit Participation Payment (up to
the Profit Participation Cap) specified under Article 4.3 (Profit Participation), any Prepayment Fee and indemnities if any, upon giving a Prepayment Request with at least [***] ([***]) calendar days prior notice specifying:

  

	 	(i)	 the Prepayment Amount; 

 

	 	(ii)	 the Prepayment Date; and 

 

	 	(iii)	 each Contract Number. 

 

	 	(b)	 The Prepayment Request shall be irrevocable. 

 

	5.2.2	 Prepayment Fee 

If the Borrower prepays a Tranche, the Borrower shall pay the relevant Prepayment Fee on the Prepayment Date. 

 

	5.2.3	 Prepayment mechanics 

Upon presentation by the Borrower to the Bank of a Prepayment Request, the Bank shall issue a Prepayment Notice to the Borrower, not later than
[***] ([***]) days prior to the Prepayment Date. If the Borrower evidences to the Bank that – taking into account the time for procuring of the Expert Determination—takes longer than [***] ([***]) days, the Borrower and the Bank will agree
on a longer deadline. The Prepayment Notice shall specify the Prepayment Amount, the accrued interest due thereon, the Prepayment Fee. If the Prepayment Notice specifies Prepayment Fee, it shall also specify the deadline by which the Borrower may
accept the Prepayment Notice, and the Borrower must accept the Prepayment Notice no later than such deadline as a condition to prepayment. 

  
 22 

 The Borrower shall make a prepayment in accordance with the Prepayment Notice and shall
accompany the prepayment by the payment of accrued interest (including any interest under Article 4.2 (Deferred Interest Fixed Rate) and any Profit Participation Payment specified under Sub-Paragraph
(c) of Article 4.3 (Profit Participation) and Prepayment Fee or indemnity, if any, due on the Prepayment Amount, as specified in the Prepayment Notice, and shall identify each Contract Number in the prepayment transfer. 

 

	5.3	 Compulsory prepayment 

 

	5.3.1	 Cost Reduction 

If the total cost of the Investment at completion by the final date specified in the Technical Description falls below the figure stated in
Recital (A) so that the amount of the Credit exceeds 50% (fifty per cent.) of such total cost, the Bank may forthwith, by notice to the Borrower, cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding up
to the amount by which the Credit exceeds 50% (fifty per cent.) of the total cost of the Investment. 
  

	5.3.2	 Change Events 

The Borrower shall promptly inform the Bank if: 
  

	 	(a)	 a Change-of-Control Event has
occurred or is likely to occur in respect of itself or a Guarantor; or 

  

	 	(b)	 there is or is likely to be an enactment, promulgation, execution or ratification of or any change in or
amendment to any law, rule or regulation (or in the application or official interpretation of any law, rule or regulation) that occurs or is likely to occur after the date of this Contract and which, in the opinion of the Borrower, would impair an
Obligor’s ability to perform its obligations under the Finance Documents. 

 In such case, or if the Bank has
reasonable cause to believe that a Change-of-Control Event or a Change-of-Law Event has
occurred or is likely to occur, the Borrower shall, on request of the Bank, consult with the Bank as to the impact of such event. If [***] ([***]) days have passed since the date of such request and the Bank is of the reasonable opinion that the
effects of such event cannot be mitigated to its satisfaction, or in any event if a Change-of-Control Event or Change-of-Law Event has actually occurred, the Bank may by notice to the Borrower, cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding, together with accrued interest
(if any) and all other amounts accrued or outstanding under this Contract. 
  

	5.3.3	 Illegality 

If it becomes unlawful in any applicable jurisdiction for the Bank to perform any of its obligations as contemplated in this Contract or to
fund or maintain the Loan, the Bank shall promptly notify the Borrower and may immediately cancel the undisbursed portion of the Credit and/or demand prepayment of the Loan Outstanding, together with accrued interest (if any) and all other amounts
accrued or outstanding under this Contract. 
  

	5.3.4	 Disposals 

If the Borrower disposes of assets forming part of the Investment or shares in subsidiaries holding assets forming part of the Investment,
neither with the approval of the Bank nor in accordance with Sub-Paragraph (c) of Paragraph 7 (Disposal of assets) of Schedule H (General Undertakings), the Borrower shall apply all proceeds
of such disposal to prepay the Loan Outstanding (in part or in whole), together with accrued interest (if any), promptly following receipt of such proceeds. 
  

	5.3.5	 Expiry of Guarantee Agreement 

If (a) a Guarantee Agreement has a shorter duration than this Contract (as modified, extended and/or prolonged from time to time) and
(ii) on the date falling [***] ([***]) days prior to the initial expiry date or, as the case may be, to any subsequent expiry date agreed under the Guarantee Agreement, the Borrower has failed to procure extension of the duration of the
obligations of the Guarantor under the Guarantee Agreement or, as the case may be, to 

  
 23 

 
replace the Guarantor by another guarantor on terms acceptable to the Bank or provide additional security for the Loan in manner, form and substance satisfactory to the Bank, the Bank may,
without prejudice to its other rights, require the Borrower to prepay the Loan Outstanding (in part or in whole), together with accrued interest (if any) and all other amounts accrued or outstanding under this Contract. 

 

	5.3.6	 Pari Passu to Non-EIB Financing 

 

	 	(a)	 If a Voluntary Non EIB Prepayment has occurred the Bank may, by notice to the Borrower, cancel the undisbursed
portion of the Credit and demand prepayment of the Loan; or 

  

	 	(b)	 If (i) a Voluntary Non EIB Prepayment is likely to occur, (ii) the Bank has requested a consultation
in respect of such Voluntary Non EIB Prepayment, (iii) the Borrower has complied with such request (to the satisfaction of the Bank) and (iv) at least [***] ([***]) days have passed since the date of such request, the Bank may, by notice
to the Borrower, cancel the undisbursed portion of the Credit and demand prepayment of the Loan. 

  

	 	(c)	 If (i) a Voluntary Non EIB Prepayment is likely to occur, (ii) the Bank has requested a consultation
in respect of such Voluntary Non EIB Prepayment, (iii) the Borrower has not complied with such request within a reasonable period set by the Bank and (iv) at least [***] ([***]) days have passed since the date of such request, the Bank
may, by notice to the Borrower, cancel the undisbursed portion of the Credit and demand prepayment of the Loan. 

 The
proportion of the Loan that the Bank may require to be prepaid shall in each case of Paragraphs (a) to (c) above be the same as the proportion that the prepaid amount of the Non-EIB Financing bears to the
aggregate outstanding amount of all Non-EIB Financing. 
  

	5.3.7	 Prepayment Fee 

In the case of a Prepayment Event in relation to a Tranche, the Borrower shall pay the relevant Prepayment Fee. 

 

	5.3.8	 Prepayment mechanics 

Any sum demanded by the Bank pursuant to Articles 5.3.1 (Cost Reduction) to 5.3.6 (Pari Passu to
Non-EIB Financing) shall be paid on the date indicated by the Bank in its notice of demand, such date being a date falling not less than [***] ([***]) days from the date of the demand (or, if earlier, the
last day of any applicable grace period permitted by law in respect of the event in Article 5.3.3 (Illegality)). 
  

	5.4	 General 

 

	 	(a)	 A repaid or prepaid amount may not be reborrowed. 

 

	 	(b)	 If the Borrower prepays a Tranche on a date other than a relevant Payment Date, or if the Bank exceptionally
accepts, solely upon the Bank’s discretion, a Prepayment Request with prior notice of less than [***] ([***]) calendar days, the Borrower shall pay to the Bank an administrative fee in such an amount as the Bank shall notify to the Borrower.

 ARTICLE 6 

Payments 
  

	6.1	 Day count convention 

Any amount due under this Contract and calculated in respect of a fraction of a year shall be determined based on a year of 360 (three hundred
and sixty) days and a month of 30 (thirty) days. 

  
 24 

	6.2	 Time and place of payment 

 

	 	(a)	 If neither this Contract nor the Bank’s demand specifies a due date, all sums other than sums of interest,
indemnity and principal are payable within [***] ([***]) days of the Borrower’s receipt of the Bank’s demand. 

  

	 	(b)	 Each sum payable by the Borrower under this Contract shall be paid to the following account:

  

			
	Bank:	  	[***]
		
	City:	  	[***]
		
	Account number:	  	[***]
		
	SWIFT Code/BIC:	  	[***]
		
	Remark:	  	[***]

 or such other account notified by the Bank to the Borrower. 

 

	 	(c)	 The Borrower shall provide each Contract Number as a reference for each payment made under this Contract.

  

	 	(d)	 Any disbursements by and payments to the Bank under this Contract shall be made using account(s) acceptable to
the Bank. Any duly authorised financial institution in the jurisdiction where the Borrower is incorporated or where the Investment is undertaken is deemed an acceptable account bank and any account in the name of the Borrower with such account bank
is deemed acceptable to the Bank. 

  

	6.3	 No set-off by the Borrower 

All payments to be made by the Borrower under this Contract shall be calculated and be made without (and free and clear of any deduction for) set-off or counterclaim, unless the counterclaim is undisputed (unbestritten) or has been confirmed in a final non-appealable judgement (rechtskräftig
festgestellt). 
  

	6.4	 Disruption to Payment Systems 

If either the Bank determines (in its discretion) that a Disruption Event has occurred or the Bank is notified by the Borrower that a
Disruption Event has occurred: 
  

	 	(a)	 the Bank may, and shall if requested to do so by the Borrower, consult with the Borrower with a view to
agreeing with the Borrower such changes to the operation or administration of the Contract as the Bank may deem necessary in the circumstances; 

  

	 	(b)	 the Bank shall not be obliged to consult with the Borrower in relation to any changes mentioned in Sub-Paragraph (a) of Article 6.4 (Disruption to Payment Systems) above if, in its opinion, it is not practicable to do so in the circumstances and, in any event, shall have no obligation to agree to such
changes; and 

  

	 	(c)	 the Bank shall not be liable for any damages, costs or losses whatsoever arising as a result of a Disruption
Event or for taking or not taking any action pursuant to or in connection with this Article 6.4 (Disruption to Payment Systems). 

  

	6.5	 Application of sums received 

 

	6.5.1	 General 

Sums received from the Borrower shall only discharge its payment obligations if and when received in accordance with the terms of this
Contract. 
  

	6.5.2	 Partial payments 

If the Bank receives a payment that is insufficient to discharge all the amounts then due and payable by the Borrower under this Contract, the
Bank shall apply that payment in or towards payment of: 

  
 25 

	 	(a)	 first, any unpaid fees, costs, indemnities and expenses due under this Contract; 

 

	 	(b)	 secondly, any accrued interest due but unpaid under this Contract; 

 

	 	(c)	 thirdly, any principal due but unpaid under this Contract; 

 

	 	(d)	 fourthly, any Profit Participation Payments due but unpaid under this Contract; and 

 

	 	(e)	 lastly, any other sum due but unpaid under this Contract. 

 

	6.5.3	 Allocation of sums related to Tranches 

In case of receipt of sums which cannot be identified as applicable to a specific Tranche, and on which there is no agreement between the Bank
and the Borrower on their application, the Bank may apply these between Tranches at its discretion. 
 ARTICLE 7 

Borrower undertakings and representations 
  

	 	(a)	 The Borrower makes the representations and warranties set out in Schedule G (Representations and
Warranties) to the Bank on the date of this Contract in respect of itself and, where applicable, the other Obligors. 

  

	 	(b)	 The Repeating Representations are deemed to be made by the Borrower (in respect of itself and, where
applicable, the other Obligors) on the date of each Disbursement Acceptance, each Disbursement Date and each Payment Date by reference to the facts and circumstances then existing. 

 

	 	(c)	 The undertakings in Schedule H (General Undertakings) and Schedule I (Information and Visits)
remain in force from the date of this Contract for so long as any amount is outstanding under this Contract or the Credit is available. 

ARTICLE 8 

Charges and expenses 
  

	8.1	 Taxes, duties and fees 

 

	 	(a)	 The Borrower shall pay all Taxes, duties, fees (including any notarial and
pre-agreed legal fees) and other impositions of whatsoever nature, including stamp duty and registration fees, arising out of the execution or implementation of each Finance Document or any related document
and the creation, perfection or registration of any security for the Loan. 

  

	 	(b)	 The Borrower shall pay all Taxes, duties fees (including any notarial and legal fees) and other impositions
whatsoever nature, including stamp duty and registration fees, arising out of the amendment, preservation of any rights under or enforcement of any Finance Document and any security for the Loan to the extent applicable. 

 

	 	(c)	 The Borrower shall pay all principal, interest, Profit Participation Payments, indemnities and other amounts
due under this Contract gross without any withholding or deduction of any national or local impositions whatsoever, provided that if the Borrower is required by law or an agreement with a governmental authority or otherwise to make any such
withholding or deduction, it will gross up the payment to the Bank so that after withholding or deduction, the net amount received by the Bank is equivalent to the sum due. 

 

	8.2	 Other charges 

The Borrower shall bear all charges and expenses, including any notarial and legal fees, professional, banking or exchange charges incurred in
connection with the preparation, execution, implementation, enforcement and termination of the Finance Documents (including, but not limited to, any Guarantee Agreement entered into pursuant to Paragraph 16

  
 26 

 
(Guarantees) of Schedule H (General Undertakings)) or any related document, any amendment, supplement or waiver in respect of the Finance Documents or any related document, and in
the amendment, creation, management, enforcement and realisation of any security for the Loan. 
 The Bank shall provide documentary support
for any such charges or expenses upon the Borrower’s request. 
  

	8.3	 Increased costs, indemnity and set-off

  

	 	(a)	 The Borrower shall pay to the Bank any costs or expenses incurred or suffered by the Bank as a consequence of
the introduction of or any change in (or in the interpretation, administration or application of) any law or regulation or compliance with any law or regulation which occurs after the date of this Contract, in accordance with or as a result of which
(i) the Bank is obliged to incur additional costs in order to fund or perform its obligations under this Contract, or (ii) any amount owed to the Bank under this Contract or the financial income resulting from the granting of the Credit or
the Loan by the Bank to the Borrower is reduced or eliminated. This Paragraph (a) does not apply to the extent any such costs or expenses are attributable to the wilful breach by the Bank of any law or regulation. 

 

	 	(b)	 Without prejudice to any other rights of the Bank under this Contract or under any applicable law, the Borrower
shall indemnify and hold the Bank harmless from and against any loss incurred as a result of any full or partial discharge that takes place in a manner other than as expressly set out in this Contract. 

 

	 	(c)	 The Bank may set off any matured obligation due from the Borrower under any Finance Document (to the extent
beneficially owned by the Bank) against any satisfiable (erfüllbar) obligation (within the meaning of Section 387 BGB) owed by the Bank to the Borrower regardless of the place of payment, booking branch or currency of either
obligation. If the obligations are in different currencies, the Bank may convert either obligation at a market rate of exchange in its usual course of business for the purpose of the set-off. If either
obligation is unliquidated or unascertained, the Bank may set off in an amount estimated by it in good faith to be the amount of that obligation. 

ARTICLE 9 

Events of default 
  

	9.1	 Right to demand repayment 

The Bank may demand (in writing) without prior notice or any judicial or extra judicial step immediate repayment by the Borrower of all or part
of the Loan Outstanding (as requested by the Bank), together with accrued interest, any Profit Participation Payment, any Prepayment Fee and all other accrued or outstanding amounts under this Contract, if: 

 

	 	(a)	 any amount payable pursuant to any Finance Document is not paid on the due date at the place and in the
currency in which it is expressed to be payable, unless (i) its failure to pay is caused by an administrative or technical error or a Disruption Event and (ii) payment is made within [***] ([***]) Business Days of its due date;

  

	 	(b)	 any information or document given to the Bank by or on behalf of any Obligor or any representation, warranty or
statement made or deemed to be made by the Borrower in, pursuant to or for the purpose of entering into any Finance Document is or proves to have been incorrect, incomplete or misleading in any material respect; 

 

	 	(c)	 following any default of any Obligor in relation to any loan, or any obligation arising out of any financial
transaction, other than the Loan, 

  

	 	(i)	 such Obligor is required or is capable of being required or will, following expiry of any applicable
contractual grace period, be required or be capable of being required to prepay, discharge, close out or terminate ahead of maturity such other loan or obligation; or 

  
 27 

	 	(ii)	 any financial commitment for such other loan or obligation is cancelled or suspended; and

  

	 	(iii)	 such other loans or obligations or commitments falling under
Sub-Paragraphs (i) and/or (ii) above are in an aggregate principal amount in excess of EUR [***] ([***] euro) or its equivalent in any other currency or currencies; 

 

	 	(d)	 any Obligor is unable or admits inability to pay its debts as they fall due, or suspends any of its debts, or
makes or seeks to make a composition with its creditors including a moratorium, or commences negotiations with one or more of its creditors with a view to rescheduling any of its financial indebtedness; 

 

	 	(e)	 any corporate action, legal proceedings or other procedure or step is taken in relation to the suspension of
payments, a moratorium of any indebtedness, dissolution, administration or reorganisation (by way of voluntary arrangement, scheme of arrangement or otherwise) or an order is made or an effective resolution is passed for the winding up of any
Obligor, or if any Obligor takes steps towards a substantial reduction in its capital, is declared insolvent or ceases or resolves to cease to carry on the whole or any substantial part of its business or activities or any situation similar to any
of the above occurs under any applicable law; 

  

	 	(f)	 any Obligor incorporated in Germany is unable to pay its debts as they fall due (zahlungsunfähig)
within the meaning of Section 17 InsO or is overindebted (überschuldet) within the meaning of Section 19 InsO; 

  

	 	(g)	 an encumbrancer takes possession of, or a receiver, liquidator, administrator, administrative receiver or
similar officer is appointed, whether by a court of competent jurisdiction or by any competent administrative authority or by any person, of or over, any part of the business or assets of any Obligor or any property forming part of the Investment;

  

	 	(h)	 any Obligor defaults in the performance of any obligation in respect of any other loan granted by the Bank or
financial instrument entered into with the Bank; 

  

	 	(i)	 any Obligor defaults in the performance of any obligation in respect of any other loan made to it from the
resources of the Bank or the European Union; 

  

	 	(j)	 any distress, execution, sequestration or other process is levied or enforced upon the property of any Obligor
or any property forming part of the Investment and is not discharged or stayed within [***] ([***]) days; 

  

	 	(k)	 a Material Adverse Change occurs, as compared with the position at the date of this Contract;

  

	 	(l)	 it is or becomes unlawful for any Obligor to perform any of its obligations under the Finance Documents, or the
Finance Documents are not effective in accordance with its terms or is alleged by any Obligor to be ineffective in accordance with its terms; or 

  

	 	(m)	 any Obligor fails to comply with any other provision under the Finance Documents (including, without
limitation, each of the undertakings in Schedule H (General Undertakings) and Schedule I (Information and Visits)), unless the non-compliance or circumstance giving rise to the non-compliance is capable of remedy and is remedied within [***] ([***]) Business Days from the earlier of the Borrower becoming aware of the non-compliance and a notice
served by the Bank on the Borrower. 

  

	9.2	 Other rights at law 

Article 9.1 (Right to demand repayment) shall not restrict any other right of the Bank at law (e.g. pursuant to Sections 314 or 490
BGB) to require prepayment of the Loan Outstanding together with any sum, interest, fee or accrued amount, irrespectively of the fact that the Contract might convert into a so called settlement contractual relationship
(Abwicklungsschuldverhältnis). 

  
 28 

	9.3	 Prepayment Fee 

In case of demand under Article 9.1 (Right to demand repayment), the Borrower shall pay the Bank the amount demanded together with
the relevant Prepayment Fee. 
  

	9.4	 Non-Waiver 

No failure or delay or single or partial exercise by the Bank in exercising any of its rights or remedies under this Contract shall be
construed as a waiver of such right or remedy. The rights and remedies provided in this Contract are cumulative and not exclusive of any rights or remedies provided by law. 

ARTICLE 10 

Law and jurisdiction, miscellaneous 
  

	10.1	 Governing Law 

This Contract and any non-contractual obligations arising out of or in connection with it shall be
governed by the laws of Germany. 
  

	10.2	 Jurisdiction 

 

	 	(a)	 The courts of Frankfurt am Main, Germany, have exclusive jurisdiction to settle any dispute (a
“Dispute”) arising out of or in connection with this Contract (including a dispute regarding the existence, validity or termination of this Contract or the consequences of its nullity) or any
non-contractual obligation arising out of or in connection with this Contract. 

  

	 	(b)	 The parties agree that the courts of Frankfurt am Main, Germany, are the most appropriate and convenient courts
to settle Disputes between them and, accordingly, that they will not argue to the contrary. 

  

	 	(c)	 This Article 10.2 (Jurisdiction) is for the benefit of the Bank only. As a result and notwithstanding Sub-Paragraph (a) above, it does not prevent the Bank from taking proceedings relating to a Dispute in any other courts with jurisdiction. To the extent allowed by law, the Bank may take concurrent proceedings
in any number of jurisdictions. 

  

	10.3	 Place of performance 

Unless otherwise specifically agreed by the Bank in writing, the place of performance under this Contract, shall be the seat of the Bank. 

 

	10.4	 Evidence of sums due 

In any legal action arising out of this Contract the certificate of the Bank as to any amount or rate due to the Bank under this Contract
shall, in the absence of manifest error, be prima facie evidence of such amount or rate. 
  

	10.5	 Third party rights 

A person who is not a party to this Contract has no right to enforce or to enjoy the benefit of any term of this Contract (no echter Vertrag
zugunsten Dritter within the meaning of Section 328 para. 1 BGB). 
  

	10.6	 Entire Agreement 

This Contract (together with the other Finance Documents) constitutes the entire agreement between the Bank and the Borrower in relation to the
provision of the Credit hereunder, and supersedes any previous agreement, whether express or implied, on the same matter. 

  
 29 

	10.7	 Invalidity 

If at any time any term of this Contract is or becomes illegal (nichtig), invalid or unenforceable in any respect, or this Contract is
or becomes ineffective (unwirksam) in any respect, under the laws of any jurisdiction, such illegality (Nichtigkeit), invalidity, unenforceability or ineffectiveness (Unwirksamkeit) shall indisputably (unwiderlegbar) not
affect: 
  

	 	(a)	 the legality, validity or enforceability in that jurisdiction of any other term of this Contract or the
effectiveness in any other respect of this Contract in that jurisdiction; or 

  

	 	(b)	 the legality, validity or enforceability in other jurisdictions of that or any other term of this Contract or
the effectiveness of this Contract under the laws of such other jurisdictions, 

 without any party to this Contract having
to argue (darlegen) and prove (beweisen) such parties’ intent to uphold this Contract even without the void, invalid or ineffective provisions. 

The illegal, invalid, unenforceable or ineffective provision shall be deemed replaced by such legal, valid, enforceable and effective provision
that in legal and economic terms comes closest to what the Parties intended or would have intended in accordance with the purpose of this Contract if they had considered the point at the time of conclusion of this Contract. The same applies in the
event that this Contract or any other Finance Document does not contain a provision which it needs to contain in order to achieve the economic purpose as expressed herein (Regelungslücke). 

 

	10.8	 Amendments 

Any amendment to this Contract (including this Article 10.8) or any other Finance Document shall be made in writing (or in notarial form, if
required) and shall be signed by the parties thereto. 
  

	10.9	 Counterparts 

This Contract may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument. Each
counterpart is an original, but all counterparts shall together constitute one and the same instrument. 
  

	10.10	 Assignment and transfer by the Bank 

 

	 	(a)	 Subject to Sub-Paragraph (b) of this Article 10.10 (Assignment
and transfer by the Bank), the consent of the Borrower is required for an assignment or transfer (by way of assumption of contract (Vertragsübernahme), sub-participation or otherwise) by the
Bank of all or part of its rights, benefits or obligations under the Finance Documents, unless the assignment or transfer: 

  

	 	(i)	 is to a Bank Affiliate; or 

 

	 	(ii)	 is made at a time when an Event of Default has occurred and is continuing; or 

 

	 	(iii)	 is made in respect of a sub-participation or securitisation (or similar
transaction of broadly equivalent economic effect) where the Bank remains the lender of record of the Loan. 

  

	 	(b)	 The consent of the Borrower to an assignment or transfer must not be unreasonably withheld or delayed. The
Borrower will be deemed to have given its consent [***] ([***]) Business Days after the Bank has requested it unless consent is expressly refused by the Borrower within that time. 

 

	 	(c)	 The Bank shall have the right to disclose all information relating to or concerning the Borrower, the Group,
the Finance Documents and the Loan in connection with or in contemplation of any such assignment or transfer. 

 For the
purpose of this Article 10.10 (Assignment and transfer by the Bank): 
 “Affiliate” means any entity directly or
indirectly Controlling, Controlled by or under common Control with the Bank. 
 “Bank Affiliate” means an Affiliate of the
Bank and any other entity or platform initiated, managed or advised by the Bank. 

  
 30 

 ARTICLE 11 

Final Articles 
  

	11.1	 Notices 

 

	11.1.1	 Form of notice 

 

	 	(a)	 Any notice or other communication given under this Contract must be in writing and, unless otherwise stated,
may be made by letter and electronic mail. 

  

	 	(b)	 Notices and other communications for which fixed periods are laid down in this Contract or which themselves fix
periods binding on the addressee, may be made by hand delivery, registered letter or by electronic mail. Such notices and communications shall be deemed to have been received by the other party: 

 

	 	(i)	 on the date of delivery in relation to a hand-delivered or registered letter; or 

 

	 	(ii)	 in the case of any electronic mail, when the electronic mail is received in readable form,

  

	 	(c)	 Any notice provided by the Borrower or a Guarantor to the Bank by electronic mail shall: 

 

	 	(i)	 mention each Contract Number in the subject line; and 

 

	 	(ii)	 be in the form of a non-editable electronic image (pdf, tif or other
common non-editable file format agreed between the parties) of the notice signed by one or more Authorised Signatories of the Borrower as appropriate, attached to the electronic mail. 

 

	 	(d)	 Notices issued by the Borrower pursuant to any provision of this Contract shall, where required by the Bank, be
delivered to the Bank together with satisfactory evidence of the authority of the person or persons authorised to sign such notice on behalf of the Borrower and the authenticated specimen signature of such person or persons, unless such person is
listed in the then current List of Authorised Signatories and Accounts. 

  

	 	(e)	 Without affecting the validity of electronic mail or communication made in accordance with this Article 11.1
(Notices), the following notices, communications and documents shall also be sent by registered letter to the relevant party at the latest on the immediately following Business Day: 

 

	 	(i)	 Disbursement Acceptance; 

 

	 	(ii)	 any notices and communication in respect of the cancellation of a disbursement of any Tranche, Prepayment
Request, Prepayment Notice, Event of Default, any demand for prepayment, and 

  

	 	(iii)	 any other notice, communication or document required by the Bank. 

 

	 	(f)	 The parties agree that any above communication (including via electronic mail) is an accepted form of
communication, shall constitute admissible evidence in court and shall have the same evidential value as an agreement under hand. 

  

	 	(g)	 Any communication or document made or delivered to the Borrower in accordance with this Article 11.1
(Notices) will be deemed to have been made or delivered to each of the Obligors or any other member of the Group party to a Finance Document. Each Obligor incorporated in Germany, for this purpose, appoints the Borrower as its receipt agent
(Empfangsboten). 

  

	11.1.2	 Addresses 

The address and electronic mail address (and the department or officer, if any, for whose attention the communication is to be made) of each
party for any communication to be made or document to be delivered under or in connection with this Contract is: 

  
 31 

					
		 	For the Bank	  	 Attention: OPS/ENPST/3-GC&IF

100 boulevard Konrad Adenauer

L-2950 Luxembourg
 Email
address: [***]

			
		 	For the Borrower	  	 Attention: Chief Financial Officer (CFO)
 An der
Goldgrube 12
 D-55131 Mainz

Germany
 Email address: [***]

  

	11.1.3	 Demand after notice to remedy 

The Bank and the Borrower shall promptly notify the other party in writing of any change in their respective communication details. 

 

	11.2	 English language 

 

	 	(a)	 Any notice or communication given under or in connection with this Contract must be in English.

  

	 	(b)	 All other documents provided under or in connection with this Contract must be: 

 

	 	(i)	 in English; or 

  

	 	(ii)	 if not in English, and if so required by the Bank, accompanied by a certified English translation and, in this
case, the English translation will prevail. 

  

	11.3	 Conclusion of this Contract (Vertragsschluss)

  

	 	(a)	 The parties to this Contract may choose to conclude this Contract by an exchange of signed signature page(s),
transmitted by any means of telecommunication (telekommunikative Übermittlung) such as by way of fax or attached as an electronic photocopy (.pdf, .tif, etc) to electronic mail. 

 

	 	(b)	 If the parties to this Contract choose to conclude this Contract pursuant to this Article 11.3 (Conclusion
of this Contract (Vertragsschluss)), they will transmit the signed signature page(s) of this Contract to [***](each a “Recipient”). The Contract will be considered concluded once a Recipient has actually received the signed
signature page(s) (Zugang der Unterschriftsseite(n)) from all Parties (whether electronic photocopy or other means of telecommunication and at the time of the receipt of the last outstanding signature page(s) by such one Recipient).

  

	 	(c)	 For the purposes of this Article 11.3 (Conclusion of this Contract (Vertragsschluss)) only, the parties
to this Contract appoint each Recipient as their attorney (Empfangsvertreter) and expressly allow (gestatten) each Recipient to collect the signed signature page(s) from all and for all parties to this Contract. For the avoidance of
doubt, each Recipient will have no further duties connected with its position as Recipient. In particular, each Recipient may assume the conformity to the authentic original(s) of the signature page(s) transmitted to it by means of
telecommunication, the genuineness of all signatures on the original signature page(s) and the signing authority of the signatories. 

  

	 	(d)	 For the purposes of proof and confirmation, each party to this Contract has to provide the Recipients with
original signature page(s) promptly, but no later than [***] ([***]) Business Days, after signing this Contract in accordance with this Article 11.3 (Conclusion of this Contract (Vertragsschluss)). The Bank may demand that the Borrower
subsequently sign one or more copies of this Contract. 

  
 32 

 IN WITNESS WHEREOF the parties hereto have caused this Contract to be executed in
three (3) originals (two (2) originals for the Bank and one (1) original for the Borrower) in the English language. 
  

									
	 Signed for and on behalf of

EUROPEAN INVESTMENT BANK
	 		 	 Signed for and on behalf of

BIONTECH SE

					
	By:	 	 	 		 	By:	 	 
	Name:	 		 		 	Name:	 	Dr. Sierk Poetting
	Title:	 		 		 	Title:	 	CFO & COO (Vorstand)
					
		 	 	 		 	By:	 	 
		 		 		 	Name:	 	Dr. James Timothy Patrick Ryan
		 		 		 	Title:	 	Authorised Representative (Prokurist)
					
	By:	 	 	 		 		 	 
	Name:	 		 		 		 	
	Title:	 		 		 		 	

  
 33 

 Schedule A 

Investment Specification and Reporting 

A.1 Technical Description 
 [***]

 A.2 Information Duties 
  

	1.	 Dispatch of information: designation of the person responsible 

The information below has to be sent to the Bank under the responsibility of: 

 

					
	  	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 The above-mentioned contact person(s) is (are) the responsible contact(s) for the time being. The Borrower
shall inform the Bank immediately in case of any change. 

  
 34 

	2.	 Information on the project’s implementation 

The Borrower shall deliver to the Bank the following information on project progress during implementation at the latest: 

 

					
	  	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  

	3.	 Information on the end of works and first year of operation 

The Borrower shall deliver to the Bank the following information on project completion and initial operation at the latest by the deadline
indicated below. 
  

			
	[***]	  	[***]
	[***]	  	[***]

 

			
	[***]	  	[***]

  
 35 

 Schedule B 

Definition of EURIBOR 

“EURIBOR” means: 

[***] 

  
 36 

 Schedule C 

Form of Disbursement Offer/Acceptance 
  

					
		 	To:	  	BioNTech SE
		 	From:	  	European Investment Bank
		 	Date:	  	
		 	Subject:	  	Disbursement Offer/Acceptance for the Finance Contract between European Investment Bank and BioNTech SE dated [ *** ] June 2020 (the “Finance Contract”)
		 		  	Contract Number [***] and [***]                    Serapis Number [***]

  
  

Dear Sirs, 
 We refer to the
Finance Contract. Terms defined in the Finance Contract have the same meaning when used in this letter. 
 Following your request for a
Disbursement Offer from the Bank, in accordance with Article 2.2.2 (Disbursement Offer) of the Finance Contract, we hereby offer to make available to you the following Tranche: 

 

	 	(a)	 Tranche [A/B] 

  

	 	(b)	 Amount to be disbursed: 

 

	 	(c)	 Disbursement Date: 

  

	 	(d)	 Cash Interest Fixed Rate: 

 

	 	(e)	 Deferred Interest Fixed Rate (if applicable): 

 

	 	(f)	 Payment Dates and interest periods: [●] / quarterly 

 

	 	(g)	 Terms and frequency for repayment of principal: 

 

	 	(h)	 Maturity Date: 

To make the Tranche available subject to the terms and conditions of the Finance Contract, the Bank must receive a Disbursement Acceptance in
the form of a copy of this Disbursement Offer duly signed on your behalf, to the following electronic mail [●] no later than the Disbursement Acceptance Deadline of [time], Luxembourg time, on [date]. 

The Disbursement Acceptance below must be signed by an Authorised Signatory and must be fully completed as indicated, to include the details of
the Disbursement Account. 
 If not duly accepted by the above stated time, the offer contained in this document shall be deemed to have been
refused and shall automatically lapse. 
 If you do accept the Tranche as described in this Disbursement Offer, all the related terms and
conditions of the Finance Contract shall apply, in particular, the provisions of Article 2.5 (Conditions of Disbursement). 

Yours faithfully, 
 EUROPEAN
INVESTMENT BANK 
 We hereby accept the above Disbursement Offer for and on behalf of the Borrower: 

 

			
	 	  	
		
	Date:	  	

  
 37 

			
		
		 	Account to be credited1:
		
		 	Account N°:
		
		 	Account Holder/Beneficiary:
		
		 	(please, provide IBAN format if the country is included in IBAN Registry published by SWIFT, otherwise an appropriate format in line with the local banking practice should be provided)
		
		 	Bank name, identification code (BIC) and address:
		
		 	Payment details to be provided:
		
		 	Please transmit information relevant to:
		
		 	Name(s) of the Borrower’s Authorised Signatory(ies):
		
		 	
		
		 	 Signature(s) of the Borrower’s Authorised Signatory(ies):

Name(s)/Title(s):

  

IMPORTANT NOTICE TO THE BORROWER: 

BY COUNTERSIGNING ABOVE YOU CONFIRM THAT THE LIST OF AUTHORISED SIGNATORIES AND ACCOUNTS PROVIDED TO THE BANK WAS DULY UPDATED PRIOR TO THE
PRESENTATION OF THE ABOVE DISBURSEMENT OFFER BY THE BANK. 
 IN THE EVENT THAT ANY SIGNATORIES OR ACCOUNTS APPEARING IN
THIS DISBURSEMENT ACCEPTANCE ARE NOT INCLUDED IN THE LATEST LIST OF AUTHORISED SIGNATORIES AND ACCOUNTS RECEIVED BY THE BANK, THE ABOVE DISBURSEMENT OFFER SHALL BE DEEMED AS NOT HAVING BEEN MADE. 

 

	1 	 The details concerning banking intermediary are also to be provided if such intermediary has to be used to make
the transfer to the Beneficiary’s Account. 

  
 38 

 Schedule D 

Form of Drawdown Certificate 
  

					
		 	To:	  	European Investment Bank
		 	From:	  	BioNTech SE
		 	Date:	  	
		 	Subject:	  	Finance Contract between European Investment Bank and BioNTech SE dated [ *** ] June 2020 (the “Finance Contract”)
		 		  	Contract Number [***] and [***]                    Serapis Number [***]

  
  

Dear Sirs, 
 Terms defined in the
Finance Contract have the same meaning when used in this letter. 
 For the purposes of Article 2.5 (Conditions of Disbursement)
of the Finance Contract we hereby certify to you as follows: 
  

	 	(a)	 no Prepayment Event has occurred and is continuing; 

 

	 	(b)	 no security of the type prohibited under Paragraph 23 (Negative pledge) of Schedule H (General
Undertakings) has been created or is in existence; 

  

	 	(c)	 there has been no material change to any aspect of the Investment or in respect of which we are obliged to
report under the Finance Contract, save as previously communicated by us; 

  

	 	(d)	 no Default, Event of Default or a Prepayment Event other than pursuant to Article 5.3.1 (Cost Reduction)
of the Finance Contract has occurred or is continuing, or would, in each case, result from the disbursement of the proposed Tranche; 

  

	 	(e)	 no litigation, arbitration administrative proceedings or investigation is current or to our knowledge and
belief (having made due and careful enquiry) is threatened or pending before any court, arbitral body or agency which has resulted or if adversely determined is reasonably likely to result in a Material Adverse Change, nor is there subsisting
against us or any of our subsidiaries any unsatisfied judgement or award; 

  

	 	(f)	 the Repeating Representations are correct in all respects; 

 

	 	(g)	 no Material Adverse Change has occurred, as compared with the situation at the date of the Finance Contract;
and 

  

	 	(h)	 the borrowing of the Credit, or any part thereof, by the Borrower is within the corporate powers of the
Borrower. 

 Yours faithfully, 

For and on behalf of BioNTech SE 

Date: 
 Name(s)/Title(s): 

  
 39 

 Schedule E 

Form of Compliance Certificate 
  

					
		 	To:	  	European Investment Bank
		 	From:	  	BioNTech SE
		 	Date:	  	
		 	Subject:	  	Finance Contract between European Investment Bank and BioNTech SE dated [ *** ] June 2020 (the “Finance Contract”)
		 		  	Contract Number [***] and [***]                    Serapis Number [***]

  
  

Dear Sirs, 
 We refer to the
Finance Contract. This is a Compliance Certificate. Terms defined in the Finance Contract have the same meaning when used in this Compliance Certificate. 

Part A – General Confirmations 

We hereby confirm: 
  

	 	(a)	 [insert information regarding asset disposal]; 

 

	 	(b)	 [no security of the type prohibited under Paragraph 23 (Negative pledge) of Schedule H (General
Undertakings) has been created or is in existence; and] 

  

	 	(c)	 [no Default, Event of Default or a Prepayment Event other than pursuant to Article 5.3.1 (Cost
Reduction) of the Finance Contract has occurred or is continuing.] [If this statement cannot be made, this certificate should identify any potential event of default that is continuing and the steps, if any, being taken to remedy it].

 [Part B – Profit Participation Information5 

We hereby: 
  

	 	(a)	 attach all reports or other documents received by the Borrower pursuant to any Key Contract which relates to
the calculation of Gross Profits or Sales Milestone Payments; and 

  

	 	(b)	 confirm that for the financial year [ *** ] the COVID-19 Vaccine Gross
Profit is [ *** ] and the Sales Milestone Payments are [ *** ] and therefore the Profit Participation Payment is [ *** ] and we set out in the annex to this Compliance Certificate in reasonable detail the calculations used to determine such
amounts.] 

 Yours faithfully, 

For and on behalf of BioNTech SE 

Date: 
 Name(s)/Title(s): 

 

	5 	 To be completed for financial years covered by the Profit Participation Period, if [***] is disbursed.

  
 40 

 Schedule F 

Conditions Precedent 
 Part
A—Initial Documentary Conditions Precedent and Tranche A Conditions Precedent 
  

	(a)	 The following, duly executed Finance Documents: 

 

	 	(i)	 originals of this Contract; 

 

	 	(ii)	 originals of the Guarantee Agreements; and 

 

	 	(iii)	 original of the Fee Letters. 

 

	(b)	 The constitutional documents of each Obligor, being in relation to an Obligor incorporated in Germany
electronic copies of (i) an up-to-date (dated no earlier than the date falling [***] ([***]) days before the Disbursement Date) electronic extract from the
commercial register (Handelsregisterauszug), (ii) its articles of association (Gesellschaftsvertrag) and copies of any by-laws and rules of procedures (Geschäftsordnungen) and
(iii) its list of shareholders (Gesellschafterliste) or list of supervisory board members (if applicable). 

  

	(c)	 A copy of the resolution of the competent body (board of directors (Vorstand), supervisory board
(Aufsichtsrat), administrative board (Verwaltungsrat) or general meeting of shareholders (Gesellschafterversammlung) of each Obligor: 

  

	 	(i)	 approving the terms of, and the transactions contemplated by, the Finance Documents to which it is a party as
and duly authorising the execution of the Finance Documents to which it is a party; 

  

	 	(ii)	 duly authorising the relevant signatories to execute the Finance Documents to which it is a party on its
behalf; and 

  

	 	(iii)	 authorising a signatory or signatories, on its behalf, to sign and/or despatch all documents and notices to be
signed and/or despatched by it under or in connection with the Finance Documents to which it is a party. 

  

	(d)	 An up-to-date (dated no earlier
than the date falling [***] ([***]) days before the Disbursement Date) structure chart showing the Group certified as being complete and correct by an Authorised Signatory of the Borrower (to be attached to and certified by way of the certificate of
an Authorised Signatory of the Borrower as required pursuant to Paragraph (e) below). 

  

	(e)	 A certificate of an Authorised Signatory of each Obligor certifying that each copy document relating to it
specified in Paragraph (b) and (c) of this Part A of Schedule F (Initial Documentary Conditions Precedent and Tranche A Conditions Precedents) is correct, complete and in full force and effect as at a date no earlier than the date
falling [***] ([***]) days before the first Disbursement Date. 

  

	(f)	 The List of Authorised Signatories and Accounts. 

 

	(g)	 A legal enforceability opinion of Noerr LLP, addressed to the Bank on the legality, validity and enforceability
of the Finance Documents and including statements as to no consents, registrations or filings are required and no stamp duty is to be paid in respect of the Finance Documents, choice of law and enforceability of judgments. 

 

	(h)	 A legal enforceability opinion of Arendt & Medernach, addressed to the Bank on the legality, validity
and enforceability of the Finance Fee Letter under Luxembourg law; 

  

	(i)	 A legal opinion of Osborne Clarke Rechtsanwälte Steuerberater Partnerschaft mbB, legal adviser to the
Borrower, addressed to the Bank, and dated no earlier than the date falling [***] ([***]) days before the Disbursement Date: 

  

	 	(i)	 which includes an insolvency search on www.insolvenzbekanntmachungen.de on the relevant Obligor conducted on
the date of such legal opinion; and 

  

	 	(ii)	 on the valid existence of each Obligor, the authority and capacity of each Obligor to enter into the Finance
Documents and perform its obligations thereunder, non-conflict with constitutional documents and on laws applicable to companies generally in Germany, all corporate and other action required to be taken has
indeed been taken, the due execution of the Finance Documents and that the Obligor is not entitled to claim immunity. 

  
 41 

	(j)	 The latest audited financial statements of the Obligors. 

 

	(k)	 Evidence of payment of all the fees (including lawyer fees) and expenses as required under the Finance
Documents. 

  

	(l)	 Evidence satisfactory to the Bank of the fulfilment of the following milestones (the “Tranche A
Milestone Events”): 

  

	 	(i)	 completion of the Equity Investments; 

 

	 	(ii)	 receipt of the Upfront Payments; and 

 

	 	(iii)	 [***]. 

  

	(m)	 A copy of any other document, authorisation, opinion or assurance which the Bank has notified the Borrower is
necessary or desirable in connection with the entry into and performance of, and the transactions contemplated by, the Finance Documents or the validity and enforceability of the same. 

Part B—Tranche B Conditions Precedent 
  

	(a)	 Tranche A has been fully drawn. 

 

	(b)	 Evidence satisfactory to the Bank of the fulfilment of the following milestones (the “Tranche B
Milestone Events”): 

  

	 	(i)	 [***]; and 

  

	 	(ii)	 [***]. 

Part C—Guarantor Conditions Precedent 
  

	(a)	 The duly executed Guarantee Agreement or, as applicable, accession letter to the Guarantee Agreement.

  

	(b)	 The constitutional documents of such Guarantor(s). 

 

	(c)	 If applicable, an original of a certificate of incorporation and an encumbrance certificate of the Guarantor(s)
not incorporated or established in Germany (“Non-German Guarantor”) dated no more than [***] ([***]) Business Days from the date of execution of the Guarantee Agreement or accession letter to
the Guarantee Agreement (as applicable) (or any equivalent document in the jurisdiction of incorporation of such Non-German Guarantor(s)). 

 

	(d)	 A copy of the resolution of the competent body (board of directors, supervisory board (Aufsichtsrat),
administrative body (Verwaltungsrat), advisory board (Beirat) or general meeting of shareholders (Gesellschafterversammlung)) of each Obligor: 

  
 42 

	 	(i)	 approving the terms of, and the transactions contemplated by, the Finance Documents to which it is a party as
and duly authorising the execution of the Finance Documents to which it is a party; 

  

	 	(ii)	 duly authorising the relevant signatories to execute the Finance Documents to which it is a party on its
behalf; and 

  

	 	(iii)	 authorising a signatory or signatories, on its behalf, to sign and/or despatch all documents and notices to be
signed and/or despatched by it under or in connection with the Finance Documents to which it is a party. 

  

	(e)	 A certificate of an authorised signatory of the respective Guarantor(s) certifying that each copy document
relating to it specified in Paragraphs (b) to (d) of this Part C of Schedule F (Conditions Precedent) is correct, complete and in full force and effect as at a date no earlier than the date of their/its entry into or accession to the
Guarantee Agreement, including a specimen of the signature of each person authorised by the resolution in Paragraph (d) above and, if applicable, confirming that guaranteeing or securing, as appropriate, the Loan would not cause any guarantee,
security or similar limit or restriction binding on it to be exceeded. 

  

	(f)	 A legal opinion of a reputable law firm, addressed to the Bank, on the valid existence of the Guarantor(s), the
authority and capacity of the Guarantor(s) to enter into or accede to the Guarantee Agreement (and execute its/their obligations therein) and on the due execution of the Guarantee Agreement (or the accession letter). 

 

	(g)	 Copies of such documentation and other evidence as the Bank may request to carry out and be satisfied with the
results of all necessary “know your customer” requirements or other checks in relation to the identity of any person that it is required (in order to comply with applicable money laundering laws and regulations) to carry out in relation to
the concerned Guarantor(s). 

  

	(h)	 A copy of any other document, authorisation, opinion or assurance which the Bank has notified the Borrower or
the respective Guarantor is necessary or desirable in connection with the entry into and performance of, and the transactions contemplated by, the Guarantee Agreement or the validity and enforceability of the same. 

  
 43 

 Schedule G 

Representations and Warranties 
  

	1.	 Authorisations and Binding Obligations 

 

	 	(a)	 Each Obligor is duly incorporated and validly existing as a corporation or company with limited liability under
the laws of its jurisdiction of incorporation. 

  

	 	(b)	 Each Obligor has the power to carry on its business as it is now being conducted and to own its property and
other assets, and to execute, deliver and perform its obligations under the Finance Documents. 

  

	 	(c)	 Each Obligor has obtained all necessary Authorisations in connection with the execution, delivery and
performance of the Finance Documents and in order to lawfully comply with its obligations thereunder, and in respect of the Investment, and all such Authorisations are in full force and effect and admissible in evidence. 

 

	 	(d)	 The execution and delivery of, the performance of each Obligor’s obligations under and compliance with the
provisions of the Finance Documents do not and will not contravene or conflict with: 

  

	 	(i)	 any applicable law, statute, rule or regulation, or any judgement, decree or permit to which it is subject;

  

	 	(ii)	 any agreement or other instrument binding upon it which might reasonably be expected to have a material adverse
effect on its ability to perform its obligations under the Finance Documents; or 

  

	 	(iii)	 any provision of its constitutional documents. 

 

	 	(e)	 The obligations expressed to be assumed by each Obligor in each Finance Document to which it is a party are
legal, valid, binding and enforceable obligations. 

  

	2.	 No default or other adverse event 

 

	 	(a)	 There has been no Material Adverse Change since [***].
(Non-repeating) 

  

	 	(b)	 No event or circumstance which constitutes an Event of Default has occurred and is continuing unremedied or
unwaived. 

  

	3.	 No proceedings 

 

	 	(a)	 No litigation, arbitration, administrative proceedings or investigation is current or to the best of its
knowledge and belief (having made due and careful enquiry) is threatened or pending before any court, arbitral body or agency which has resulted or if adversely determined is reasonably likely to result in a Material Adverse Change, nor is there
subsisting against it or any of its Subsidiaries any unsatisfied judgement or award. (Non-repeating) 

  

	 	(b)	 To the best of its knowledge and belief (having made due and careful enquiry) no material Environmental Claim
has been commenced or is threatened against any Obligor. 

  

	 	(c)	 As at the date of this Contract, no Obligor has taken any action to commence proceedings for, nor have any
other steps been taken or legal proceedings commenced or, so far as the Borrower is aware, threatened against any Obligor for its insolvency, winding up or dissolution, or for any Obligor to enter into any arrangement or compositions for the benefit
of creditors, or for the appointment of an administrator, receiver, administrative receiver, examiner, trustee or similar officer. 

  

	4.	 Security 

At the date of this Contract, no Security exists over the assets of any Group Company other than Permitted Security. 

  
 44 

	5.	 Ranking 

  

	 	(a)	 Its payment obligations under this Contract rank not less than pari passu in right of payment with all
other present and future unsecured and unsubordinated obligations under any of its debt instruments except for obligations mandatorily preferred by law applying to companies generally. 

 

	 	(b)	 No financial covenants have been concluded with any other creditor of any Obligor. 

 

	 	(c)	 No Voluntary Non EIB Prepayment has occurred. 

 

	6.	 Anti-Corruption 

 

	 	(a)	 Each Obligor is in compliance with all applicable European Union and national legislation, including any
applicable anti-corruption legislation. 

  

	 	(b)	 To the best of its knowledge, no funds invested in the Investment by any Obligor or any other Group Company are
of illicit origin, including products of money laundering or linked to the financing of terrorism. 

  

	 	(c)	 No Obligor is engaged in any Illegal Activities and to the best of the Borrower’s knowledge no Illegal
Activities have occurred in connection with the Investment. (Non-repeating) 

  

	7.	 Accounting and Tax 

 

	 	(a)	 The latest available consolidated and unconsolidated audited accounts of the Borrower and the other Obligors
have been prepared on a basis consistent with previous years and have been approved by its auditors as representing a true and fair view of the results of its operations for that year and accurately disclose or reserve against all the liabilities
(actual or contingent) of the Borrower and the other Obligors, as relevant. 

  

	 	(b)	 The accounting reference date of the Borrower and each Obligor is 31 December. 

 

	 	(c)	 No Obligor is required to make any deduction for or on account of any Tax from any payment it may make under
the Finance Documents, except for withholding tax (Kapitalertragssteuer) which have to be deducted pursuant to Sub-Paragraph (e) of Article 4.3 (Profit Participation).(Non-repeating) 

  

	 	(d)	 All Tax returns required to have been filed by each Obligor or on its behalf under any applicable law have been
filed when due and contain the information required by applicable law to be contained in them. 

  

	 	(e)	 Each Obligor has paid when due all Taxes payable by it under applicable law except to the extent that it is
contesting payment in good faith and by appropriate means. 

  

	 	(f)	 With respect to Taxes which have not fallen due or which it is contesting, each Obligor is maintaining reserves
adequate for their payment and in accordance, where applicable, with GAAP. 

  

	 	(g)	 Under the laws of the jurisdiction of incorporation of each Obligor, it is not necessary that the Finance
Documents be filed, recorded or enrolled with any court or other authority or that any stamp, registration or similar tax be paid on or in relation to the Finance Documents, or the transactions contemplated by the Finance Documents. (Non-repeating) 

  

	8.	 Information provided 

 

	 	(a)	 Any factual information provided by any Group Company for the purposes of entering into this Contract and any
related documentation was true and accurate in all material respects as at the date it was provided or as at the date (if any) at which it is stated and continues to be true and accurate in all material respect as at the date of this Contract. (Non-repeating) 

  
 45 

	 	(b)	 The Group structure chart is true, complete and accurate in all material respects and represents the complete
corporate structure of the Group as at the date of this Contract, and other than as set out therein the Borrower owns no other equity and/or shares in any other business entity. (Non-repeating)

  

	9.	 No indebtedness 

No Obligor has Indebtedness outstanding other than Permitted Indebtedness. (Non-repeating). 

 

	10.	 No Immunity 

No Obligor, nor any of its assets, is entitled to immunity from suit, execution, attachment or other legal process. 

 

	11.	 Pensions 

The pension schemes for the time being operated by the Obligors (if any) are funded in accordance with their rules and to the extent required
by law or otherwise comply with the requirements of any law applicable in the jurisdiction in which the relevant pension scheme is maintained. 

  
 46 

 Schedule H 

General Undertakings 
  

	1.	 Use of Loan 

The Borrower shall use all amounts borrowed by it under the Loan to carry out the Investment. 

 

	2.	 Completion of Investment 

The Borrower shall or shall procure that the Investment is carried out in accordance with the Technical Description as may be modified from
time to time with the approval of the Bank, and complete it by the final date specified therein. 
  

	3.	 Procurement procedure 

The Borrower shall secure goods and services for the Investment (a) in so far as they apply to it or to the Investment, in accordance with
EU Law in general and in particular with the relevant EU Directives, and (b) in so far as EU Directives do not apply, by procurement procedures which conform to the relevant requirements set out in the Bank’s “Guide to Procurement for
projects financed by the EIB (2018)”. 
  

	4.	 Compliance with laws 

Each Obligor shall comply in all respects with all laws and regulations to which it or the Investment is subject. 

 

	5.	 Environment 

The Borrower shall: 
  

	 	(a)	 implement and operate the Investment in compliance with Environmental Law; 

 

	 	(b)	 obtain, maintain and comply with requisite Environmental Approvals for the Investment, 

and upon becoming aware of any breach of this Paragraph 5 (Environment): 

 

	 	(i)	 the Borrower shall promptly notify the Bank; 

 

	 	(ii)	 the Borrower and the Bank will consult for up to [***] ( [***]) Business Days from the date of notification
with a view to agreeing the manner in which the breach should be rectified; and 

  

	 	(iii)	 the Borrower shall remedy the breach within [***] ( [***]) Business Days of the end of the consultation period.

  

	6.	 Integrity 

The Borrower shall take, within a reasonable timeframe, appropriate and legally permissible measures in respect of any member of its management
bodies who has been convicted by a final and irrevocable court ruling of an Illegal Activity perpetrated in the course of the exercise of his/her professional duties, in order to ensure that such member is excluded from any Borrower’s activity
in relation to the Loan or the Investment. 
  

	7.	 Disposal of assets 

 

	 	(a)	 Except as provided under Sub-Paragraph (b) below, the Borrower
shall not, and shall procure that no Group Company shall, either in a single transaction or in a series of transactions whether related or not and whether voluntarily or involuntarily dispose of all or any part of any Group Company’s business,
undertaking or assets (including any shares, real estate or security of any entity or a business or undertaking, or any interest in any of them). 

  
 47 

	 	(b)	 Sub-Paragraph (a) above does not apply to any such disposal
(“Permitted Disposal”): 

  

	 	(i)	 made with the prior written consent of the Bank; 

 

	 	(ii)	 made on arm’s length terms in the ordinary course of business of a Group Company; 

 

	 	(iii)	 made on arm’s length terms and at fair market value for cash, which is reinvested in assets of comparable
or superior type, value and quality; 

  

	 	(iv)	 made on arm’s length terms in exchange for other assets (other than shares, businesses and real estate)
comparable or superior as to type, value and quality; 

  

	 	(v)	 by (A) one Obligor to another Obligor, or (B) a group Company which is not an Obligor to another
Group Company which is not an Obligor; 

  

	 	(vi)	 constituted by a licence of Intellectual Property Rights on arm’s length terms in the ordinary course of
business of a Group Company; 

  

	 	(vii)	 made in relation to non-material assets which have depreciated to less
than [***] % ([***] per cent.) of their initial value or which are obsolete; 

  

	 	(viii)	 excluding any disposal otherwise permitted under (ii) to (vii) above, disposals where the higher of the
market value or consideration receivable for such disposals does not exceed EUR [***] ([***] euro) over the lifetime of this Contract; or 

  

	 	(ix)	 arising as a result of Permitted Security. 

 

	 	(c)	 A disposal shall in each case only qualify as Permitted Disposal within the meaning of paragraph
(b) above, if the relevant disposal is not of assets forming part of the Investment or shares in subsidiaries holding assets forming part of the Investment, which may not be disposed of unless either (i) such disposal is made in accordance
with Paragraph (b)(vi) above, (ii) the Borrower consults the Bank in relation to such disposal, and the Bank approves such disposal (such approval not to be unreasonably withheld), or (iii) the proceeds of such disposal are applied to
prepay the Bank in accordance with Article 5.3.4 (Disposals). 

 For the purposes of this Paragraph 7 (Disposal
of assets), “dispose” and “disposal” includes any act effecting sale, transfer, lease or other disposal (Verfügung). 
  

	8.	 Maintenance of assets 

The Borrower shall maintain, repair, overhaul and renew all assets required in relation to the Investment as required to keep such assets in
good working order (ordinary wear and tear excepted). 
  

	9.	 Insurances 

The Borrower shall, and shall procure that each Group Company shall, maintain insurances on and in relation to its business and assets with
reputable underwriters or insurance companies against those risks and to the extent as is usual for companies carrying on the same or substantially similar business. 
  

	10.	 Change in business 

The Borrower shall procure that no substantial change is made to the general nature business of the Borrower or the Group as a whole from that
carried on at the date of this Contract. 
  

	11.	 Merger 

The Borrower shall not, and shall procure that no Group Company shall, enter into any amalgamation, demerger, merger or corporate
reconstruction (including the conclusion of any domination and/or profit and loss transfer agreements (Beherrschungs- und/oder  

  
 48 

 
Gewinnabführungsverträge) or any other enterprise agreements (Unternehmensverträge) with the meaning of section 291 AktG) unless: 

 

	 	(a)	 with the prior written consent of the Bank; or 

 

	 	(b)	 such amalgamation, demerger, merger or corporate reconstruction does not result in a Material Adverse Change
and is on a solvent basis, and provided that: 

  

	 	(i)	 only Group Companies are involved and if a Guarantor is involved, the surviving entity will also be or become a
Guarantor; 

  

	 	(ii)	 the resulting entity will not be incorporated or located in a country which is in a jurisdiction that is
blacklisted by any Lead Organisation in connection with activities such as money laundering, financing of terrorism, tax fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time; and 

 

	 	(iii)	 if the Borrower is involved, (A) the rights and obligations of the Borrower under this Contract will
remain with the Borrower, (B) the surviving entity will be the Borrower and the statutory seat of the Borrower would not as a result of such merger be transferred to a different jurisdiction, (C) the merger will not have an effect on the
validity, legality or enforceability of the Borrower’s obligations under this Contract; and (D) all of the business and assets of the Borrower are retained by it; or 

 

	 	(c)	 the enterprise value of the company (including any Indebtedness remaining in such company) involved in an
amalgamation, demerger, merger or corporate reconstruction not already permitted under Paragraph (b) above (i) does not exceed an amount of EUR [***] ( [***] euro) in a single transaction and EUR [***] ( [***] euro) during the Term of the
Credit and (ii) provided Paragraphs (b)(ii) and (iii) above are fulfilled. 

  

	12.	 Books and records 

Each Obligor shall ensure that it has kept and will continue to keep proper books and records of account, in which full and correct entries
shall be made of all financial transactions and its assets and business, including expenditures in connection with the Investment, in accordance with GAAP as in effect from time to time for a period of five (5) years following the last
repayment of the Credit under this Contract. 
  

	13.	 Ownership 

  

	 	(a)	 The Borrower shall maintain more than 50% (fifty per cent.) of the share capital, directly or indirectly, of
each of its Material Subsidiaries, unless a prior written consent of the Bank is received by the Borrower. 

  

	 	(b)	 The Borrower shall in aggregate maintain not less than 100% (one hundred per cent.) of the share capital,
directly or indirectly, of each Guarantor and each Material Subsidiary, unless: 

  

	 	(i)	 the percentage of the share capital in the relevant Guarantor or Material Subsidiary at the date of this
Contract is lower than 100% (one hundred per cent.) (“Initial Ownership Stake”), in which case the Borrower shall maintain such Initial Ownership Stake; or 

 

	 	(ii)	 prior written consent of the Bank is received by the Borrower. 

 

	 	(c)	 The Borrower shall immediately notify the Bank in the event of a new entity becoming a Subsidiary of the
Borrower through any means, including but not limited to acquisition, creation and spin-off. 

  

	 	(d)	 The undertakings in Sub-Paragraphs (a), (b) and (c) above shall be
calculated in accordance with GAAP as applied by the Borrower on the date of this Contract and as GAAP is amended from time to time and tested annually. 

  
 49 

	14.	 Acquisitions 

The Borrower shall not, and shall procure that no Group Company shall, invest in (including by way of payment into the capital reserve
(Kapitalrücklage)) or acquire any entity or a business going concern or an undertaking (whether whole or substantially the whole of the assets or business), or any division or operating unit thereof, or any shares or securities of any
entity or a business or undertaking (or in each case, any interest in any of them) (or agree to any of the foregoing), save for an acquisition or investment: 
  

	 	(a)	 [***]; 

  

	 	(b)	 with the prior written consent of the Bank; 

 

	 	(c)	 by one Obligor of an asset sold, leased, transferred or otherwise disposed of by another Obligor;

  

	 	(d)	 by a Group Company of all the shares or other ownership interests in any limited liability company or
corporation, limited liability partnership or any equivalent company, provided that: 

  

	 	(i)	 such entity has not yet commenced commercial operations; 

 

	 	(ii)	 such entity is incorporated in a country that is a member of either or both of the European Union or the
Organisation of Economic Co-Operation and Development; and 

  

	 	(iii)	 no Event of Default is continuing on the date the relevant acquisition agreement is entered into or would occur
as a result of the acquisition; or 

  

	 	(e)	 of shares or other ownership interests in any limited liability company or corporation, limited liability
partnership or any equivalent company, the consideration for which does not exceed an aggregate amount of: 

  

	 	(X)	 EUR [***] ([***] euro) during any financial year, and 

 

	 	(Y)	 EUR [***] ([***] euro) during the term of the Credit, 

provided that: 
  

	 	(i)	 no Event of Default is continuing on the date the relevant acquisition agreement is entered into or would occur
as a result of the acquisition; 

  

	 	(ii)	 the acquired entity is engaged in a business similar or complementary to the business carried on by the Group
as at the date of this Contract; 

  

	 	(iii)	 the acquired entity is not incorporated or located in a jurisdiction that is blacklisted by any Lead
Organisation in connection with activities such as money laundering, financing of terrorism, tax fraud and tax evasion or harmful tax practices as such blacklist may be amended from time to time; and 

 

	 	(iv)	 the Borrower provides a Compliance Certificate for the [***] ([***]) [***] ([***]) month financial periods
immediately following the acquisition, updated on a pro forma basis as if the acquisition has occurred. 

  

	 	(f)	 In relation to Paragraph (e) above the Parties agree, that if: 

 

	 	(i)	 the EBITDA of the Borrower is positive for the Relevant Period ending on the most recent Semi-Annual Date prior
to that acquisition or investment; and 

  

	 	(ii)	 the revenues of the Borrower exceed EUR [***] ([***] euro), 

(together the “Replacement Conditions”), the threshold included: 

 

	 	(A)	 in Sub-Paragraph (X) of Paragraph (e) above will be replaced
by a threshold of “[***]% of the Total Assets during any financial year”; and 

  

	 	(B)	 in Sub-Paragraph (Y) of Paragraph (e) above will be replaced
by a threshold of “[***]% of the Total Assets during the term of the Credit “, 

  
 50 

 (together the “Replaced Thresholds”), whereby (x) the amounts of
already done acquisitions or investments permitted under Paragraphs (a) to (e) above shall count towards the Replaced Thresholds and (y) to the extent and for so long as the Borrower complies with the Replacement Conditions. In case the
Borrower does not further comply with any of the Replacement Conditions, the thresholds included in Sub-Paragraphs (X) and (Y) of Paragraph (e) above shall apply again and the Borrower shall use its
reasonable best efforts to comply with such thresholds within a reasonable timeframe. The Borrower shall provide evidence satisfactory to the Bank of the fulfilment of the Replacement Conditions and compliance with the Replacement Conditions upon
reasonable demand of the Bank. 
  

	15.	 Indebtedness 

The Borrower shall not, and shall procure that no other Group Company shall, incur any Indebtedness, save for any Existing Indebtedness and
Indebtedness (“Permitted Indebtedness”): 
  

	 	(a)	 incurred with the prior written consent of the Bank; 

 

	 	(b)	 incurred under this Contract; 

 

	 	(c)	 incurred under the Existing EIB Finance Contract; 

 

	 	(d)	 under Permitted Hedging; 

 

	 	(e)	 in respect of a Permitted Guarantee; 

 

	 	(f)	 owing by an Obligor to another Obligor; 

 

	 	(g)	 unsecured Indebtedness to trade creditors and, in respect of the German trade creditors, Indebtedness secured
by customary retention of title arrangements (Eigentumsvorbehalte) incurred in the ordinary course of day-to-day business; or 

 

	 	(h)	 not permitted by the preceding Sub-Paragraphs and the outstanding
amount of Indebtedness (including drawn down debt provided by the Bank and other existing outstanding interest-bearing liabilities) which does not exceed twice the last 12 (twelve) months EBITDA. 

 

	16.	 Guarantees 

  

	 	(a)	 The Borrower shall not, and shall procure that no other Group Company shall, issue or allow to remain
outstanding any guarantees or sureties (Bürgschaften) in respect of any liability or obligation of any person save for: 

  

	 	(i)	 any guarantee or surety (Bürgschaft) under any Guarantee Agreement or with the prior written
consent of the Bank; or 

  

	 	(ii)	 guarantees or sureties (Bürgschaften) issued by any Group Company under or in connection with:

  

	 	(1)	 under any negotiable instruments in the ordinary course of trade; 

 

	 	(2)	 in connection with any performance bond in the ordinary course of trade; 

 

	 	(3)	 in connection with any Permitted Indebtedness; 

 

	 	(4)	 issued by one Obligor to another Obligor; 

 

	 	(5)	 any bank guarantee issued the benefit of a contractor in connection with construction work to secure such
contractor’s claims (Bauhandwerkersicherung); 

  

	 	(6)	 any guarantee created or subsisting in order to comply with Section 8a of the German Altersteilzeitgesetz
(AltTZG) or pursuant to Section 7e of the German Social Law Act No. 4 (Sozialgesetzbuch IV); or 

  
 51 

	 	(7)	 any guarantees or sureties (Bürgschaften) not permitted by the preceding Sub-Paragraphs and the outstanding amount of which does not exceed EUR [***] ([***] euro) (or its equivalent) in aggregate for the Group at any time. If and for so long as the Borrower fulfils the Replacement
Conditions prior to issuing the guarantee or surety (Bürgschaft), the threshold amount of EUR [***] ([***] euro) increases to EUR [***] ([***] euro). In case the Borrower does not further comply with any of the Replacement Conditions,
the threshold of EUR [***] ([***] euro) shall apply again and the Borrower shall use its reasonable best efforts to comply with such threshold within a reasonable timeframe. 

 

	 	(b)	 The Borrower shall procure that, as soon as any Group Company becomes a Material Subsidiary (as identified in
any accounts delivered to the Bank from time to time pursuant to Paragraph 2 (Information concerning the Borrower) of Schedule I (Information and Visits), that Group Company shall promptly notify the Bank and on the Bank’s request
enter into a Guarantee Agreement and provide the Bank with the documentary conditions precedent (each in form and substance satisfactory to the Bank) listed in Part C of Schedule F (Guarantor Conditions Precedent) within [***] ([***])
Business Days following the date on which such Group Company qualifies as a Material Subsidiary. 

  

	17.	 Hedging 

The Borrower shall not, and shall procure that no other Group Company shall, enter into any derivative transaction other than Permitted
Hedging, where “Permitted Hedging” means: 
  

	 	(a)	 any derivative transaction entered into by a Group Company with the prior written consent of the Bank;

  

	 	(b)	 any derivative transaction by a Group Company to hedge actual or projected exposure arising in the ordinary
course of trading and not for speculative purposes; and 

  

	 	(c)	 any derivative instrument of a Group Company which is accounted for on a hedge accounting basis but is not
entered into for speculative purposes. 

  

	18.	 Restrictions on distributions 

The Borrower shall not, and shall procure that no other Group Company shall, declare or distribute dividends, or return or purchase shares,
save for: 
  

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 payments to a Group Company as a result of a solvent liquidation or reorganisation of a Group Company which is
not an Obligor; and 

  

	 	(c)	 any dividend payments made by any Subsidiary. 

 

	19.	 Restrictions on loans 

The Borrower shall not, and shall ensure that no other member of the Group will, be a creditor in respect of any Indebtedness, save for: 

 

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 any trade credit extended by any member of the Group to its customers on normal commercial terms and in the
ordinary course of its trading activities; 

  

	 	(c)	 any loan made by one member of the Group (other than an Obligor) to another member of the Group;

  

	 	(d)	 a loan made by one Obligor to another Obligor; 

  
 52 

	 	(e)	 a loan made by one Obligor to a member of the Group (other than an Obligor) not exceeding an amount of EUR
[***] ([***] euro) during the Term of the Credit; or 

  

	 	(f)	 any other Indebtedness or loan advanced to or made available by any member of the Group with the prior written
consent of the Bank. 

  

	20.	 Restrictions on intercompany loans 

The Borrower shall not, and shall procure that no other Group Company shall, make any payment in respect of any intercompany loan, save for:

  

	 	(a)	 with the prior written consent of the Bank; 

 

	 	(b)	 where the lender of the intercompany loan is the Borrower or an Obligor; or 

 

	 	(c)	 the payments to a Group Company as a result of a solvent liquidation or reorganisation of a Group Company which
is not an Obligor. 

  

	21.	 Intellectual Property Rights 

The Borrower shall, and shall procure that each other Group Company shall, (i) obtain, safeguard and maintain its rights with respect to
the Intellectual Property Rights required for the implementation of the Investment in accordance with this Contract, including complying with all material contractual provisions and that the implementation of the Investment in accordance with this
Contract will not result in the infringement of the rights of any person with regard to the Intellectual Property Rights and (ii) ensure that any Intellectual Property Rights required for the implementation of the Investment will be owned by or
licensed to the Borrower, and where such Intellectual Property Rights which are owned by a Group Company are capable of registration, are registered to such party. 
  

	22.	 Maintenance of Status 

The Borrower shall, and shall procure that each other Group Company shall, remain duly incorporated and validly existing as a corporate entity
with limited liability under the jurisdiction in which it is incorporated and that it will have no centre of main interests, permanent establishment or place of business outside the jurisdiction in which it is incorporated, and that it will continue
to have the power to carry on its business as it is now being conducted and continue to own its property and other assets. 
  

	23.	 Negative pledge 

 

	 	(a)	 The Borrower shall not (and shall procure that no other Group Company shall) create or permit to subsist any
Security over any of its assets. 

  

	 	(b)	 For the purposes of this Paragraph 23 (Negative pledge), the term Security shall also include any
arrangement or transaction on assets or receivables or money (such as the sale, transfer or other disposal of assets on terms whereby they are or may be leased to or re-acquired by any Group Company, the sale,
transfer or other disposal of any receivables on recourse terms or any arrangement under which money or the benefit of a bank account or other account may be applied or set off or any preferential arrangement having a similar effect) in
circumstances where the arrangement or transaction is entered into primarily as a method of raising credit or of financing the acquisition of an asset. 

  

	 	(c)	 Sub-Paragraph (a) above does not apply to any Existing Security
and any Security listed below (“Permitted Security”): 

  

	 	(i)	 any netting or set-off arrangement entered into by any Group Company in
the ordinary course of its banking arrangements for the purpose of netting debit and credit balances and any Security arising under general business conditions (Allgemeine Geschäftsbedingungen) of banks or financial institutions;

  
 53 

	 	(ii)	 any payment or close out netting or set-off arrangement pursuant to any
Permitted Hedging, but excluding any Security under a credit support arrangement in relation to a hedging transaction; 

  

	 	(iii)	 any Security arising by operation of law and in the ordinary course of trading; 

 

	 	(iv)	 any Security over or affecting any asset acquired by Group Company after the date of this Contract if:

  

	 	(1)	 the Security was not created in contemplation of the acquisition of that asset by a Group Company;

  

	 	(2)	 the principal amount secured has not been increased in contemplation of or since the acquisition of that asset
by a Group Company; and 

  

	 	(3)	 the Security is removed or discharged within [***] ([***]) months of the date of acquisition of such
asset; 

  

	 	(v)	 any Security over or affecting any asset of any company which becomes a Group Company after the date of this
Contract, where the Security is created prior to the date on which that company becomes a Group Company, if: 

  

	 	(1)	 the Security was not created in contemplation of the acquisition of that company; 

 

	 	(2)	 the principal amount secured has not increased in contemplation of or since the acquisition of that company;
and 

  

	 	(3)	 the Security is removed or discharged within [***] ([***]) months of that company becoming a Group
Company; 

  

	 	(vi)	 any Security arising under any retention of title including extended retention of title
(verlängerter Eigentumsvorbehalt)), hire purchase or conditional sale arrangement or arrangements having similar effect in respect of goods supplied to a Group Company in the ordinary course of trading and on
the supplier’s standard or usual terms and not arising as a result of any default or omission by any Group Company; 

  

	 	(vii)	 any Security created or subsisting in order to comply with Section 8a of the German Altersteilzeitgesetz
(AltTZG) or pursuant to Section 7e of the German Social Law Act No. 4 (Sozialgesetzbuch IV); 

  

	 	(viii)	 any contractor’s lien arising by operation of law (Werkunternehmerpfandrecht) in connection with
repairs and maintenance work and any landlord’s pledge (Vermieterpfandrecht) arising by operation of law under a lease in favour of the relevant third party landlord; or 

 

	 	(ix)	 any Security securing indebtedness the principal amount of which (when aggregated with the principal amount of
any other indebtedness which has the benefit of Security given by a Group Company other than any permitted under Sub-Paragraphs (i) to (viii) above) does not exceed EUR [***] ([***] euro) during the term
of this Credit. In relation to this Paragraph (xi) the Parties agree, that if and for so long as the Borrower fulfils the Replacement Conditions prior to providing the security, the threshold in this Paragraph (ix) will be replaced by a
threshold constituting the lesser of (A) [***] % ([***] cent.) of the Total Assets during any financial year, and (B) EUR [***] ([***] euro). 

  

	24.	 Other Undertakings 

The Borrower shall take note of the Bank’s group statement on tax fraud, tax evasion, tax avoidance, aggressive tax planning, money
laundering and financing of terrorism (as published on the Bank’s website and as may be amended from time to time). 

  
 54 

	25.	 Data Protection 

Before disclosing any personal data (other than mere contact information relating to the Borrower’s personnel involved in the management
of this Contract) to the Bank in connection with this Contract, the Borrower shall ensure that each data subject of those personal data: 
  

	 	(a)	 has been informed of the disclosure (including the categories of personal data to be disclosed); and

  

	 	(b)	 has the information in (or has been provided with an appropriate link to) the Bank’s privacy statement in
relation to its lending and investment activities set out at the relevant time at https://www.eib.org/en/privacy/lending (or such other address as the Bank may notify to the Borrower in writing from time to time). 

 

	26.	 Sanctions 

The Borrower shall ensure that all amounts borrowed by it under this Contract are not made available to, or for the benefit of, persons or
entities designated by restrictive measures adopted pursuant to Article 215 of the Treaty on the Functioning of the European Union insofar as the giving of and compliance with such undertaking does not and will not result in a violation of or
conflict with or liability under section 7 of the German Foreign Trade Regulation (Außenwirtschaftsverordnung, AWV) (in conjunction with sections 4, 19 paragraph 3 no. 1a) of the German Foreign Trade Act
(Außenwirtschaftsgesetz, AWG) and section 81 paragraph 1 no. 1 AWV) where the Borrower need not comply but only to the extent of the breach. 
  

	[***]	 

  

	29.	 Clauses by inclusion 

If the Borrower or any Group Company concludes with any other secured and unsubordinated creditor a financing agreement that includes a loss-of-rating clause or a covenant or other provision regarding its financial ratios, if applicable, that is not provided 

  
 55 

 
for in this Contract or is more favourable to the relevant creditor than any equivalent provision of this Contract is to the Bank, the Borrower shall promptly inform the Bank and shall provide a
copy of the more favourable provision to the Bank. The Bank may request that the Borrower promptly executes an agreement to amend this Contract so as to provide for an equivalent provision in favour of the Bank. 

  
 56 

 Schedule I 

Information and Visits 
  

	1.	 Information concerning the Investment 

Subject to Paragraph 5 (Confidential information) below: 
  

	 	(a)	 The Borrower shall deliver to the Bank: 

 

	 	(i)	 the information in content and in form, and at the times, specified in Part 2 (Information Duties) of
Schedule A (Investment Specification and Reporting) or otherwise as agreed from time to time by the parties to this Contract; 

  

	 	(ii)	 any such information or further document concerning the Investment as the Bank may require to comply with its
obligations under the EFSI Regulation or the Horizon 2020 Legal Basis; and 

  

	 	(iii)	 any such information or further document concerning the financing, procurement, implementation, operation and
environmental matters of or for the Investment as the Bank may reasonably require within a reasonable time; 

 provided
always that if such information or document is not delivered to the Bank on time, and the Borrower does not rectify the omission within a reasonable time set by the Bank in writing, the Bank may remedy the deficiency, to the extent feasible, by
employing its own staff or a consultant or any other third party, at the Borrower’s expense and the Borrower shall provide such persons with all assistance necessary for the purpose. 

 

	 	(b)	 The Borrower shall submit for the approval of the Bank without delay any material changes to the Investment,
also taking into account the disclosures made to the Bank in connection with the Investment prior to the signing of this Contract, in respect of, inter alia, the total cost, plans, timetable or to the expenditure programme or financing plan for the
Investment. 

  

	 	(c)	 The Borrower shall promptly inform the Bank of: 

 

	 	(i)	 any action initiated or any objection raised by any third party or any genuine complaint received by the
Borrower or any Environmental Claim that is to its knowledge commenced, pending or threatened against it with regard to environmental or other matters affecting the Investment; and 

 

	 	(ii)	 any fact or event known to the Borrower, which may substantially prejudice or affect the Borrower’s
ability to execute the Investment; 

  

	 	(iii)	 a genuine allegation, complaint or information with regard to Illegal Activities related to the Loan and/or the
Investment; 

  

	 	(iv)	 any non-compliance by it with any applicable Environmental Law; and

  

	 	(v)	 any suspension, revocation or modification of any Environmental Approval, 

and set out the action to be taken with respect to such matters; 
  

	 	(d)	 If the total cost of the Investment exceeds the estimated figure set out in Recital (A), the Borrower shall
notify the Bank without delay and shall inform the Bank of its plans to fund the increased costs. 

  

	 	(e)	 The Borrower shall, and shall procure that each other Group Company shall, promptly inform the Bank if at any
time it becomes aware of the illicit origin (including products of money laundering or linked to the financing of terrorism) of any funds invested in the Investment by the Borrower or another Group Company. 

 

	 	(f)	 The Borrower shall provide to the Bank, if so requested: 

 

	 	(i)	 a certificate of its insurers showing that all assets required in order to carry out the Investment are insured
with reputable underwriters or insurance companies against those risks and to the extent as is usual for companies carrying on the same or substantially similar business; and 

  
 57 

	 	(ii)	 annually, a list of policies in force covering any aspect of the Investment, together with confirmation of
payment of the current premiums. 

  

	2.	 Information concerning the Borrower 

Subject to Paragraph 5 (Confidential information): 
  

	 	(a)	 The Borrower shall deliver to the Bank: 

 

	 	(i)	 as soon as they become available but in any event within [***] ([***]) months after the end of each of its
financial years: 

  

	 	(A)	 its audited consolidated and unconsolidated annual report, balance sheet, cash flow statement, profit and loss
account and auditors report for that financial year; 

  

	 	(B)	 a Compliance Certificate signed by [***] ([***]) directors (Vorstände) which, during the Profit
Participation Period and if Tranche B has been disbursed, should have Part B (Profit Participation) of the Compliance Certificate fully completed; 

  

	 	(C)	 the unconsolidated financial statements (audited, if available) of each Obligor for such financial year.

  

	 	(ii)	 as soon as they become available but in any event within [***] ([***]) months after the end of each of the
relevant accounting periods its interim consolidated and unconsolidated semi-annual report, balance sheet, profit and loss account and cash flow statement for the first half-year of each of its financial years together with a Compliance Certificate
signed by [***] ([***]) directors (Vorstände); 

  

	 	(iii)	 such further information, evidence or document concerning its general financial situation or such certificates
of compliance with the undertakings of Article 7 (Borrower undertakings and representations) as the Bank may deem necessary or may reasonably require to be provided within a reasonable time; 

 

	 	(iv)	 any such further information, evidence or document concerning the compliance with the due diligence
requirements of the Bank, including, but not limited to “know your customer” (KYC) or similar identification procedures, when requested and within a reasonable time; 

 

	 	(v)	 such further information, evidence or document concerning the factual information or documents provided to the
Bank for the purposes of entering into this Contract, as the Bank may deem necessary or may require to be provided within a reasonable time; 

  

	 	(vi)	 any information, report or other document received by the Borrower in respect of an audit undertaken pursuant
to a Key Contract subject to a non-disclosure agreement signed by the Bank and the Borrower. 

  

	 	(b)	 The Borrower shall deliver to the Bank as soon as possible but in any event within [***] ([***]) days after the
start of each half-year a budget for that half-year (“Budget”). The Borrower shall ensure that each Budget: 

  

	 	(i)	 includes [***] ; 

  

	 	(ii)	 is prepared in all material respects in accordance with GAAP and the accounting practices and financial
reference periods applied to the consolidated financial statements of the Group; and 

  

	 	(iii)	 has been approved by Authorised Signatories of the Borrower. 

 

	 	(c)	 The Borrower shall inform the Bank immediately of: 

  
 58 

	 	(i)	 any Default or Event of Default having occurred or being threatened or anticipated; 

 

	 	(ii)	 to the extent permitted by law, any material litigation, arbitration, administrative proceedings or
investigation carried out by a court, administration or similar public authority, which, to the best of its knowledge and belief is current, threatened or pending: 

 

	 	(1)	 against any Obligor or its controlling entities or members of the Borrower’s management bodies in
connection with Illegal Activities related to the Loan or the Investment; or 

  

	 	(2)	 which would if adversely determined result in a Material Adverse Change; 

 

	 	(iii)	 to the extent permitted by any law applicable to the Borrower, any measure taken by the Borrower pursuant to
Paragraph 6 (Integrity) of Schedule H (General Undertakings); 

  

	 	(iv)	 any Change in the Beneficial Ownership of the Borrower and any material update of or change to the Budget; and

  

	 	(v)	 any Voluntary Non EIB Prepayment that has occurred or is likely to occur. 

 

	3.	 Visits by the Bank 

 

	 	(a)	 Each Obligor shall allow the Bank and, when either required by the relevant mandatory provisions of EU law or
pursuant to the EFSI Regulation or the Horizon 2020 Legal Basis, the competent EU institutions including the European Court of Auditors, the Commission, the European Anti-Fraud Office, the European Public Prosecutor’s Office as well as persons
designated by the foregoing: 

  

	 	(i)	 to visit during normal business hours with prior notice, except in cases of emergency, the sites, installations
and works comprising the Investment; 

  

	 	(ii)	 to interview representatives of each Obligor, and not obstruct contacts with any other person involved in or
affected by the Investment; and 

  

	 	(iii)	 to conduct such investigations, inspections, on the spot audits and checks as they may wish and review the
Obligors’ books and records in relation to the execution of the Investment and to be able to take copies of related documents to the extent not prohibited by the law. 

 

	 	(b)	 Each Obligor shall provide the Bank, or ensure that the Bank is provided, with all necessary assistance for the
purposes described in this Paragraph 3 (Visits by the Bank). 

  

	 	(c)	 In the case of a genuine allegation, complaint or information with regard to Illegal Activities related to the
Loan and/or the Investment, the Borrower shall consult with the Bank in good faith regarding appropriate actions. In particular, if it is proven that a third party committed Illegal Activities in connection with the Loan and/or the Investment with
the result that the Loan or the EFSI financing or financing under the Horizon 2020 Framework EU Programme were misapplied, the Bank may, without prejudice to the other provisions of this Contract, inform the Borrower if, in its view, the Borrower
should take appropriate recovery measures against such third party. In any such case, the Borrower shall in good faith consider the Bank’s views and keep the Bank informed. 

  
 59 

	4.	 Disclosure and publication 

 

	 	(a)	 The Bank acknowledges and agrees that the Borrower may be obliged to disclose the terms of this Contract and
make any other public written disclosure regarding the existence of, or performance under, this Contract, to the extent required, in the reasonable opinion of BioNTech’s legal counsel, to comply with (i) law, statute or regulation
applicable to the Borrower, including the rules and regulations promulgated by the United States Securities and Exchange Commission or (ii) any equivalent governmental authority, securities exchange or securities regulator in any country shares
of the Borrower are listed. Before disclosing this Contract or any of the terms hereof pursuant to this Sub-Paragraph (a) of Paragraph 4 (Disclosure and publication), the Borrower will inform the
Bank with at least [***] ([***]) Business Days prior notice of the intended disclosure and will consult with the Bank in making any such disclosure acceptable to the Bank. Further, if the Borrower discloses this Contract or any of the terms hereof
in accordance with this Sub-Paragraph (a) of Paragraph 4 (Disclosure and publication), the Borrower will, at its own expense, seek such confidential treatment of confidential portions of this
Contract and limit its disclosure of such terms to that the extent required to comply with law, statute or regulation applicable to the Borrower. 

  

	 	(b)	 The Borrower acknowledges and agrees that: 

 

	 	(i)	 the Bank may be obliged to communicate information relating to any Obligor and the Investment to any competent
institution or body of the European Union in accordance with the relevant mandatory provisions of European Union law or pursuant to the Horizon 2020 Legal Basis or the EFSI Regulation; and 

 

	 	(ii)	 the Bank may publish in its website or produce press releases containing information related to the financing
provided pursuant to this Contract with support of the EFSI and the Horizon 2020 Framework EU Programme, including the name, address and country of establishment of the Borrower, the purpose of the financing, and the type and amount of financial
support received under this Contract. 

  

	 	(c)	 To the extent legally and practically possible, the Bank shall communicate and/or publish such information only
upon prior coordination with the Borrower. To the extent the Bank has coordinated such communication/publication with the Borrower, the Borrower will ensure that to the same extent and at the same time such information is made available to the
United States Securities and Exchange Commission. The Borrower agrees to cooperate with the Bank to ensure that any press releases or publications made by the Borrower regarding the financing and the Investment include an appropriate acknowledgement
of the financial support provided by the Bank with the backing of the European Union through EFSI and Horizon 2020 Framework EU Programme. 

  

	 	(d)	 The Obligors are entitled and, if requested by the Bank, each Obligor undertakes to refer to this financing and
other Bank financings in its public communications, if appropriate, during the availability period, and in connection with any drawdowns, and communications on major corporate events. 

 

	5.	 Confidential information 

Where the Borrower provides information to the Bank in connection with this Contract, it shall clearly indicate whether such information is
already public or being maintained by the Borrower as confidential information. If regulated or prohibited by applicable legislation including the rules and regulations promulgated by the United States Securities and Exchange Commission and
securities law relating to insider dealing and market abuse, the Borrower will not share (and is not obliged to do so) any inside information with the Bank before it is published to the market. For the avoidance of doubt the Parties agree that the
Borrower shall only be required to provide information to the Bank to the extent legally permissible and in particular in compliance with applicable laws on inside information. The Bank is not responsible or liable for any determination as to
whether any information provided or to be provided to it is non-public information the use of which may be regulated or prohibited by applicable law or regulation relating to insider dealing or otherwise. 

  
 60 

 Schedule J 

Existing Indebtedness 
  

	1.	 Indebtedness in connection with a secured EUR 10,000,000 loan agreement dated 21 November 2017 and entered
into by BioNTech Innovative Manufacturing Services GmbH as borrower and Deutsche Bank AG as lender. 

  

	2.	 Indebtedness in connection with a secured EUR 9,450,000 loan agreement dated 18 July 2018 and entered into
by JPT Peptide Technologies GmbH as borrower and Deutsche Bank AG as lender. 

  

	3.	 Indebtedness in connection with Existing EIB Financing Contract. 

  
 61 

 Schedule K 

Existing Security 
  

	1.	 EUR 10,000,000.00 loan agreement dated 21 November 2017 with BioNTech Innovative Manufacturing Services
GmbH as borrower and Deutsche Bank AG as lender. 

  

	 	•	 	 First-priority land charges (Grundschulden) of EUR 10,000,000 on commercial property
(Betriebsimmobilie) in 55743 Idar-Oberstein, Germany, Idar-Oberstein [***], granted by BioNTech Innovative Manufacturing Services GmbH; 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	2.	 EUR 9,450,000 loan agreement dated 18 July 2018 with JPT Peptide Technologies GmbH as borrower and
Deutsche Bank AG as lender. 

  

	 	•	 	 First-priority land charges (Grundschulden) of EUR 9,450,000 on commercial property (Betriebsimmobilie)
Berlin-Adlershof; Germany, [***] granted by JPT Peptide Technologies GmbH; 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	3.	 Security granted or to be granted under and in connection with the Existing EIB Finance Contract.

  
 62

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]